var title_f2_40_2688="Reperfusion checklist STEMI";
var content_f2_40_2688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Reperfusion checklist for evaluation of the patients with STEMI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     STEMI: ST elevation myocardial infarction; BP: blood pressure; GI: gastrointestinal; GU: genitourinary; CPR: cardiopulmonary resuscitation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:588. Copyright &copy; 2004 The American College of Cardiology Foundation and the American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2688=[""].join("\n");
var outline_f2_40_2688=null;
var title_f2_40_2689="Cyclic neutropenia periodontal disease";
var content_f2_40_2689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Periodontal disease in cyclic neutropenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 3-year-old child presenting with lower incisor mobility who was diagnosed with cyclic neutropenia. Gingival recession and splaying of the lower incisors is caused by the advancing periodontal disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Delaney JE, Keels MA. Pediatric oral pathology. Soft tissue and periodontal conditions. Pediatr Clin North Am 2000; 47:1125. Copyright &copy; 2000 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2689=[""].join("\n");
var outline_f2_40_2689=null;
var title_f2_40_2690="Types of lice PI";
var content_f2_40_2690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Types of lice",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three types of lice can live on or close to people's bodies:",
"    <br>",
"     (A) Crab lice (also called pubic lice);",
"     <br>",
"      (B) Head lice;",
"      <br>",
"       (C) Body lice.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Courtesy of John T Crissey, MD.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2690=[""].join("\n");
var outline_f2_40_2690=null;
var title_f2_40_2691="Chickenpox prevention and treatment";
var content_f2_40_2691=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/40/2691/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2691/contributors\" id=\"au4221\">",
"       Mary A Albrecht, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/40/2691/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2691/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/40/2691/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2691/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2691/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2691/contributors\" id=\"de2799\">",
"       Constanza Villalba, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/40/2691?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CHICKENPOX OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Many people remember either having chickenpox or seeing it on someone else. The itchy, red bumps caused by varicella, the chickenpox virus, are hard to miss. Before the vaccine became available, more than 90 percent of people had the infection by the time they were 15 years old.",
"    </p>",
"    <p>",
"     Today, thanks to the advent of the varicella vaccine, chickenpox is relatively rare. This article will discuss the prevention and treatment of chickenpox.",
"    </p>",
"    <p>",
"     Shingles, a painful rash caused by the reactivation of the chickenpox virus in people who were previously infected with chickenpox, is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"      \"Patient information: Shingles (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CHICKENPOX PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     The chickenpox vaccine protects against infection in 70 to 90 percent of those who are vaccinated. People who do not develop full protection from the vaccine may develop chickenpox after exposure. However, their illness is usually mild and causes a less severe rash and often no fever.",
"    </p>",
"    <p>",
"     In the United States, the varicella vaccine is recommended for all children at 12 to 18 months of age. A second dose is recommended at 4 to 6 years of age. Both doses of the vaccine may be given in a formulation that combines vaccines for measles, mumps, rubella, and varicella (MMRV, ProQuad). The varicella vaccine is not needed if a child is infected with chickenpox before being vaccinated. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"      \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Chickenpox vaccine precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;The varicella vaccine contains a live virus, so it is not recommended for children with a compromised immune system or if the child has a fever or other severe illness. The vaccine should not be given to children who have a severe allergy to neomycin or gelatin. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link\">",
"      \"Allergic reactions to vaccines\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Chickenpox vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effects of the varicella vaccine are redness or soreness at the injection site and a mild rash (about five spots). Contrary to popular belief, having the varicella vaccine",
"     <strong>",
"      does not",
"     </strong>",
"     increase the risk of developing shingles.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Vaccination in adults",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most adults have not been given the varicella vaccine because they already had the infection in childhood, prior to the availability of vaccine in 1995. People who had chickenpox in the past are immune to varicella infection.",
"    </p>",
"    <p>",
"     In contrast, adults who do not have immunity to chickenpox can benefit from being vaccinated. In fact, experts recommend varicella vaccination for adults without immunity who are at risk of infection. This includes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Healthcare workers",
"      </li>",
"      <li>",
"       Those who are in close contact with people with a compromised immune system (this includes transplant recipients and people with HIV)",
"      </li>",
"      <li>",
"       Teachers of young children",
"      </li>",
"      <li>",
"       Daycare employees",
"      </li>",
"      <li>",
"       Susceptible young adults in colleges, military bases, or correctional facilities",
"      </li>",
"      <li>",
"       International travelers",
"      </li>",
"      <li>",
"       Women of childbearing age",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     However, women who are pregnant or plan to become pregnant soon, and those with a history of severe allergic reactions to neomycin or gelatin should not receive the varicella vaccine.",
"    </p>",
"    <p>",
"     If you are at risk for chickenpox but are unsure whether you have had the infection, you can have a blood test to check for immunity to varicella.",
"    </p>",
"    <p>",
"     To be fully vaccinated, adults and children 12 years and older need two doses of the varicella vaccine, given four to eight weeks apart; children younger than 12 years old need two doses of varicella vaccine given 3 months apart.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      CHICKENPOX SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The first symptoms of chickenpox usually include fever, feeling ill, sore throat, and loss of appetite.",
"    </p>",
"    <p>",
"     The rash associated with the infection (",
"     <a class=\"graphic graphic_picture graphicRef66287 \" href=\"UTD.htm?33/48/34575\">",
"      picture 1",
"     </a>",
"     ) usually does not develop until a day after these symptoms begin. The chickenpox rash starts out as clusters of small, usually itchy, red blisters that eventually blister and then pop (",
"     <a class=\"graphic graphic_picture graphicRef66287 \" href=\"UTD.htm?33/48/34575\">",
"      picture 1",
"     </a>",
"     ). After bursting, the blisters dry up, crust, and form scabs. The rash tends to form on the face, chest and back, or limbs, and new clusters of blisters continue to appear for a few days. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"      \"Clinical features of varicella-zoster virus infection: Chickenpox\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      How long does the rash last?",
"     </span>",
"     &nbsp;&mdash;&nbsp;New blisters can develop throughout the body for about four days following the first sign of the rash. By day six, the blisters have completely scabbed over in most healthy people. The scabs then take a week or two to fall off, and may leave marks on the skin that take time to fade.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      How does the infection spread?",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have not had chickenpox and have not been fully vaccinated against varicella, you can become infected by breathing in airborne traces of the virus or touching an area of chickenpox rash on an infected person. Chickenpox is highly contagious, and an infected person can spread the infection even before developing a rash or showing any signs of being sick.",
"    </p>",
"    <p>",
"     After being exposed to the varicella virus, you will begin to show symptoms about two weeks later. This period following exposure and preceding the onset of symptoms is called the incubation period. You can start spreading the virus during this period, starting two days before you show signs of a rash. You remain contagious until the last of the bumps have completely scabbed over. During this time, persons with chickenpox should avoid contact with others who might be susceptible. This may mean staying home, away from other children and adults.",
"    </p>",
"    <p>",
"     Although chickenpox is generally a mild illness in children, susceptible adults and other high risk persons may become seriously ill after exposure. These risk groups include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pregnant women",
"      </li>",
"      <li>",
"       Newborn babies",
"      </li>",
"      <li>",
"       People whose immune systems may be compromised, including those with HIV, or who have received an organ or bone marrow transplant",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you develop chickenpox, you should avoid contact with people at high risk for chickenpox complications until your lesions are scabbed over.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Catching chickenpox from someone with shingles",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children or adults who have never had chickenpox or the varicella vaccine can develop chickenpox by breathing in virus particles that are airborne following exposure to a person with widespread shingles, although this is uncommon.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Can you catch chickenpox twice?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who have had chickenpox do not develop chickenpox a second time. However, there are rare cases in which a person can develop chickenpox a second time. In some people, the virus can resurge later in life, causing a related condition called shingles, which is discussed elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"      \"Patient information: Shingles (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      CHICKENPOX DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Healthcare providers can usually diagnose chickenpox just by looking at the rash. In some cases, additional tests may be used.",
"    </p>",
"    <p>",
"     If you believe you or your child has the chickenpox, call your healthcare provider to find out if and when you should come in to be seen. In cases of possible chickenpox infection, healthcare providers must take steps to protect other patients. The clinician may need to make special arrangements so that you",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     your child do not infect other patients. For example, your healthcare provider may ask you to come in at the end of the day, when all the other patients have gone, and may ask you to enter the building through a different entrance than that normally used by patients.",
"    </p>",
"    <p>",
"     Most children get over the chickenpox on their own with little or no treatment. If you believe your child has the chickenpox, check in with your healthcare provider to find out if your child should be evaluated in the clinic.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CHICKENPOX TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are two types of treatments for chickenpox: Those that ease its symptoms and those that target the infection. While most people can benefit from treatments to ease symptoms, not all people who get infected need treatment for the virus itself.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Managing symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Simple treatments can usually ease fever and itchiness caused by chickenpox.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fever &mdash; To manage fever, you can take acetaminophen (Tylenol&reg;). (Note that children should not be given aspirin, as it can cause a dangerous condition called Reye syndrome). Children should be given acetaminophen according to their weight, rather than their age.",
"      </li>",
"      <li>",
"       Itching &mdash; To manage itching, you can take antihistamine medications, such diphenhydramine (Benadryl&reg;), which can make you sleepy, or loratadine (Claritin&reg;), which does not usually cause sleepiness. Skin treatments, like calamine lotion and oatmeal baths, may also help with itching, although there is scare scientific evidence that these remedies work.",
"       <br/>",
"       <br/>",
"       Scratching the skin can cause a skin infection because bacteria hide beneath the fingernails. Scratching may also increase the chances of developing a scar. Fingernails should be clipped to reduce these risks.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Targeting the infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;A medication called acyclovir (Zovirax&reg;) can help shorten or combat the varicella infection if it is started within 24 hours of the rash developing. This medication is not necessary for everyone who develops chickenpox. However, it may be appropriate for people who are at risk of developing a more serious illness, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Adults and children older than 12",
"      </li>",
"      <li>",
"       Children of any age with chronic lung problems (such as cystic fibrosis) or chronic skin conditions (such as eczema or atopic dermatitis)",
"      </li>",
"      <li>",
"       Children of any age who must take steroid medications (also called glucocorticoids) or aspirin on an ongoing basis",
"      </li>",
"      <li>",
"       Children or adults with a weakened immune system, including transplant recipients and people with HIV",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Acyclovir can be taken in pill form or as an injection. It is generally well tolerated but can cause stomach upset or headache. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link\">",
"      \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CHICKENPOX COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Most people who develop chickenpox fight off the infection without additional complications. Still, complications can arise, especially in adults and people with compromised immune systems. People who develop serious complications of chickenpox are usually hospitalized and treated with acyclovir.",
"    </p>",
"    <p>",
"     Potential complications of chickenpox include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Skin infections",
"      </li>",
"      <li>",
"       Pneumonia, an infection of the lungs (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"        \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Encephalitis, inflammation of the brain",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Children with a viral illness should be given acetaminophen for fever to avoid the complication of Reye syndrome, a rare condition that can cause severe brain and liver damage.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      PREVENTING INFECTION AFTER EXPOSURE",
"     </span>",
"    </p>",
"    <p>",
"     People who have not had chickenpox or who have not been vaccinated are at risk of getting sick if exposed to a person with chickenpox. However, infection can be prevented.",
"    </p>",
"    <p>",
"     If you or your child has been exposed to someone with chickenpox or shingles, call your healthcare provider immediately and ask what you should do. The varicella vaccine can be given, even after being exposed to the virus. If you cannot take the varicella vaccine, there is another injection (varicella immune",
"     <span class=\"nowrap\">",
"      globulin/VariZIG&reg;)",
"     </span>",
"     that can temporarily protect you from becoming infected. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"      \"Post-exposure prophylaxis against varicella-zoster virus infection\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      CHICKENPOX DURING PREGNANCY",
"     </span>",
"    </p>",
"    <p>",
"     Coming down with chickenpox during pregnancy can lead to complications, such as pneumonia in the mother, or in rare cases, birth defects in the baby. Chickenpox is also very dangerous for newborn babies, so pregnant women who are not immune should contact their healthcare provider right away if they develop any signs of chickenpox or if they are exposed to someone with chickenpox or shingles.",
"    </p>",
"    <p>",
"     Pregnant women who are exposed to the virus cannot receive the varicella vaccine, but they may need to take varicella immune globulin (VariZIG&reg;), an injection that can help to protect against infection. Pregnant women who get chickenpox need to be closely monitored for signs of infection",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"      \"Varicella-zoster virus infection in pregnancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193301\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193316\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=see_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/37/30289?source=see_link\">",
"      Patient information: Acute cerebellar ataxia (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193324\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/12/13507?source=see_link\">",
"      Patient information: Shingles (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1193332\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33480?source=see_link\">",
"      Clinical features of varicella-zoster virus infection: Chickenpox",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4278?source=see_link\">",
"      Varicella-zoster infection in the newborn",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22278?source=see_link\">",
"      Epidemiology of varicella-zoster virus infection: Chickenpox",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41016?source=see_link\">",
"      Post-exposure prophylaxis against varicella-zoster virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Allergy and Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"      www.niaid.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC) National Immunization Program",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/nip/default.htm\">",
"      www.cdc.gov/nip/default.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Foundation for Infectious Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Tel: (301) 656-0003",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nfid.org/\">",
"      www.nfid.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Children's Hospital of Philadelphia Vaccine Education Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.chop.edu/service/vaccine-education-center/\">",
"      file://www.chop.edu/service/vaccine-education-center/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/40/2691/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/40/2691?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2691/abstract/1\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2691/abstract/2\">",
"      Macartney K, McIntyre P. Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults. Cochrane Database Syst Rev 2008; :CD001833.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 2000; 105:136. (Updated May 16, 2006).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_40_2691=[""].join("\n");
var outline_f2_40_2691=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CHICKENPOX OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CHICKENPOX PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           CHICKENPOX SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           CHICKENPOX DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CHICKENPOX TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CHICKENPOX COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           PREVENTING INFECTION AFTER EXPOSURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           CHICKENPOX DURING PREGNANCY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/48/34575\" title=\"picture 1\">",
"           Chickenpox rash PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_40_2692="Inguinal anatomy sagittal section";
var content_f2_40_2692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Inguinal anatomy sagittal section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 508px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH8AdsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiimSyxwrulkSNfVmAFAbj6Ky59f02EHN0rn0QFv5VRfxMH4s7G4m9z8o/TNYyxFOO8jaOHqy2idFRXKvqmtzf6q1hhX1PJ/U/wBKhaPW7j/XXxQf7Bx/LFc8swpLbU1WEl9qSR2FQy3VvF/rZ4k/3nArkxo0kn/HzeTPnr8x5/OpY9Cs16o7n3Y1i8yXSJX1aC3l+BuSa3psf3ryI/7p3fyqtJ4m0xekrv8A7qH+tVY9KtF6WyfiM1OLOFRxDGPoorN5hUe0R+xoruRN4ssv4Iblj/uj/GmHxSp/1dhcN+OKuLEB0UD6CnBKj67Xew+Wivs/iUD4nn/h0ub8WP8A8TV3StbN5K0dxayWx6hicqfbOBipNgpCgprGV07vUUo0mrKNvmzVBBAI5FLWSjvH9xiKtQ3fRZeP9oV2UsdCektGc0qTW2pcoo60V3GQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVQv9WsrIETzrvH8C/M35UpSUVdsqMXJ2irl+iuUuPEtzcHbp1rgH+OX/D/APXURtNR1Dm/u3CH/lmnA/KuSeNpx+HU6VhJLWbsb95rVhaZEtwhYfwp8x/SsqTxO0p22FlI57M5wPyH+NLbaNaQYIjDN6tzV5YEQZVQv0Fck8ZVl8OhooUYdGzLZtbvB+8uUtkP8MYwf8f1qMaDGW33U0s7dyxrcRR3pJOmFFc03OSvJlKs1pFW9ChBYWsH+rgQH1xk/nVsL6U7FJzWHL3E5N7iBacqA0m1qdvVRyauMF1RLfYUAdhS4qJ7hR0qFrlj90VblGIKEmXMU1mUdSKzpLk/xSKvtnmoXk3DgSt9BxQnKXwRbK9mluzUMyDvTDcIO9Ys10sX3/LT/fkA/rVKXVoF+/dQj/cBb+lWqFd/ZsWqcXtqdN9pSmtcqen865F9etQcBppT/sqF/qap3niiKD76JAPWaYL/ADAp/VsR5Gioo7g3APQD86a1wcdBXm8nja1Q/wCvgb/c3y/+gZqtJ49VfuRu4/2YiP8A0MioeDrPeS+//gGqwreyZ6xZal5bBJj8h6H0rZBBAI5FeEN4+uT/AKq2Yj/aCj+W6uo8CfENbq+TTdWjEPnOFgl3ggMf4T8oxk9OvJr0MG5UlyVJJ9jDEZdVs6kYPTc9Qooor0DygooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoqlqGqWmnr/AKTMA3ZByx/CsV9bv9QO3S7bykP/AC1k5P8Ah/OsaleFPRvU2p0JzV0tO50VxcQ20fmXEiRp6scVh3niaEMY9Phe5f8AvYwo/rVJdEaWXzdRuHnk9Ca1bWyghXEaBQPSuGeMnN8sFY6FSow1k+b8jHdNY1M5uJjBEf4I/l/z+tTW2hwQ4Ljc3vW0g2kgDilkGea5pKU1zSepft2tI6LyKsUMcX3FAqXNPjQMKkKqoyamNJ2uZOd3qQqTnipApPWkiIJp7OqjLECtKcU1dslt3EKhRzTcZ5qCW9TOEBY+1Vp7woP3kix+3U1ag5v3FdDs1uX2KKPmIqtJcqCQtZUmoxDoHkPucCsy+11bdSWkhhUdT6fUmtfqkpbuxcV2VzoXnYgnkiqr3aqeXQfVsn8hXCan40s4wdrTXDfkufqePyrnNQ8aahNkWcUdsn94je31yeP0NP6vQh8Tv/XkddLB4ir8MbL+u56tJqKL0LMfYBR/U1h6j4v0+0fZLd2aydNhkDN+WSf0ryK7uLvUsm8u7i4z/C0hKf8AfI+X+VNit1hXCqsa+gO0fpz+tP2tOGkIno0slk9akjv9R8dIufKnm2/9MYSv6ttH61hT+L5ZyfKgnmz3knx+gDD9a50omd212b1WPB/76b/GoZJrcNtkWMseiyyb2/Ac1LxEnsjvhldGC1ZrS+I7tyVU2cXsMl//AEL+lQyajqEn3ru4PtHEI/1AX+dJb2t+6Ax2cscf96RBCv5uRn8qla3CD/SNQtUP92MtIR+QA/Wj99LYprB097P8f8yqRO4Jka4f182bOf51EkUKnP7lW9ASx/IVNNJpcX+turqVv9hEj/U7jVb7dZyvstrCe5b0eaRj+SFR+lHsZvdh9box+CP4WJJGij+8GJ9o9v6tTrdmuDi0hklb/Z2sf/Hc0sYv1ObfTLO09GkjjVh+LfNUskuqSqFn1gADjagdsfoBT9gl8TJ+uzl/Dh+b/JE39lai65e3mjH+0Sv88U0aRKvzTT28OP4nuACPyJqkbWNj/pF9ez+y4QH+dKLWzTkWgJ9ZXZv5nH6UctJdQ58XPZJfL/N/ofSfgm+k1Hwtp9xNPHcSlCjSochypK5zgc8c8da3K8c+DWuG31BtGdkW1lUtBGMAK45OPqM/iK9jrupTU43R8ljsNPDVnCfXX7wooorQ4wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorO1LWLPTwRNJulHSNOW/+tWDNe6pq7FYQbS274PJ+prnq4mFPfc3p4ec1d6Luze1LWbPT8rNJul/55py3/wBasRtQ1bVCVt1FnAf4v4vz/wAMVPY6LBb4Zl8yTqWatdVCgACuKderV0WiN17Kl8Ku+7/yMW10OGI75g00nUs/PNakO2MYAwPapyeMCmBQKw9nyu6YpVJT+IQ/Oc9qULilXFLmqUVuyGxQKCR0pjNUTTLHyxpuaWgKLZKTt6VDLKq8uwFVLu+C/eby1/U/hWLeaqsSl8pEv9+Q8/rWiw86m+i/roUkbc10+3KYRf778Vmz38Yz8zTN+QrFW5ub45tILi6J/iwVUfif6VdttEvpzm6uY7ZP7kI3N9Cx4/KuungoR1av6/5CdRLr9ws2oSlTlxGvovFcrqXi6xtiywB7uUdo8Yz7seB/P2rE+JkUun6ptJnFisY27nYrJ6s3bOTjoRXLW/n3cPmWlnPcJ/fWMrGP+BtxU1K0k+WCPaweX0p01Vqysn0/4JtX/izVrskRNDaRnosS72/Fm4/IVhyRz3Em+eSWV/70jk/l6VYS0um5luLGzX0LmZ/yQEfrUn2WxX/j5vL67P8AdiVYF/8AZjWLjVn8TPThPCUP4cbvyX6sqNHHEN0sqp7k4/Wm280Ez7LSOW7k9IozIf0FW/tFpb/8emm2cbf3nXzn/N81DcapcuhElzIE/uq21fyHFCoLqy3jZP4Y29Sw1tqOMvbwWa+t3OqH/vkZb9Kj+zRA5uNWkf1Sztwv/j7/APxNY0+pKvEY3t+dAttSucbx9njPO6Q7ePXHU1pGlBdDmniK0nZy+7+rmjcHTIjua2eYjp9quGf/AMdXaP0qIeIpIAUsRHbKeMW0Sx5/IZNRQabaRn96813IOyfKv59f5VdQGMbYlhtF/uxLlvxbrSdWMNvwHHC1Kusl95SI1K7bfIpjU/x3DY/n1qWPT42/4+buSX/ZgXaPzP8AhU5Vc5AJP95zmpxZylBJL8kZ6NIwRT9M4z+FZ+2lL4UdH1SlTV6kv0IYoLGA/u7SNm9ZiXP5dP0qwb2YrsRhGnZVGAPwFNH2GHhpnnb+7AnH/fTY/QGmS6kkOfJtoIsdDKfNb8un6Ucs38Tt/XkNTox+CF/l+r/QVElnfaivK57AZz+HNTGwljH+keVAB1ErhSPwJz+lZcupXk4Ia5cIeynaP++RxVCaaKLmR1HuxxQqUeoSxFR7WX4/5HQE2EY/eXrSe0EZI/NttRm+tFwLayLn1mkJz+C7f51lx2l3JEssdrIIm6Sy4iQ/QtgH8M1ZSzjT/j5vN57x2qkj6F2Ax+Cmr5VHp/XzMeeU/tN+n/A/U7r4YXU114tsYglpCilmZViG84QnrjPp1Ne818sWd29g+6w325/veYWb8+n4gCvTvhZ41kaeLRdWlLhuLaZzkg/3GJ657d+3pjalXjflPKzHLask66W3Tr6nrNFFFdR88FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFUtbnkttGv54G2yxW8jo2AcEKSDzXl3hPxT4h0/wADx+Jtci1+/i+wQXc39oy6dDCysFLtbi3HmFsElUk254GQxoA9eorye28f65e+JdFu7axs18P3ei3WpyQG83SmKOaICQbYj+9CN/qtwXLsCwKglNI+LOoahb2sx8JXUaXslqlrIzTxxP57lQDJLAg3L8pwm9SDw3FAHrNFec23xB1Qa01rqGgWcNnDq0ejT3EWpNIyzvAku5UMK7kG8DJKnvjsOX1v4o3Otafqen2lsbJhDb3tpqFlPcbJovtkUbbWkgiyCHHKF1IJGfUA9uooooAKKKKACuW8R6tcC/8AsFm/lYA3yd+ew9K6muH1pP8AiprnPG5VIP4CuHMKkqdFyidmBhGVT3uxNp2kIku+Vt565PU1uRgR4G35R2Fc8gniB8uQmpI727iI80b1rwI4uKXvJ3O6pSlUd73OhL7uBwKljA7nNZsN5E6glsH3q3BMjEhHGfSu+jWUpanDOm0ti0wHaomUinqeOTzTJHAFdNSzV2Zq43cBxTJJFUZJxVe4uAoLAjA/iPArB1DV0WUR26tPO3Cqq5J+g/xrKFKrV0ijWyWrNme8VU3MwRT3PesG81xPN8m1V5bj+6g3P+XQfjThpNzcqZ9Zuvs8WMmKNsED3b/Co11axsIzBoNj5zDjcq7V/Pqa9Ohg409XqzKVXohqaZql588zrZqevHmSH+gqX7Ho2lMJLtkluAM7rhvMf8F9KpynWdR5ubg28X92L5f16/rS22l20R4QyuTkk85NdiikZOTe5c/4SMScWlrLIo4DNhF/rSf2hfz/AHikI7bRk/rViOBEA3gKPQdar3j7WwmI1x1PWnoSZ+q2zzWzmSctLjK+YAwB9gc4rzvUftM05FxK7kHjc2a7i/u18mQREs2CN3p+NeeahcYcguAO+KxrI9PL3qyGUxx8E7m9BVK4uMA8hVFNU3F0zLZRblH3pXO1F/GpBYWyH/SZHupv7q5VB/U/pXJKSjuezTjKbtBXKCSS3LlLSJpG6k9h7n/69KdOLOPtcpYd1j6fTP8AgCK2AzMgjULHCP4EGB+lNZVU5OB61zyr9Io76eBb1qP7v8yvbRrAo+ywpEf7/wDF/wB9Hn8sU8wktmUlyefQVox2hVd904t0PIDDMjfRf6nAqGa/tbZv9HiUuP4pTvP5dB+RqXGctZaFxq0KWlJXfl+r/wCHCCzmlTcoCQjguTsQfif5U1/sUDYaSS4buIl2r/303+FU7vUbi5YM7E4GA0h6D2qjJOO5Ln8hVKEV0uRKrUnu7en+f/DGq1+yc2yRW/8AtKNz/wDfR6fhiqFxOHcvIWkc9WdiSafbWF3cRCYhYLbp50p8tPwY9foMmpxBYWwxma8kPdf3KfmwLt+S1o7210RguXm9xXf3v5v/ADZlTXD9C2wHoF4J/rVmLR791V5YBaRN0kvG8oH6KfmP4A1pW1xPCp+xxw2uf44U2tj/AH2y/wCRFMiheWbC75p3/ugszfj1NZupFbam6oVXrJqK+/8A4H5lT+y7VH/0m8uJ1/u2y+Sp/wCBMC3/AI6Ks23l2pzp1pBbN/z0VN8v/fxskfhitqy8N3VwwMxjtl/2zub8h/XFb0HhXT41H2l57hu+W2L+Q5/WqSqy8v6+8xnVwtPe83/XojgpW3zFpnaSZuMuxZmP9a0bPQ9XvCPs+nzKh/jmxEv/AI9yfwFei2MNlYrtsbSGJvVEAJ+p6mrBkkc5Jq1Qj9p3MJ5lU2pxUV5/0ji7bwLeOwN7qFvAvdYUMjf99NgfpXQ6V4U0SxmjkkFxdyqQQ00p6/7owv6VqfU0qlcjnmtIwjHZHHUr1qqtOb+Wn5HpVnJ5ttG/qBU1Z+hPv06I+gxWhXSj56atJoKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFADZI0ljeOVFeNwVZWGQwPUEVg6f4K8K6bJv07wzolo+5X3QWEUZ3KdynIXqDyD2NdBXmHxA8A6l4h8R3N9aJpUwuLWCC3uryR1n0l45GZpbcKhBZgw/iQ5UZJHFAGxBJ4TutDv9dHh+08rQry9k+ayi8xJ4JGEssXozNGSGyCeCcGrvhrRPCkga70fw3p9nI7RTs40xYSzlRIjBtoDkbvvKThsjOQa8+b4VavJqmqTpBodpJPcatOL+GZ2uLtLsSiOGYeUNqL5isfmflOB3q1d/DTV2vXuJYND1e1N5DcNpl/M6284Swit8v+7cbleMsoKsMHsegB6odJ04uzmwtN7XAu2byVyZgoUSnj74AA3dcACs6z8G+GLJpms/Dmi27TDEpisYkMg3BvmwvPzKp57qD2rx3Svh34nuvBCQ6dBp1s+p6DDpdzFqDy272rRzyvuVBG24ESYwSuMA89K6fw78N9U034nS+Iru5iuYWvLm5W4W4jSYxyhtsLp9l3uq7gADPtG0EKMBaAPWaKKKACiiigArj/E42eIbd+zQ8/m3/wBauwrlPGC7dR09/wC8GX9R/jXFmCvh5HXgn+9S9SFWHrTxyaqhTnirADha+UjK56clYQRKcnpUciMoLIxDDoRVgfcFNNXKCBSYy21S6VCCoYjvmo9R12KOMszbmHHHQH096hl+Uvj1rl7WZl8QXGQsgiRDGrjIUndk/pXrZZRdde/J6GGKcafvJHQW1vqesfvrljY2HXe/32HsO31q3FcW9mpg0K3DMeGuH5z9T1NZ0uqXWqarDZSlRbtCZnC8ZwQAPpzW7awoi4UAYr6KMFBWR5cpOT1KY0w3Ugl1GVp267ScKPoK0I44YRiJFGPQdKVunXioGm/hjGT61RI6VV5aVsD0qINxiMBE9T1qN2CndIdzfyrMv9RADBTkjsDgChK4Fm9vkgUiL55PX0rndQvAoMlzJkdh2/8Ar1DcXxb7h3HGcngAev8A9c8Vz2p6nalsNm6k9ATsz7nqfwwPc0p1I0leTOjDYWpiZctNXIdS1W6vS0dhHiIHa0rHai/j/QVj+TbxPudjeTDqWGIx9F7/AI/lT555bkjeflXgKvCqPQY/pTVTaPmP6cV5VXFOT0PrsHlUKS9/X8v+D/WgsjSzY8xiQOijgD/PtTgFUYwB7VYFsUjD3LeQrDKgjLuPUL6e5wPeoZNRS3JSzUo/d85k/wC+ui/hz7msVTctZaHZLEQguWkr/l9/+RN9mKE/an+zgdVIy5/4D2/HFV5tTitgVs02EdXzuf8AFu34Y/Gsq4uSQd7fL/dXp+J71Dbw3N7MIrSFnbGcAcKPU9gPc1tFJfCv8zlqNz1qu67bL+vUluLx5STI5APYHr+NNtUnu5hDYWzySnsq5NaFvpdlakPfzm5fvFAcLn0L9/8AgIP1q5NeyPbmCJI7W0P/ACyjG1T9e7H6k0nKMdxxhUqfAtO7/r/geZnJpYT5tQuhuH/LKDEjfic7R+efarUEkcHFlbRxH/now82T/vojA/4CAaWCGW4lEVtDJNL2ULk/kOlbln4Zmfa19cCL1ii+dh7E/dH60k5z+BWHUVCj/Gld9v8AgL9TCkUySeZPIzOeNzsS35nmtCz0S+nI8u3ECHnzLj5c/QdT+VdhYabbWRBtYFjcf8tD8z/99Hp+GKuhAOSee5PWrjh1vJ3OapmUrctKPKvx/wAvzOes/DNtHhruSS6f0/1cf5Dk/mK2IbVIk2wokSf3Y1Cj9Ks7lHQZNKBI3QYrZRS0SOCdSc3ebv6kaR7emB9acwUDLMSaXy1B+d8n0FPUR9hmnYjmIo2OfkTj1qTEh74qUey0EE9wKdhORFsPdjUkaDPAyaULjvUybCBkgUJEuR3Hh1s6eoxjFalY/hp0NltTOF7mtit1seNV+NhRRRTMwooooAKKKKACiiigAooooAKKKKAPIZPjKY59TQaLFcRQWEt/aT29xOIrpElSMgPLboP+WgOUMi8EZ6Z1B8RdTOtv4fGg2P8AwkK3f2by/wC1D9k2/Z/P3ed5O7dt42eX15zjmt7Vfh54Wv8ATtStY9E0+wbUI2iuLmytIopnVmDMC23nJUZznOKv/wDCH+Gv7IGk/wDCO6N/ZYl877H9hi8nzOm/Zt27vfGaAOFj+LV1c28t5Z+HopNPtLSzu7yR9Q2ugnlkixGojIk2mNiDuUMPSmS/F+4C63cweFr6bTdPjvmW5C3CqzWwYkSOYPKQMUYArI5BwCAeB6T/AGFpHlSRf2XYeVLHHDIn2dMPHGSY0IxyqknA6DJxUC+F9AXVZtTXQ9KGpThlluxaR+dIGGGDPjJBHByeaAOU1D4jvDrTaZY6Sl3cebYwqftgQbrqOZxu+Q4C+UM9SQ2QOAC22+Il82pRQ3GhQC2k1CXSQ0Oob5jdxxs7ARtGuYyUYB9wOMMVANdXpvhTw7pYA0zQdJswJFlAt7OOPDru2t8oHI3tg9tx9TUreHNEbVZdUbR9NbUpUMcl2bVDM6EYKl8ZII4xnpQBwNr8Rr+9l0uK50trG/k1JLaTT4Z384Bra4lCyrPbJwTDgeWcEjIfAIbpvAPiu58TLfJqGnxaZeWvll7PzJmmjDgkeYssMWPunBXepwcMR10rHwl4bsLcQWPh/SLaAS+cI4bKNF8zaU34C43bWZc9cEjoas6HoOj6BDJDoWlafpkUjb3SztkhVmxjJCgZOKAMqbxVdxyug8J+IpArEb1S3w3uMzdKZ/wlt5/0KHiT/vi3/wDj1dVRQByv/CW3n/QoeJf+/dv/APHq53xd4nupDYufCviCPZIfvpBznHTEvtXplc742X/iWwP/AHZh/I1z4pXpSOjC/wAWJxcfiW6DD/iltf8A++IP/jtWf+Enuv8AoVfEH/fEH/x2t5FywxVk5xxXykJRt8J6M733OTfxNedvCviDH+5B/wDHahPii7z/AMivr/8A3xB/8drsyOKrOoyaqbW9vzHFvucZN4lucMT4Z14cE/cg/wDjtc9p2uzvrt7IPDutOfKj4CQ5HLdf3nrXoV0MRSk9Nhrm9BJXxDegd4I//Qmr3soS9ndK25z4y/cu6e//ABU8Q27f9APHp+8FdTG2B7Vy1mn/ABVzqeos8Z/7aV05wicngV7LPOYSEydOFFU57uOMbY/0rN1HUWkYojeXAO/dqwr3Udsb7DsQD5mJxx7k0W6saTbsjV1HU1QFSct/dB/me1cvqeqRxf698t1WFOv/ANb6n8Aay9Q1YvmOzY89Zcf+g5/mefTFZW3adzEkk8k8kmuGtjVH3aZ9DgcjlO08Rou3UtXl9cXg2M2yMnOxeh9z6/j+FVQi8gcnvUkUUk7qiIxLdEXkmpwYLZRu2Ty9o1P7tf8AeI+8fZTj37V5/v1Xds+h/dYWPJBfJf1+LC3tZJYzJlY4U4aWQ7VB9Pr7DJpj3UVqwNuGLjpI4+bPqq9B9Tk/Sq2oX5yGuZeRwqgYx7Ko4A+lZMlyZAf4F9M8mtYxUdjnnOdT49uy/Xv+Rbubt3ZjI7bmOW5yx+pql5jyusUCFmY4CqM5P9at22mySqstyTBARuBIyzj/AGR3+pwPer6ypChjso/Lj7tnLN/vN3+nA9qbajuEIOppFafgVLfSkjPmag+SP+WSMM/8CboPoMn6Vbaf9wIIESK3ByVUYUn1Pdj9c0lvBLdTrFCjzStyFUZ/T/Irp9N8NJHiTVJPm/54Rtk/8CYdPoPzqVz1NtEVUlQw2s3eX4/JdPX8Tm7a3luJdsETO/c46D19APc1v2Hh9M7rtjM5/gQ4UfVup/AD610CwqiCOGNIYR0VRVmKPAwo/E1rCjGO+pw18fUqK0dF/XX/ACIba2jt4BEipHH/AHIxtU/XufxzU6HkALx7U/ywoy36mmPMi8ZH8hWxwb7EoDH2preWD8xLN6Dmq7TlugZvrwKdG0h4C4+gxRcOVk4LfwIFHqaQgH77s3sP/rUwhv42VfqaTfGODKT7CmFuxIML9yMfiaUGQ/xov0GaYHX+GN2+tKHk7RgUCsP2sesjH6YpwQj+JvxNM3Sd9o/GjJ7lfzoFqS4+lOGMVBv/ANpamScYx8p/GgTTOx8HshtJVXO4NzXQVz3hAhreRlGATXQ1tHY8fEfxGFFFFUYhRRRQAUUUUAFFFFABRRRQAUUUUARXdzBZ2k11eTRQW0KNJLLK4VI0AyWYngAAEkmodK1Ow1ixjvdJvbW+s5MhJ7aVZY2wcHDKSDggj8Kmu5XgtZpYoJbmSNGZYYioeQgZCqWIXJ6DJA9SK8U0rwf4tbwXpNi8esaZcad4ZltooLbVRAP7RUgRE+VLtYEAkFjtwcNjpQB7TbXdtdPcJbXEMz28nkzLG4YxPtDbWx0OGU4POCD3qevC5/CXjG0j8TnS7fVYtS1C/hvWuk1LMU8JjtxLEkYuIys29H+YeX8g2iQDArc8G+GvFL6ppI8Q3uujS4ba7aRJLwwsJTPC0KNsuZncBRJhjIx2/KxwSCAesVSudUs7bU7LT55tt5eLI0Ee0neIwC/IGBjcOpHWvHrDw3470rw7a+Wmrajfz6Gsd/Dda3Ix+2+dFko3nqVYRmU/I6K2MFsnNX/h54e8XQa1o914lhumis7rUNj3VyJHjgljg8sHM8zfeEgwZHIx1xigD1+iiigAooooAKw/GSbtEc/3XU/rj+tblZfihd+g3Y9AD+TA1lWV6cvQ1oO1WL80YkL8K3qKmMg7VTtTutoj6oP5VZjQlgSK+NTadkevJLqWP4c1Vd+WGKsnpVOfjJq6j2Jpq7M7UnxZzH2A/M1zuiceI7z/AK9k/wDQ2rd1dv8AQH92X+YrD0YZ8RXn/Xqn/oZr6PKV+5i/X8zmxm7NSzH/ABWEw44sV6f9dGrV1m4Ftp8jmsqH5PGE/wD14x/+htUniQl7B89K9c8/qcJeay5nYYyucVyy68mrOpmfyl6pDn5R+Pc+5/TpWnqACzED1rzONzGgGOCM1wY2UtEfS5HSheU2tUejbdi9MCnxwkxmaQiKHkB2GSx9FHf+XqRWB4YvXaGczjzlhRTHGxOMlgOe+Oa3pGa5IknO5iMYAwFHYAdh7VxQpreR7lbESvyw08/8hxl3xtHCvlwsMNzln/3j6ewwPr1qjeTeQv7sDd/eParE7iJCT+VYtzIZSS3T0q2zGMUlcrIJLm5CQo808hwMDJNbtja2+nAyy7bm7/hPBjj+gP3j7nj68GoZb+20WytIooZfPuoPNllRdxwWYbfYcdB171DZ30V3NEke/wA2ZgsYdcZJ6c9B+NKUnF2W46UI1Fzz2/rf+vXsXJ5GlcvMzEsc8nJb61uaX4bnuFSbUG+yW55EYH7xh9O31P5Vt6NocWmhJW2z3x534yqf7vv7/lWwsBzulJLHnmtYULaz1ZyYjMHL3aOi79fkVrWGK1hMVjCtvCfvMPvP9T1NOTJ4iXPq5qwyqfvcj0qGSfHEePrWzOBeQ9UEY3yNk+ppPtByfLX8TUYBf53Ofc0pP/PNST6npSC3cGVnO6R6bvhQ/KNx9aQruPzuWPotAKqcAKP1NBQ8SO/3IwB6mnhS335W+i8Uwlvp7saaWB6szeyigViTZED0BPuc04Sxr90AfQVX3KP4V/4E1OEuOjov+6tFw5SwJSeisfwp3zHqh/E1V81T1nf8Bil3xf8APWQ/jTuLlLPl+qgfjR5a98fnVcNGekjD8anQuBkNuHvzQJpocI0PTbUoAAxtX8qjznqo/KpFIPtTIdzsfB7yG3kVxhQflroq53wj/qHwc10Vbx2PGxH8RhRRRTMQooooAKKKKACiiigAooooAKKKKAKetala6NpF7qeoSeXZ2cD3Ez4ztRFLE478DpXnevfEW687S4LDSNZstQ/tC0E+nzx2/nXFtMk23YfMKDLREZLKQVOcV6Ve2sF9Zz2l5Ek1rPG0UsTjKujDBUjuCCRXKr8N/DC2zRLaXuTLFN5/9p3Xnq0Ssse2bzPMUKHYBQwAyeKAOYuviU8urNc2bT2thFZSLPaXFskkkN0l9HbsGCuMkbmHEm3nPzdDsXHxR0yBpZG0nWDp6i88q/CQ+VObVHaUIDLv/wCWbAEqASOuOa1o/AHhmO0jtk0390kRhGZ5SSpmEx3NuyzGRQxYkknqeTVG4+G2it4js9UtlkiiR7p7izeWWSCb7QjLJtjZ9keSxY7V+bvQBFr/AMUdB0IN9vS5RvItJ0DGKMP9pMnlrveRUUgQuSWKqBjk10HgzxPp/i/QYtW0kt9nd3iKsyMVdGKsMozKeRwVYgjBBNc5ongnwVcnVrfTYLuWa1nhs7qR7+7MsMkKCSJUlZ9y7VmGChHDYzxgdppWnw6XYx2ls908SZw1zcyXEhyc8ySMzHr3PHTpQBbooooAKKKKACqOtrv0e8H/AEyY/kM1eqG+XfZXCf3o2H6VM1eLRUHaSZx2nHNnD9MVog8VlaUc2MftkfrWiqEr1r43aTR7VRai5Lk88VHOuEOamjGBg0y54iak1pdkp6mDrP8Ax4n/AH1/nWLoa/8AFQ3vP/Loh/8AIhrZ1k/6Dn/poP51laCM+Ib3/rzX/wBGV9Nlf8CHz/M5sXuy+n/I3T/9eUX/AKG9S6+CdNmx1xmoUP8AxV1z7WcX/oT1Z1vA0+bP9016p5/U8ku3LXJJ9R/OvOXHyAegxXot2uJHbpz+deeyIUaQ9g7Aj8a8/HdD6bI/t/I3PCJLPdxDGDCMHHpIldMCQu1R06muZ8JKVmuBzxCRkd8uv+FdIqMVAPyqK5U9EevJe/L+uhWviBFhcknqay5UGBvYjnt3rX1DCQjHHNZRyWBx36mmhMk8QsVurCMA7VsIz+byUnhvDeINOBAOJ1/+tTfETgavAmeljB+qk/1pvhrH/CSaX2BuUH5nFTL+L8x0/wDc36M90gMUNhBJtzI0a/U8VSkLOxeQ4HXAqVZ4orODI3SFBwKb5Mko3yDavpXfPex85R0imyo7NJwg+X17UihV5HzH1PSnzsOikBB1JqJdz/6sYH95v6VmdS2HMwHLY+rf0FINzngEj1bgflSEJGcnLv6mo2kebjPy+3A/OkNIkJVfvvu9l4FMMwHC4HstCwezN9BgfmamW3mP3IVX3Y0aheKK4YseASaeI5G/5ZsfrxVkWtw3V1UfWniwY8tOPwp2E5pdSqsMn/PJPxNSKsy9IYjUrWRHSQ1Gbdx1dqLC5k+o4PMOsC/hR5rfxW/6UCCQfdmP40H7SncMKYtGHmx94SPwpwkhPQlTUf2iQffQ05Z434ZV/EUXBx8idcEcNkVIoI7ZqKMRjlRjPpUq8H5TTM2dl4SB8hyRgV0NZXhlCulRlup5rVreOx4tZ3mwooopmQUUUUAFFFFABRRRQAUUUUAFFFFAGZ4ohvLjwzq8OllxqElnMlsY32MJShCYbIwc45yMV5a3grxTbG9ls9Q8QvNDbaZJZiXXJXVrkSn7XuVpcMNgX5WGzk7RXstFAHj8mneO/tosGh1sWsN7qszajBfwkywzRzfZljR5QSyF0AVwqqyrzjkVNN0TxjHZWKalp/iCbTYbuU3Fvba28V9cqYlEchZrxwiq+8FFnAPDbRyte10UAeHaz4W8aI1++jQ6hbWN1rEl1Jbx3ebmSI2VtHGxdLuEna8cgYGbJODhhXq/hm31S28H6fb39w82rx2io813GoYyhesio7DOeu1znnB71tUUAcr5Hjf/AKCPhv8A8AJ//j1HkeN/+gj4b/8AACf/AOPV1VFAHK+R43/6CPhv/wAAJ/8A49R5Hjf/AKCPhv8A8AJ//j1dVRQByvkeOP8AoI+Gv/ACf/49TXt/HDIy/wBo+G+Rj/jwn/8Aj1dZRQB49pMXi02pCX2ggBiObOY/+1a01Txht/4//D//AIBTf/Ha0dNXY9zH/dlI/wA/lWsEAXGK+QnJqpJWX3Ht1ErnMKnjAk/6f4f/APAKb/47UV3H4w8vBv8Aw+fpZTf/AB2ulYYYgVHOhKcVk60rWsvuFGCunc4fVovFn9n/AD3uhFd46WcoPX/rrWbocXig6/diO80QSfZASWtJSMb/APrp1rtNZGNNPs6/zrJ8ND/ip73/AK8v/Z6+kyuXNQj8zlxUbNmUsXir/hJrs/bdD8wWsWT9klxjLY482ptUg8WPZyeZfaHtxk4s5f8A47W1CN3iu9/69Yv/AEJ6uarFus3A4GDmvWODqeH38evGRybjTML6W8mP/Q64uaDVBPdZmsuJWU/um65P+1XpuqHdPIifdWuE1An+09Qj6ZuZMf8AfRrgxuiR9HkkVKUk2aXhHfGJjMyFhCMlRgH516CuiWU7enJ6VznhQlrm7BwMQ/8As610O4/w8e/c1xrZHtte/L+uhBfriMM559Ky5mU7d2dueg71o3/+rBY/hWbI4GCQOvHFUiZaDvE8f/FQTD+5DBEPwhSo9BJ/t3SyeGF3CD/32Kt+KVB8SagM/dkUfkiiquiqD4g0rHDfbIR/5EWob/e/MuCthF/h/Q930+C3jsIp5CC5XuenNVbu7MpKxjj0pIY5JII0A+QEgn8TT2VIxgYJHfsP8a9Ge7sfMUUkk3qyp5QyGlO49h2FKN8nEaZ/3qmYjjcDnso6n/CrNnazXB2hMf7I6D61CRvKdldlEWiuf30jOf7qcCrVvZjIWKLn0Aya6C00qNFBk+c+g4A/GtCOFVwI0B/DC/8A161jSvucVXHJaR1MK30iVjmQhPr8xFXU0+xQfvJZHbuBir8sSD/j4l/4CP8ACmF41H7uIY9WrVU4nFLFVJdbFUW1n0S3dvqTTxZxnpafzqYTSvwgP4DFPWO4bnI/E1XLHsZ+1n3ZALKPPzWg/WhtNgccQMp/GrQgl7gH8aURlT86HH1pcq7Aqs11ZlTaQuPuuvvjIqjLprJkqNw/2TXTLHk/uX/CphHHL8kq7X9alwRtHFTXU4aS0YH5Tz6Hg1VkhwcOmD713F1ppP8ACHB6VkXenEcYP+639KylS7HZSxi+0c4sRXmJiPY9Knj3FQWGDU8ts0bYwR7GhF5xnr61nax1uXMro77w8MaTB9K0qo6Khj02BSQ3HUVerdbHh1NZMKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRXivi3whFpPi3xHq3hjwtZxXkGjWk1hcW+kxuFvPtM+9k+QgybdhOPmxtz2qbxPrPjXSvG2n6fpTa/e2kd5apcSy2aPBcQySDzWXyrTChFYrlp0I2A4bkkA9korxtL/wAfQWVtcy6jqe++tdRMiy6QJFsZI5VFuVSKLzCWUnht+7qBxTYdf8eRaBaX1la6xezTzXGmmC9tU3LK6r5F3xbwOIVcMrbo14YkjABoA9morxm91X4hWnjp7AzXDWEEsUcTmykeK6h8ob5CY7R1WQvuPM8aggDbjkt1bUfHFj4O8L38mqa5NqV3ZrcX9la6UBMJPKj/AHalbSZYyGL5WULljwyKpAAPaKK8lt/Evi3+17XTJrfWI5hrF558z6SzwpY+RK0GZFTY3zeV9w7iRgnnB2/hLqWvahbakniJtVmlhaMJc3lt9njlJB3eUjW0DgDjIYPjIAdsGgDv6KKKACiiigDhoRs1bUk9JiR+ZrUHSs65GzxFqC+pDfoD/WtBfuivksQrVpI9qWsU/JAVGcmoLnCrUrviq1y2UrnnawQTuZergHTJvw/nWV4XH/FUXv8A15D/ANDrV1b/AJBkv1H86yfC/Piu8/68x/6Ga+hyj+Cvn+hhi9y7Cm3xbegHraRH/wAeererZ+wyKvUjFV1H/FX3g7fY4v8A0J6u32Ps0jHoFNe0eb1PIdWHlSuo+8etcHqS7tX1ED7wuHI/76Nd1rBJmlc+prhtQBOr3xHXzmP61w474UfRZE/3kvQ0vCeftV22OkOT/wB9rW2X5461jeGpI4F1GWWRI1MA5YgDPmJxTpNf0mNiv9o2zuOqROHb8lya4km0rHtynGM5czt/wxfuxmLOMms2XOV4zz+VJNrMUkLC3s9RlHqLV0B/FworMkvdQkx5WlNGP+ni4Rf/AEDdVxTMp1ItO34am54nbPijVR/02B/8cWo9DjMmv6UFJDtdwgex8xeazNe/tmXW7iWU6fbNKkUh2B5hgxL0J2fyrU8HLJ/wkWkJPKJZFuo3Lqm0EBtx49gKiUf3nzNadS+F205f0Pa4GJtYg2duM49cmkbJk2oMsPyX/wCvT7NXmghVeAqAZrXstPUAHGAOpPQV6PK5PQ+W9pGlHUq2OnkkMwJY9z1NbtrbCP5cZP8AdH9TT4YwFyuVT+8erVIkgIKwDp1J6VrGFjhrV5VB7Ko5kPA7dqYWll4i+RP73c09YhndIdx9T0qQBm+78q+verOcgW2jU85Zvfk1MlsCc7fz5NRXF3FaKcKWb0HJNZU2sXGSWKRr2HU0DsdAIAPT86R42xwB+dcrJroj+ZjI3vjAp9r4lDuAqq4/3uaLMLHQSTPGfnRSvripLWcTbsZGD3pttdQ3UfAwT2NECLCsmOmTSEShV8zO0A+oqXaGA7iqFqWMrtng9qvxkdaGA0uftKqG5VTn9KlMaXBZHUEKOT6VURsySORg5CjH+ferFtIAszt/Exx9BSYIztS0wpyo3x+vcVgXNntbKfka7yEB4yW5Vu1U59JglB6g1Elc6aVfkH6ICumwhuuKvVFawiCBYwchalpoxk7ybCiiigkKKKKACiiigAooooAKKKKACiiigDO1zWbXRLVbi9jvnjZtn+iWU10wOCclYkYgcdSMe/NcXa/FDSW8S3kNxcr/AGG1jY3dlew2kzqfPaUEyuAVjX5IwC+3knJPbe8deC9P8ZwWMWpzTxpaSmVVSOGVHJXaQ8c0bo3XjK5B5BFc9a/CHSLWzSxh1bWhpxtLaxubQvAUu4oHdkEh8rcOXbOxlyDigC1qHxH02PxTp2n2U6tY+ZdrqF3LazLDEIImdtkxAjYqykMAWxg9Kuj4k+F/sxmN5eL+9ihELabciZmlDGPbEY97BgjYIUg44NUpPhbpE0rJc3+qz6Zm8MemvJEIIhdK4mCkRiTB8xiMudp6YHFWbL4d2UOoQX97q2r6lfwzW8qXF3JFu2wLII48JGo2jzpCeNxJyTQAz/haHhq4069uNPvXd4LO5vE+1WlzbxOIBmQbzEeVOAwUMy/3SRir1v4+8PTaumli8lF8Z1tTi0n8kTNGJBH5xQJuKkEAkE/XiszVvAHh+LQDa6hqF1bWKR6hAZpJ40wL9yZMsVxkM+E/DO6tKDwLpkJYrPeHdqsWrnLr/ro4kiC/d+5tjUkdck89qAGeHfH2kaymmxwvLNeXlvDcFbK0ubiGJZAShaXylCA4ODIEPHQV11ef2Pws0mzufDsiX+oMmhRxRWqNHbBiI+m6UQiXBPJUOFPpjivQKACignAyelYOpeMvDOmP5eoeIdItpegjlvI1cn0C5yaAN6iuSPj/AEWQf8S+LV9SPb7FpVzKp/4GE2D8Wpf+En1m4H/Ev8Gaww7SXc9tbqfw81nH4rQBDqo2eKLj/bjU/oP8KtRnKCuT1yXxhP4giZrDQtOZ4uN13LdHGTyQI4xn2BP19BdL8Tz/APH14nigB7afpqR4+hlaX+X+FfL42KVeV2evF81ONl0OqkGeaqXm2OIu7BEHUk4ArAPhJJv+QlrniC89c37W4P4QCOj/AIQbwxzJLotndSLyHvF+0sD65k3GuWUabW/4GkXJPYpa94u8OQWcsEmu6Z55xiJblGkP0UEk/lWJ4b8WWf8Awk129nZ6tfbrUKPs9hLg/MT95gFx75rsL20trHSJo7O3ht4+BtiQIOvoKzfCRLeLb8elqo/8eNfQZVb2Onn+hy4q99TP/t3WZvFV21n4Xu0ZrWJcXt1DDxubn5Gc4OfTPHSrd63i+6hZDFoNhuHQSTXeP0irW/5nC9PpaQ/+hPV+5+WFv7xB5r2Dz2eFaxp2qNNIlzrbDaTn7LapGCf+B7z+tcZqGlxtqN3511ezt5hOXnZc9+QuB+lel66uLmf0DGuH1IBdWuyeAH/oK48bpFWPeyWMZVWpK+hZ8LaJpX2bUZpNPtZJI0jIaSMOykyDOCckVuIY412wIqL2CDAqr4Y+a31VcDBiTP4ODVwFV7VwttxVz34RjGpNRVtf0Qj8xtuFZE/OMjOD0rZJ3qRkAVkXSlSQpyc0RHNC64T/AMSycj5ZrXyz/vRuQR/3yU/OtT4fWZm8TRyL80cMbnP90uNi/q36VY8P6K3ijT302OaOG6tZPtEbSAkFHAVxx7qlep+FfCEHhm1t4N/2i6u5g0spXbnCMQAOwGP510U6DlUU+h5WKzCFHDSofa1VvJ/8A27O3VUUn5YhwMdW9hWjtVFDSjao+7H/AI0pCwy4JDzY4UD7opjMEcF/nlPQDtXoJWPlpScndjm3SfNL8qdl7n61NApJGBhR2pYYCTvmI+nYVOg3k4+VB39aCRCFClnYBF6segrK1LVEhjZidkY6A9T9aNZuwrBAcIvRe31NeK/ErxxDZRSAuSinGFPLn0FNIqKu7HUeJPGkFtHJI06RRJ953bAryXWvizG85i01HvDnHmF9if415xqupXvie+H2qZY4AcpFu+Vfr6mtTS9F0qNdt04PH31Gc/hkVzSxtKnK1rnvYXh/EYmPNdROns/iRrSTfNpIljPO6C5C/wDoVdGvxDeKOKS60HWUkx96NYWH5+YK4CDRtHlB3TLA3brz+VaFroNxB/yCdVOf7ocHP4GtoZhhJP34yXpZl1eGMZD4Zxf3r9D1/wALfEyeeRYU0HU7nf0CTWgcH6Gcfriu4i8V6oYNh8GeIGcjk+dYf/JNfNrHU7Zgt/ZpcYO7cq7Gz6j1P412nhX4k31rIsa3f2kDg2999/8AB+v55rup0KOJ/wB2qJvs9GeLisHicJrXptLvuvvR7Lb+I9VVR/xRPiE5/wCm9h/8lVYPibVtpA8EeIh/230//wCSqzPC/wAQtL1SRLe7BsLvIASVhtY9trd/xwa7tAJCADnPFc1WlOlLlmrM5VJS1RyH/CS6qqoD4J8Qgklv9dYf/JNMbxPqrqI18FeIcEhP9fYduv8Ay8/Wuk1CbyzNIP4V4+pOBTtKi3TxKf4E3H6n/wCtWfmMpp4n1cKB/wAIJ4k4H/PfTv8A5Kp3/CUav/0IniT/AL/6d/8AJVdVRUDMPRtav9QuzDd+GNY0uPaW8+7ltGQn+7iKd2z+GOOtcL4412PR/ieHg1Rhd2/hq/vU057+QQyTxmMxloA4VjsMx6ZIUn+EEerUUAeFeJfGfilUtYL/AFbRtNMMukahJfRW0scMcNw8qtHKDPyitGMsWUMDjC9Q+6+LWvRa/qdnFBo0kVotyER5IY5JUjgaRLhAbrzHRyobasX3DkOcZr3KigDyXWfGXjCzt3kil8Phk0GbXmVrKZhtTbiEHzhknJ+fHp8vrXn+K13/AMLB0rRrX7HJa3V1BbT28kCxzQ+ZCHLKxuN7qCV+YQBOcb8jn2KigDyjwlrV34e/Z38Oanp0UEt1FYWSIk+dh3vGhzjnox/+v0pNR8TeJNO8TXWlwzaU+oS3thaG4kgnMCrMk7FhCZyAQI1+6V3c57bfWKKAPC9Y+LOuWOj3Us9x4e066s7S/l827gkaPUZ7a4khEMCeapUkRhjlnI3jg4Jr22wma4sbeZwA0kauQOmSM1meI/DOmeI0SPV1vJYFUo0Ed7PDFKpxlZI0dVkBx0cEYyO5rZACgBQABwAO1AC0UUUAFFFFABXnvxFk8VNrPk+HL7UbK1i0W9vN1rZxTCW6RohDES8b8nc/yjBIBx0yPQqKAPIBqnjjSpmN1Pq2oWcUmlXM0n9mK0gjlMou4kSOLLBNsZwAzqD1NUb7xN41k8m6jHiBIHv7tUsYNJaK4eDz8Qku9rLGo2dnMZOcl+K9tooA8V1qbX9Y0TXbXVJPEMmqC8ATS00nFksKXkex451hzIfLAb/Wnq2VGONHwbrHji6+Ic9trolg04T3SPbvay+UIgT5LRSC1CZICk7rh85PAPyj1migDmr7TPE93eTGPxJaWVmXJjS20wGVUzwGeSRlJx3CD6VB/wAIdLP/AMhLxT4lvM9QLpLUf+S6RkV1lFAHJj4d+FH/AOPzSI9R9TqUsl7n6+czZre03SNN0tdumafZ2a9MW8Cxj9AKvUUAFFFFAHK+KBt1qwf1Rl/n/jSQ96l8YDF1pj/7bL+e2q2SOlfL5n7uIbPYoa0Y/wBdRZjzimIco1NYlic06McGvPTuza1kZmtj/iWzfh/MVk+DR/xU2qt6QRj9W/wrY1o50yb8P51k+DOPEOr+0MX/ALNX02VL9yvn+hx4rcvMf+Kv1AAf8u0HPpy9W7j5/lXp0qjI5HirVAv3jDbr/wCh1pSqIoxj7xFeweczyfxSAt7NEn8JOa891CT/AImV0TyNwyMew5r0XxUmy+nX+LJLV5tqDBdUn5/iAP4qK48b8J9Bkf8AFfodB4SPy6nGx6wAg+24f41eZEVsA5xWT4W3bNUYZ+WFE/ORa0OB1rz3sj6CK9+b9PyJsisy+ASQ89asNn+/iqN2gLAlg1NMJI6L4a3n2bxvYqG+S4R4W/LI/UCvdNSkMd1pzDkozH/xxh/WvnPwzL9n8U6NKOAt0gP0JxX0peRK1xYORx5hXn/dY/0r0sM7wPlM5hy4hPuiFv3Klz800nNWLKIAl5Dl6RoQbliTn0z2qwjKmSeg71vc8gkZuPm/AUrnZCzN2GSKbECT5j9T0HpRdfNCwHofzpAeceOtX+wafczM2G2nn2r5L1S8k8S6q813Pstw58sc9PWvoz43b/8AhGJ5I84CkMR24rznwj4V09YQ7QK4T5cv82T681rGtCjrNXOilh5VtIuxxMGi6UV2xPcyMOpQNV2LRtOAA86/jf8A3dw/nX0L4f8ACGk/Zlkns4WZuQNgwP0roU8HaOy8abbEH/ZFbPMcPL/lwv6+RoqNWk9KzXp/w58uf2JZHk38vHZoyP8A2Wkj0oIV+y6oULdmB+X+VfTs/gvRG4TTLZXzjiPj8RWFrPw+0Z49sulxjOfniG3H16Vk8XgpfFh18mdEKuMT93EP5/8ADnimnXGvW3ypJBewj+EsAT+BqzNcabfsIdYs3srg8K5BHPsa7jUvh/BFEI7YMhH3WVikn6/K3+ea4vUrPWNHLpeW4v7NRljt+ZR6sp6fUce9Zyw+Ara024P71/mehh80x9P3aqVRdtm/ns/R6kFyLzSHARlv9PcdWYZUe56Y9+K7nwb8Q9T0hDbQSNPCvDWtwSJY+P4GPI47HPHTHWuEs4LO8+fTLp7V8ZMXVfy/wqGULHcJDfalbyRxH5YyDE6Z/uNyQO+OVz1Br1KKxUYqGISq0+kk1f8AE8rHRwVVudC9OfWLTt8rXt/Wx9MaL4nsPE0MaWkgWUyKZo2+VowBjBB/HnpXa6EBIJ5/77nH0HAr5B0vUJopkkN/A0yfcmglKyD6cfnXsvw8+KEdlGbPxGGeIkbL2FM7f99Bz+Kj8BU4nLZxjz0dV+J5caqvaR7fRVbTb+01Ozju9PuIrm2kGVkiYMDVmvIatubBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzvjQYt7OT+7OB+n/wBaqyAbM1d8aLnR1b+7Kp/Qj+tUI2+X1FfO5qrVk/I9XDa0V8yJxhqFbANJKfmpua8i+p1JaFHVTu0+4X0x/OsnwaR/b+s+vlw/+zVqaqf9Cn+g/mKyfBoz4g1g/wCzEP519LlDvRXz/NHHi9GaMG0+KtZkb+GO3H6NVy4lCx+a4/3RVC3Td4l1zngPAp/CPP8AWrmobTgv9xR0r2jzTzPxVG6X0sj9ZckV5vrlu0V/5uMrPGjceoUK3/jymvWvENs93IZj1zjA7CuYu9P+XOyORQ24LJErgH1GRx0H5VjiKXtI2PSy/FLDT53qjndEZ7XSbmQuENzIqKW4yqcsfzK/r6USXkIJ3XSk/WteSzurlhuuZQQMDEcY2j0Hy8D2px0BnA33lx/46P5Cub6rK1rnqLNqSbbWrMB72HtMp/GqzXse8nep/GtHUNEaM4F1Mfq2ayW0pxub7QVA7lRUvCzXU0jmtF9GW7S7UXls6g5SZGGAfUV9U6m2yDTJFHBuVP5xv/jXyVaWdxLcqbdTMsbAswjAGB74FfWWs86TpjJ/z2hP/jprooQcFZnk5pXhXnGUCVmyxJxzToozI+W+6vak+VFDdXPT2qQHChR1PWtjyrkzsAvvTVTK47U6OMnlqcXGcIMmmScN4u0BNS0+9s7hQUmUhfyrw/QppdI1CbStSBWZOjno47MPr+hr6iu7Pz0DHhvWvNPHXgiDV8SxbormM5SRRgg98e3tUTipqx1Yav7KVxNC1aF7ZEklTIHZhW5DfK/Mbbh6qQa8iki1/Q28q+sHuoh0liHUe9Qt4wurfIt7GYNn7u7bz+Rrm9lU2seg50Ze9zHtRvT64+tW4r0yJtlAZfU9RXhNt4z1uaYi4sVt4xzmRmJx+ldb4b8YIzJHqKtAGOFlByh+vpTdKpFXaMualJ2T1PRpbGOWNsBWiPAB6iuc1TRQw2yLvQHKtnDJ+NbdpeAgbWBU9COhq+mycbSBk1mu6K5nHR7HhfirwIjSm5sWEE+c71G1SffH3T7jg+lcHe+bHP8AZ9YgkW5i4WaPiQD19GH0r6Y1rTjCGYJlcfMOvFcRrXhuz1Fo0uUJhJ+VgcPEfY/5966qNecbxi9909n6rv5m6qQaTqptLZr4o+j6ryfyPL7V4mWGc29ncvGfluYoFf8ACSJuGHqP0rutB07QfG4aDw7PBoviSIHfYOzfZ7rHVot3zJ/u849Mc1g+KPBd34fl+1S7zZSHCX0Ix16CRemffofUdK5xp57edJLyAyeSweO7twQyEdDkcqfzrrwtajCf7ubpT7PWL+f+ZeNwtfE0vaWVaPSS0kvVdTtIrjxB4H1fEgu9Ju8/MMZimHuOVce/OPUV7F8OviM/ia9TTb2yCXfls/n27ZjOPVTyv5n615z4e+KFxc2iWfiK3ttf0lwFZZUXzgPUH7rn2OD716t8ObLwdCs9z4QEXmyjMqmRmljGfulXO5Rn8K9LHO8L1qfvdJLZnzFNWdov5HbUUUV4Z0BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGL4vGdCm9mX+YrNtSDbI3qoP6VseKF36Fdj2B/Jga5+wc/ZIv9wfyrwc20qRfkenhdaPzHXPWoV5YCpZTuNNGAff1rw5au52x0Rm6x8tnP/uj+YrP8Dru1rWGA4zGv/jtXNZcGzkyeCyr+tJ4GiwuqTA/M92VB9gi/4mvpsmX7hvzf6HDjd7C2LA6zr0p6G7Cf98xoKuzQiRN8x2p1xWd4XzcR3d0RlZ7uaUE9xu2j9FrbEYcCSXJXPyL/AHvevaZ5xiT2PnAkptQ9BjtVN9IiiGQFOfUV00zqindy3p6Vh3d2qsckE0hpmNd6dEqFiAtZE0C8hDx61r39xn7x/CsJnudQvvsGmIHuAMySN9yEere/oKG7GkU2YusW6tMkMIea6f7kMfLN7+w96E8KTKgm1MqcDPkIeF+p713On6ZaaBA5iJmvJP8AWXD8u5/oPYVQuxJcbst16AUlFz9DTmUDmBIiQvFGgVApAAGAK9x1Ccf8IlpM4GdzWp/76x/jXjMlgYtxfPQ8V6zcNu8AaL/uWR/VKGknZEVbtJs11Bd1xyRV1EWMZfrVe24JPc8CrQTA3OcUjnE+aQ46LTspEOOajkkyMLwv6mkClhlzhR0FAhQzytnotEkMUoI49yacMuML8qDvTWI+4hANMDMudJic8cj2rMn8PQqGYQIW/wBoV1KBUBweRyWPaqcsr3khih4iH3m9aCkzjl8J2N/LteEGMHLOf4jVLVPA1jIS1oCqLwuO/vXe3GyNRbw9T94+1U5HBkVFPyrVKT6Bc83jtNT0SXZAnn2y/eT0HtW9p2peaiyITt9+o+orrUtFnT5kHzdz3rKvdGjRiYcRFu+OA3+eD/8AWFYVaanqtzpo4jl92exbtpheWrK+C6fqKwdUsTEWdBlDTrGfZIynhkbawz0P+Fbu1J4MgZXGGB9a5d9Gdl+R3WxS8PXsdxF9hvFSVcYUSDcHXupB64/z3rn/ABX8J1muPtnhCSGzd/8AWWcrFYvqhAO3/dxj0x3tXVvJZ3QeIlWU7lI9a7jQdUjv7YMvyyLw6f3T/hVu1RcsxRrVcHP2uHdk9+33HHaZ8H9EXw99m1JS2qyHfJe27FSrdgueCo9xz147czofgjxL4W8c6W8Uf2yzE4H2yHgCInDB1PI4z6j0Jr3RTkA0tejh8VUoQdOOsX0Z5leTr1HVqfEwooormEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUdcXdo96P+mTH8hmuV0r5rKI+2P1rsb9d9jcr/AHo2H6GuL0d8WK+xP868TOF8LPSwb/dyXmWZAQagzip2bc1UL6YR5x1PSvn5eR3wV9DE1+ceSEzgGZf8auaBONN8DSX7Z3uktwAe5Zjs/P5awNThl1PUbPToCQ1w53Efwp/E35ZrofE7I9zpejW4AiDCeRB0EacKPoWx/wB819flVPlw0b9TzsdJOo0i9otulhYW1o3KxRKrY7nHP5mrc92AN5xuPAHoKqMwVcnqao30+1Dz8x/QV6RwEWoXjMSAeP51jzTAZz1pbqbaCT17Csl/PvrlbO0OJ35Z8ZESd2P9Pek3YuMRCtzqmoGzsGCleZ5zyIR/Vq6KBLXR7MWlgvGcsx5Z27sx7moo44dMs1s7BcBeXfux7knuaoM7yvsj5PdqlK/vS2Nopt8sdx88zO/GXkNSwW5XDNy/8qs2NsFYAKWPc1aMkMMhBGWPf0qHOVR2jsdfJDDq8tzn9WG1WDdcV3cZz8P9EPXC2P8A6NjFcHrzZlbHpXd2xz8N9Lk6hYrU/wDfMyf4VUdGjjrO6udDCAmSfwqVt0nX8vSmQEBck9qVpCeF4FUcg4lU/wBpqEBkOX/Kmxx9zTmbnanJoAWWTGETr6elNAEfU/Oe9CgIPVjSOmByeepNAEFy/mL5S8DuaYswt0CRj5j0FNmkEY4+8egqIYiUySffP6U7ANuJDENqnMr9TSWcPmuR/AvU+tVYFe4mLj7znavtXS2VokUSoBwOpoegxsUeF3EYHQfSsvX5FS1IH+sf5RWvcyKgJPCgfkK4+9uWurtpP4V4UelKKuBRvbTbCkkGTcL1A/jH+PpU+kXiyYBbnH51PGCCD1Y9KqajpcozdWQJYcug7n1H+H+TlXpX95HZh6yt7OfyNO8gW4ix/F2rFhln0y7E0Jww4Know9DU2mar5iqJOCfyNXb6BbqHK4z61ynWly+7LY67R9SivrJZojx0IPVT6Grhmz0rzTR7uTSb4MxPlMcSL7ev1FegRt0wcg1tGd0cNaj7OWmxaEp71MjbhVWpYetWmYNE9FFFUIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBHXcjKe4xXn+kti1ZT1Dkfyr0GvObfKS3CDtIRXjZz/Diz0svV+Zehenfy4i2cViXUhkkZmOPc9qv38oKrGp9zWHdI2p6lb6VExUT5MzL1WMfe/P7v414uGouvVjBdT0ZS9lByZq+DLZX+1a1MAscq+XbluNsK9W/wCBHn8BVTSm+33l3qzA4um/dA9ol4X8+T+NaPi2XZaWui2Y8v7UNr7ePLgUDd+fCj61CoEUSxxAKoAUAdBX28IqKsjwJtt3YTSgBpG+4v61kXNxkNLIeOwqfUpxuEKnEcfLe59K5+9uQ+55GCQxjJJ6AVQoohvrpsghS8kjbIox1dj2rf07TzpVgyFhJeSnfPJ6n0HsKzfDloZJBqlyCsjDFtG3Hlp6/U10jozwkAHnqaykzohHoYEjNK/kQcsx+ZvWtzTNIVAA5G7vT7WxjhOIkAY9TWzazQfLDkb+5qJSc/Q6NKKstxEsl8hkQAe9c9dWLRyMZGGBXWXUqxRHFcfrN4WJRDknqadOTitDCX7x6mLqhSRxx04rtbDK/CuD/ZhQj8JRXD+RI86LtJLHgV29huk+FgAHzLC64/3ZW/wqou7Jrq0UdNAu9VGe1WRGqD3plqoiiQty20VG7tK21elXucY5nLnan4mlACfKvJo4QbV6mnooQZPJ/nQAKu0ZbljVW7lCqT1/qasuT+Pc+gqoyK773+4nQUICGGMj97LyewqnelnkEY+83U+gq9LJwXbgDoKhsoDcXHzdW5b2HpVbAXtHs8KJCMcYUe1asxEaYFOjURoMDgcCqGqXSwQvIx+6OPc1nuxmLr14c/Z4z8x+9WYkYRBmkUtNK0r/AHmOTVmJN7ZI4HStdgHWsRZtxHzHt6Vq28YAHoP1qO2hxx37/wCFXkTpmspzKSOT8T6WtuzX1uAsTECVB2J/iH49fz9apafdMvyO2RXcXMMc9vJDMu6ORSrD1BrjpvD99byEQbZ4/wCFtwVse4P9K5JK+x30aqceWTI9UiXy94PNddoDNJpNozZz5YH1HY1iWWgXNxtF9IqRD+BDlj+Pb9a7O2tkijVUUBVGAB0AqoRZniKsXFRWo1VJqeNMCngAUtbJWOS4UUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFedkYv74ekzfzNeiV5xfSbL3USOpnbH/AH0a8jOP4KPSy34pFO+n2NIwOFUdTVnwPZ+RYT6vefJJd/OC/GyEfd+meWP1FY15E+oXdrpsZIa7fEhH8MY5c/lx+NdB4wmU21tpEJ2G7OH28bYVwW/PhfxpZNhrRdZ9dF6f1+RePq6qmum5l2Er6jeXOqSggTkLApH3YR938+W/GrNxMIwx/ujA+pqYBYkGAFAHAHaue1a8xHweXJI+le+eYtWUL653NsU5LHJqtp1ouqXWWy1jbNyO00g7e4X+f0qrFHJf3n2aJmQsN0sg/wCWaf4noPzrtdNs47e3jihQJEihVUdhWcn0N4xsrmaA8kxwDuJwB6V1WnqIoMSYLYwaLWzjA3YUOe+KfcsLWA4IJbpSlLmskEVu2VtRuVQeXGAPUiqVorPKJCcIpyTUJ3TS49epqSWQ8QxdutW7QjZGavUlfoO1K9kmzHFk/SqltY7hvl6+/arqJFbxNLcOqRoNzOxwAK4XxFr8ms5t7Fnt9O5DMPlaf/Bf1NYpN6I6bqKLGt+IlE7WeibS/wByS7xlU9Qvqa7rSMQfCVFRj8tvJhj1Pzvya8hCrFiOLaAOAAOler6cS3wuVMcmBh+bn/GtlBROerPmOskuPIsnuJBIyxRF2EaF2IAycKAST7AZNV9D13StbtWm0a+gu1U7XCN80bf3XU8qfYgGr8TbIwoHNY+teE9J1edby7t2h1JBiO+tXaC4T2EikEj/AGTkHuDSOc3UATluWp2T3+96elccsfizQeUeLxNYg8JJttr1R/vDEUh+oj+prQ0XxbpWq3n2BZZLPVcZexvozBOo7kK33hz95dy+9AG7JyMZ4HU1VY+Yc9I16VJI3nP5cf3F7+tQXkojTavAFNAVrmUFgByB29TW1pNt5cIZxh25NZWk2xuJ/MYfKvSuj+6uB0pSfQaGzPtUn8q5PWLn7Rc+Wp+SPqfetXW73yYsJ/rH+VB/WudSMudoPyj7x9TTiragPhXf04QfrWra25yD0/pTbO26Ej6D+taHCjAqJzsNIfGqqMCnM1QBuaXNc7LHE5p6IW+lLEmTzVgD0q4xvqxNiIuCMVeTpUEUfc1YqyQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8uv23XtyexlY/qa9QdtqM3oM15BfXIgtLi5Yj5FL/U15ObXcIxW7Z6eW6OUmangu286+1DUn5wfssPsq8sfxbj/AIDVS1m/tPVbzU25jZjBB/1yQ4z+LZP5VfJk0LwHHHk/a2iCL6+dIf8AFifwqC2hjsrKKFOERQo+gFevQpqlBQXTQ4as+eTk+pX1W58pCAeoxXHajcvLMkcS755T5cSevqT7dzWl4hv0VDIXwo5/wqHQ7J4IGvJ0/wBOuBwp58pOw/xrSTsVTiW7KGPTYvJgO+Rjulkbq7ev+A7Ct/T7rzIwduSOoFYCRsSFGS7V0dvaraWI5Ikb0qaloq3U1ppyd3sa1vdRzSbGXaQKytWnLTMD0HAptxc7YgmPn9az5H3OM80Uv5mRXXK+REyMY4+Pvv8ApVu2iEcZeQgADLMaq2g3y5PXtWF4z1bzpTpNq5EEeDdup+8e0YP86htzZUUoIx/EuttrMzRQnbpsZwB/z2I7/wC7/P8AnmshMRyOT0oT97MDtG1eABwKuxwM+TjJreMVFGU5XZkQozXKgdc817PaQCL4e6ch48xIQf8AgTD/ABryuCMRS5AyR1NezX9v5fh/RrXoQ9suP90qT/6DRLoRI2rYLgs3ajO4736dhTI+mD0zzT+pyenYVBkHPX+I9B6VleItJ07WrVbDUbK3vUJDETIG2HsVP8J9CORWlLJ5anHLn9KjjUQoWbl25NAHIPoet+HY/wDimdX+1W4/5h+rs0qgeiTjMif8C8z6CqUXjC2+2R2niS2m0G4Zgoa7INvIT/cnHyHPYMVb2rrryQ9Ort0FX7DTojaul1EkqyrtZJFDBgexB603oCL9lEkMC+WQVIzkdDTbuYRoSTgAZJrlZ/Bq6STN4P1KfQn6/ZFXzrJj7wMQE/7ZlDXP6v4s1TTSYPFOlNFCpy1/ppa5gI/2lx5kfvlSo/vVCVyjbuJnurkyHqeEH90VoWVsAORwvb1PpVLw/PaalZpeaddW95DL92WCQOh/Eelb6KEUAdu/qfWqlK2iBIVRsXHc9ajY809jUZOa55MtBk1LGueTTUXNWIUqEhscgJPFXYowBk1FGvPFWlGBWsSGLRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCrqkvk6bdSf3YmP6V5Fcw/aTp9keftNxGjD/ZB3N+imvU/FDbNAvSO8ePz4rzvRYvP8VWI7W8Es34nag/9CNediFz4qlHtd/cehh3y4ecvkaHiyT7RrGlWI+7Huu3H0G1f1Yn8KzNcnKJ5anDNx9P881Pdy+b4p1Wdvu26RW6n/gO8/q1cvr1+4jldfmkIwi+rMcAV6+yONK7KNrGNT1Z5X/487MjIPRn7D8B/P2rsNMiEpaQkEnqPT2rnrK2+xWUdmpy/wB+Vu7MeTXSaHZymNnThcYJqHG65mbKXLoTCFFkMhAAHTin7zIQT0HQU57eX7p5A9Kgmcx5XGD/ACrCzk7HUmoR5n0K87ZcnPAqtGd7HH8XT6Ul0xPyjv1qSyVfMy/3R1rabsuVHLBczc2Ra5qY0bTw0QDXk/yQIfX+8fYda4X5ghBYu2Szuersepq3q+onVdTmux/qVJhtx/sjq34kfoKSCLG1SPc1cI2Vyakug7T7ckAY5P6VqyR+TGsaKTI/AA60ltGIyAoye/8AhXU6VpOP9Iuh+8boP7oq2zEwYNGePT55ZG2MUwDjkk8Yr1XxAoF5pUQHHnE/gI2/qRXK3Efn3FharjE11EhH+yG3N+imup1N/N8RRJ/DBbsx+rMAP/QWqXuhNlmPlcdu9OkYIMn73YelCfJHuf8A4CKgJMsnP41JARjJ8xug6VHcyqiNJJ91e3r7VM5ydo6DrVOGI6hc5I/0eM/L/tH1pgSaZatPJ9pnHB6A1rlh+FNbCgIo4HpUFxLsQ8/Wp3GV9Ru/LQnueAKx7aEyzF35wefrUk7tNLn8BV60hCoPQU2+VDSMG/8ABmm3N3Jf2Jn0nVZPvXunv5Tsf9tcFJP+Bq1VmvvFOg5/tGyi8QWK/wDLzp4ENyo5+9Cx2v25RgT2SuvZsVETmsGykjJ0PxJpWutKmm3iSXEP+utnBjnh/wB+NgHX8QK11XNZGu+G9K17yzqdmkk0X+quEJjmi90kUhl69iKzBY+KNC50y+i16yX/AJdtRIiuVHok6ja30dc+r1G5Wx2CDFW414rmdF1t9ZhvIIbS80vVIE+aLULU4jYg7WyrbJVyD9x+2Miuc0bxjrtjqGoDxBLZX1vbawNFhg0vTHjmnla3SZX3PclVHzlcYPQEkDOKSJbPU40wMmpK88n+LGjWmuzaRfWV5bX0VvPcNF9os5mHlRGV0KRTuyNtBxuCgkdac/xU0yHT7y6vdI1iza2jtp/JuBArPFcFhHJu83y0XKNkyMm3HOK0JPQaK4c/ErS0hLT2V/HO8EFxbwKYZmuhNMYVWJo5GR2D7QfmwAynPXGOfjd4V83U0jF1KtlBc3GYnt3aZYD84WMS70PUjzFTIBxQB6hRXEv8QrWPxPZaFcaPqdtfXe1o/tMlrCCjOyh1DzBn4UsVRWdQRuUEgVzmufFi1vLXWNP0Iy2ms2Ihl3Ga0uVMZuo4n/1UsgU/PjDhT82cegB6zRXnX/Cz7G1uUtbq3ubi4mv7y0iZBb2iDyJzFt3TTgO3H8J3MAW2L0Fv4i6zq9nrvhXSdIGoRx6lcy/aLixW2MipHGW2jzztAJwScE7VIHJGQDuqK80i+MmgOmrZtbzztNSOSaOOe0n+V5fLyZI52jTDfe8xk2jk4FbGkeP4NYvLa10rRNUvJXhjuJzBLaPHaxyOyozyCfY2QjNiMucDkZ4oA7OivM5Pi3pOm6Zodxq6St/aSI6zRtbQkbpTH/qGuDKcHBOwOAOc9QPTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMbxgceH7rHfaP/AB4VxfhFd+u6hJ/zygijH4s5P8hXaeMAT4eusdtp/wDHhXGeCedR1tuweJfyTP8AWuJxvi0+0X+aO2Dthn6/oYl1cbjqUgP+vvJQD7A7P5LXOwObvXUAGYrYea/+8eFH4DJ/EVJJeqNHE0pwo3yk/Via3Ph94Xv5rQ3t+VgFy3m7duXYduvAHpnP0r0Zu2hlTXVk1lpF3PmbYcOc812VlYLFZCM8HHJqwNGiChHnuGPtcOn6IQP0pG0sQlfJv7iFj0Dy+Zn2w+6s3NtWZTte6Od1eGW2yyMc56g1lpI8jHcS7HjJrp9UtbyOBzdxx3EWeXgUhgPUpk5/A/hWJsiigMkJDKy7lYHII9QaIyUUW06m5nTf6zA7dax/FN60GnLaQPtuLs+WCOqr/E35cfjWpnn3Y1xl9cfbdRur4HMSE29v9B1b8TmiK5mOT5YiWyKZAEGIohtFamkxm6uCQDtzWXbKxhVEBJY9B3Nei+FtGEFqjyAFjyfc+n0rp2ONsl0jSVhInlXnqqnt71rTNsj9zwKshC30HU1k30plfCdFqNyS34bi+1eKbc4ylpE8v/Aj8o/QtWzARPrGpTE/KrpCD6hV3fzciqPgGPZBq1/KeDIIgT/dRcn9WP5VPo7EabFK4IectOQeo3ktj8M4/Cl1BmhLIWYAdegFPUCNPc02JdoLv1P6VFczbCAvMjcKPSkSNlBmcQJ3++R29q1IoxBEEjABxxUNjbiCLe3LH9TU8h2qSxxxlj6D0pN3KIpGCDr9Kyr2fdlc/Wpbq43Et2/hFU7aJriTJ+7n86a0ES2cJY72GBV4nAwKThBgUwnNYzkWkBOaQDJop4FZ7lCqMVIq5pFXJqzDEWI9KpK5LY6CPNUl8LaP57z/AGP96+oDVGbzX5uRGIxJjP8AcUDHTjOM81tIgUU6tCTkG+HHhdr6a7awnMkr3DshvrjyladWWYrFv2KWDtkqB1z1rQn8IaPM0rrFd28slvBatLa309u5ihLGNd0bqQAXboec854rfooA5u28D+HLd9EeLTI/M0UyNYO0js0Rk5ckkkuSeSWzzz15qGTwB4ekg1C3a3vPsV+ksc9mNRuRbFZCS+2ESbEySTlVBGTiuqooAxNW8LaXq+p299qKXk0lu8ckcRvpxb70bcjGAOI2IbByVJyB6Csey+GXhOyQpBp9wY/JFsqS39xIscQkSQIgaQhFDxocLgcehNdnRQBy174C8PXsLwT2159lknluZbdNQuEhmkkkMjmSNZArguScMCOwGOK2tR0ew1K7tLm+txNNaeZ5JLEBd6FH4BwcqSOc1fooA4+w+HHhvT0ZbGHU7cmBLVXj1e7V44VbcscbeblEBH3VIHUdDU1n4A8O2Nxaz2NteWs9uMCSDUbmNpR5jSfvSsgM3zu7fvN3LN6muqooA4yX4Y+E5FRP7OnSNY44Wjiv7iNJEjYugkVZAJNrMSNwOM12dFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFbU41m0+4jcAqUPFef8Ahpfs9x4jC9UkU/8AkJTXo8i7o2X1GK4S2t2h13xJDj76wuPxjI/9lrJQ/fc/lb8UbRn+75fM4LwppEet6jpdlOu61ihF1OOzBcbVP1Yg/hWx8aviBJ4OsYbXTdovpl3biM7F6DA9Sc/kat/CSMSW19cfxBYLcH2C7j/6HXH/AB78JT+KNQjm0OSK8vbdNk1rE4aRQCSDtBz/ABEUYpys+U9PKo0ZYiKrWtra+zfS5wXhH4v+IYdZRry4a5iZstHJghh3HTj8KzviX4k1HWvG1zPJJL5PmlYEbOEjBwoA7cYP15q74B+Fmr3WpLPq9vJYWURzJNONnHouepr3280zwVe3EMt/a2U88SqgfaRkAYGT/FwO9a5Pi1hpylUV09v6Z0cSYWnXjCNG3Or3t26XtpcufDC6u7/wBpM2oyPJOUZS8nUqGIUk/QDmoPENkLCXzkXbazvtlUdI5G6MPQMeD7kHua6iFkMcf2PyvJC4SMDAx7VHeWsV9YT2s+TFIhQjoQCOR9R1FKpJTm5LS55FNOmkn0PJteuJLKyuZVP7xV2Rj/bY7V/U5/CuemgWGG3to/uxqB9a09faWTUoLO6/1sczPNjoxjG3P0JbNLptg11ceY3IzkVpRjZajxE03oafhTSftN0gYfKOWPt6V6Wtv5cYVRjtx/KszwnYrEjyEYA4B/rWlqd0UUJEMyvwq1bd2chRv5iXFtARk/eIqjexpbW7sxwFBYk+wrWsrI2qM8wzMeefWsXUojqGoW1guT58oV/90ct+gNCA1E3af4GsLU8XF9gN6jeS7/iFz+VadpGWPmScY6D0qnqUi3XiIqMGKyjESjt5jYJ/IbfzNX5JVhhyx+UfqaQmOurhYk3Hr/CPWl021aRjPP1PP0FQ2Fu93P50o+X+EGtdsBdo+4OvvUt9AQpb+L8FFZl5ceYxRT8i8sfU06/ucfIp+c/oKzCTIwjj6dzQkAoVrmXC52Dgn+laqRrCmBjNMgjW3jHHNRySFjUykUkDsM03NMLAUK4JrnbLSJl61Kq5pka7jVuNPWkMIo/Wr8KgCoEXNWlGBWkCJC0UUVoSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVznxFme38E6vJFqn9kSeTtW+2sfJJIGTtBIHONw+7nPagDo6K8G07xy+iwXP9manYRwSahaWsmpXmtzazpsIkSYsY5pGjcONilkLYGV5Gc03VPjD4itrKweK00dBNFcyR31w0cFrqHlztGnlNNdReWrKqvnMpAcHaRyQD3uivKb/wAa+KGtb+5sl0aBI9dg0WGKe3klYGWSBd7MsoHyiVuAOeDkYwa9p498S2d/F/bb6PNYnUNR05/sdjMsoNtBLKJQDM2d3lY8vrzw3agD16ivnQ/FLXNft5fL1fSbC30/UdMmbUkhCxGGZ5FYTLHdyAKCi5BkBwSCFPNdOPH99a30ls2q6FptpPqN1G2taj5stp+7igZEUNOApk8xmADhQEOATk0AeyUVxHjzxVc6Db6D5OoaRZQahKUm1i/jZrSECMuOBIvLkYXMgHueK52D4i6k3im308XuhXKte2tmlnDE/wBovYZIkdr6EiVgIcsxA2sMIcvmgD1mivH4viB4g/sbw5f6jfeHNItta80/bLm1laG18sHCNmZd7yHG0ZXG1h85IrY+Fz6wnwd8GHQoNPml/s6HzBeTvEANg6FUbJ/KgD0iiuV8/wAcf9A7w1/4Hz//ABmjz/HH/QO8Nf8AgfP/APGaAOqrk9SAg8ajsLuxHHqY3P8AST9Kd5/jj/oHeGv/AAPn/wDjNc14tbxjFfaNqE1h4fUxTm3Gy9mIIlGOcxDAyFpoa3K/w4lNjZ+I7NR/pFtKZFUdT8pUfrGa8X+ErX0/xGtZ/MkUIZJZpGJ+7tO4n65x+Negm78U6J4znufseiqZJRHIv2qXYRLtwc+XnAcdcdzXYfY9TgtNUubvStDsxNCd0mnyMzu3fdmNeMZOcmuqlivYQnG1+ZDlQ9tODvszK1K9ufEN4HBKWsbERx9APf61Re0l2nZt3A42nvTLRpDpk6Wyh5slQhbbgHqazdJW/e5trh0d0kGwSyDdgDqev868ffVn1H8N8sdkdT4Wv7iz1GO1lJEUrbNhOQGPQj8a9Bjbeyr/AHl+bPfFeWWLNPr8PlnOJVI/A5/kK9MEqQW7XMrBIkRizHgBRyTWlJ3RwZhCKmmla6PI/FSH/hOtZbkqFijQf7TIGb+ldFpFl5carjngf/WrF04PrOsS38qFRNIZ8HsD90H6KFH4V22lwhrpMdF55/nXfHRHj1HdmxGUsbD5+i8n3PpUOlWzXUhvJVbJPy5PFMlb7ZPsVN0CHv3q+90IodiqAFH3R2pbGZVvpMAsWyo6AcAmqHh4xx3d/qtycRWMJGe24/MfxAA/76qHU7phDJNJk4GQB/IVLqMBstF0/SnP726Y3F2R6DBYfmVX6U/IaE0ppWi8+4+WSUmWQn+Esc4/DOPwrTtonvpg7AiFfuj1qpp0JvJADkQjt6100aCFAqAA9valJgOUCNNicHufSqd5dLCh5+gp13cCJSM8965+aR7mcgHjufSpSAkMjSucHk9TV+1jESbiOT0qvbQquDjgVYd6ipO2hUVcc756mombPSmnJNOUVzSnc0SEC+tSKvNCrnpVmKPHJqFdjZJEMCrKZNQqKsIcCtopLchvsWIgMVLUETc1PWqt0IYUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFLUtLs9Saza9h802dwt1B8xXZIoIDcHnhjweOau0UUAFFFFABRRRQAUUUUAFFFFABRRRQAVj+MLR73w1qEcQzMsfmxf76Hev6qK2KDyOaFoB5J4ySO7fT7xRm3v7cxMfXjev6F60PDeur5aWOsSDzHGxZH4WYduegb1H5UuraeR4VubWMZl02ZmjHtG5IH4of1rGaBJYSkirJC46EZBFaOKkjWM+Uval4UvrS9NzpJE0Df8ALMsAV/OqE2ma2zkJaTLu68cCo7e51XSMjSbyTyO0FwDKg+hyGH0zj2qSTxd4lkGyOOxRz/EFc/pmud0Ox6EcdJJXs7G7oHh46Yn23U5UiKjJ3EAIPUn1rI8Sa23iSZNO0nP9mKR5kgH/AB8eij/Y45Pf6Zqj9g1LWsNrN5Lc5OfLbCxr77BwfxzXT6Tp0NlHmNSWPG49T71rCkoHJWxDqO73KdjZizgCY/eH7xratovLi8osFmkwX9QPSpo4QgM8wAC9Ae5qxZQwgmeSVXZ/XjFa3ORgkSomFV2+g2imtE0hwwHHIjH3R7mrzsgQMeF7D1+lZeq3v2e2YRxlnc7FReSzHoPc0gKunQf2jr8cDYeG3/fzEdOPuD8Tz/wGkctrevXksRzAjC3Q9sJncf8Avokf8BFXzbyeGPCN/cuwfUZRuZh08xsKij2BIH5mrXhbTl0vSoI25fYMn1/z1pX6jL9taraxKqjnsPWmXVwIlPOWNT3EwiRmY/N/L2rnbudnfav326ewpJXAZeTvNJ5ack9fapbeEIoH5n1pkESxLzyTyT61MTmpnUUdEVGNyTdxgUAZpqLUgFccndmqQAVIiFqckeetWETAojFyE3YSNABwKlAoAxThW1lEjVj0Wn0xDUqipKHKMCrCdKiVSamAxVwREmFFFFaEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzTWwTxHqEDD93dRJcgepA2OP0T8642C1fT7qbTLgHdAcRk/wAcf8Dflx9Qa9A1oCLUNKuen71rdj/supP/AKEiU3WtJi1SFct5VxHzFOoyyH+oPcf/AK6uMrDucnFp6Dk9T29KU2cW48ZxwT6+1TSi7sSsOoosbs21JVOUf6HsfY8/WtPT7QNh8blHT3NXcV2N0vSkA3NnLVpfZok+4o44BNWQAifp/jWffXPlFVAJ3HnHYVO4iOeJ55V27DEp6HnJqwUUchI0x3xmooHjXhXlY++TUV3KqMCYXd2OF39M/SmIjvbiGKF5TJ8qjLyk9B6CrPhrTmkK6neIVlYf6PE3/LFD3x/ePf649aoaTajWdTLyfNYWbYIxxNL/AFC/zrsqmTtoUc/40Qz2VlbAZM13GMf7uW/9lq/I6xLljgAce3/16z9ZlEviPT4AeLeJ7h/YkhV/9n/KqGq34ZwifMf4V9fehLQB19eF3wOSfurUMSbRk8seppsEW35n5c9TU6jJqJz5VoVGNwUZ61Kq0qLU6R+tcbZqMVCanjjp6J7VKBiqjG4m7CKoFOqlrGr6botoLrWdQs9PtSwTzrqZYk3HoNzEDPB4qDTvEOk6jdzWtnfwSXEUzQGPOCzqiSELn74CyIcrkfMOa1vbREb7mqKKKciljgUkMkiUk1aRMDmqWk6jZahLfxWU3myWFx9luRsZfLl2I+3kc/LIhyMjn61asbu2v7SG7sbiG5tZlDxTQuHR1PQqw4I9xVqPclsnoqE3duLwWZni+1mMyiHeN5QHBbb1xkgZ96mqyQoqC+u7awtJru+uIba1hUvLNM4REUdSzHgD3NT0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVFdCM2swuI/Mh2HemwvuXHI2gHPHbHNAEtFeF+EbTXrTw3oGm+Go9W8PWnkatcXYh0hYmMyyxm3DCaE43Kxxx8wBA+7ws/i7xhDf6I2r3Gr6bNc3ujwJaR6Uv2WeOcQ/afNlaJikgdpV2B0K7RwetAHudFeEeINf8AGl/4Wk0w6bqlzqEenaqt+s2ib4ZplcC2Vd0RSTK5wFyGzzk9Ooe98ZQeImvfP1O4sBr72X9nCxj8s2X2csJQ+wP98ABy+3nBzQB6TeXdtYwefe3ENvDuVPMlcIu5mCqMnuWIAHckCiW7t4rqC2luIkuJwxiiZwHkC43FR1OMjOOma8AXUvG3iGzv7PUrDXZrBn0y5iS8siJYpF1CEyIWW1gB2xjcwXzFG0kORnHc/GKz1KeW3n0qwlvJIdG1dVVbX7Qhka3URoyFSrbiMBSDu6YPSgD0yivFp/E/iaw8Vadb3txq9sZdVjtItOj0xFs5rT7PuyJ2j5kLA/KJFIwRtAGazNO8SfEW8h1SOKPX4Fkjsmt5LrTg81u73kaTLzaQoSIWYkASKNpIc44APfKK8jil8fafqCyR6hqeqomsz6ettd2ECRy2wtpJI53eOJCP3oRN4Kp0GM9cTw7rPxIv4oYru61G3eeezjnJ01zLbbpCJiheyii2BT6y7doO4g0Ae70V4rBD4kk8b+GL3XLvxB5Vlc6pp32qDTUYyx/aIfJMoWEhUkRDmQBVwgIK5JPpur2viaW9LaNq+jWlptGI7rSpbh89zvW4jGPbb+dAG7RXK/YfHH/Qw+G//BDP/wDJlH2Hxx/0MPhv/wAEM/8A8mUAavidcaQ8wGTbyRz/AII4Y/oDV4dBXMzab41mheKTxB4aKOpVh/YM/IP/AG+Vm6VB43KSWsuv+Hlntj5bB9DmYsv8L5+1jII56dcjtT6AdrcQRXMDw3EayROMMjDIIrIhgl0kFBulsyflfq0Y9G7kD16+vrW0m4Ku8gtjkgYBP0pHGUI9aE7AUZpV2hkwykfLg9qyBcKJDJNEdxPykMOlT3kShSttcpEuTlGHQ/QkEVWw7KEa7JH91R/9lWiE0TNqKgEKpGP7xqmguNTmaK3cCUqQHxkRZ/iP9B3NTizGABGee7k8/TpWvpsYtowm4Kuc7FAHPvihtLYLF3TLKHTrGG1txiKJcDPU+pPuetVPEgvv7OLabqNvp0kZ8ySae289fLAORt3Ljsc57dOa1FYMMqciuD8Waub26fT7X5oFfbK3/PRgfuj/AGQevqRis0rsZyiL4skklvZdesheXuCIjphyqAfKP9bxxz9Sas22j+KAzO3iKwLt1J0sn8P9bW7ZW20mRzvmb7zGtJFwKJSKsc4umeKT/wAzFp//AIKj/wDHqmTSvFR6eI9P/wDBUf8A49XTRRk1aRQo4rllJtmiRyyaT4qH/Myad/4KT/8AHqlXSvFn/Qy6d/4KT/8AHq6dRUijFShnMDS/Fg/5mXTv/BQf/j1H9meLf+hl07/wUH/49XUUCtL9ERY434g2GsXfgN7G2tn1fU3lg3fZhHAG2yq7NiSQADC4xuJyR745a+8PeMxqfiCfQxLYG+ub24hY3KBSz2dqkJYBjyHjkAJB2kZ6EZ9dp6KWNOIM8Q1W31+wt7ZZLbxPbabeavZww6e+siS9kHlS+cBP552qx2YBlH3SRtyBWhFpHxC07Sbgx22rXkl3pV/a20C6nGZbGV5i1u0sjyje6xkL5ilmBXGe9e1RRBR71LWqViGzxfQvDPiuz8WyTrZ6vbyT6xBeTXp1JDZvai1iSVXhEpLyMyMMmPj5Tu4xVrwbo3iy0vNCPi618Q6gY7GzRZLXWAkdtOufONygnTzstgk4lBXjHY+vUUxHm/jXw7qNx4/ttZsLLVLhTpM1mktlqJgWCfeGRpEMqBk69A3IGRwCOR8Z+G/Hy+H9Mt/D0esy6n/ZqSzXg1iRnW92qGRlN3FGF+UYOyVclvl5JPu1FAHi/inwp4j13SfGWn39jrlzqN+lwLC7j1fy7ARlAYojAJ1w2RtJMRBOSWwePVPDEXk6Faxm01GzIDfuNRuvtM6fMfvyeZJu9R854IHGMDUooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzJvD+jTa1HrE2kadJq0Ywl61shnUYxgSY3DgnvWnRQAUUUUAFFFFAGWvh7RV1xtaXSNOGssMNfi2T7QRt28yY3fdAHXpxWpRRQAUUUUAFFFFABRRRQAVQ1Sye4CzWjLFexf6t26MO6t7H9OtX6KAMywvTPmKeJre6UZaJ/wCYPQj3FXKS8tIrtFEgIdTlHHDKfY1knVBDpsslwdskLGOTHUkHHHuccU21uPctajcQRRN5r4x1Ibbj6mstWaY/uEnZfUsUX8zz/wCO0tlZyTut1f4L9Y4R92If1Pqa1MY6VyTxL2ibKkupn7L2LJhSAn3c5/PH9Kih1ApMIriIwTf3GOQ30Pf/ADxWpketQX1pFe27RTA46hh1U9iD61Ea809dRunFkOt6g9pos81q37yQCNCP4WY4z+HJrldLtVhhVivzYwM9q1ZkkbStRtbo/wCk26CQMOkijkMPywaqWeCgYn8K6+dSjoZKNmWUXbjjmr1umeW6VXiGTk1bhPOO1Q9dCi0BgcU4c02noKxY0PUU+kHAp3Wp1KEpRTglPWPJraKuZvQaiFjVuKMKKIkwKlrZKxDdwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4/WrUSeKrWAD9yw+0uvq/3R/I/nXYVzl+u3xZGzDhrQKD7hm/xrKu7QZpT+I0KgupjGuE5bGcdTj6VYrN1AxShEdjgns3Ujsa4GdCKsFxJLLuRRuOSqv0XHGfbvxWrE/zbcAj+8pyDXOG4CsJIVEgKlWVz83J7Vq6SqIPlaLLfNgHJAPvUpjaF1qECNbrBxGCkoH8UTcN+XX8KwIVe3naBiCUOM+vv+PWuxIDKQwyCMEGuT1CDyJE2k/ITCSf9nlf/ABwr+Rrqoy3iZSXUvRsM4qxCf3gqjAflWrkR+cVs9FcjqaFSRimKOBUyDtWKKFqaOPjJojjxyalFdEIdWZyl2ECipY0pUTuakrS1iAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5/xF+71XTJugbfGf0I/rXQVg+MoidKS4T71tMkn4Z2n+efwrOqrwZdN2kiwxGw5OBjrnFZEqS/O7MEcqxLK3YYx254zzWvCwaJWByCMisi+VkuTt3qwjP3QcYz0P/wBavPlsdKM+NYC7FCZVhXcvGMnPfj3q3ZykwI0SJ5Z2iTcxJHpmlmtzHuKRLuYkbQe3qfwqeEi2UM8iIuSoU8554ycelQkUakIxGv0FYuuxfvJsfxRCYfWM4P8A465/Kti3fzIw2VPuOlV9TjB+zyHokgVv91/kP/oWfwrem7STM5bGBbSBIMt9OO9WLe5knikeGIbkkKAu2F44JJ9Acj8Kx57s2lg8jELKvyqTyFY8ZI7gck+wNQWljqEmoSwwwyqjQrHsPO5PkDDPsJjk+qE12NXVjFuzOn0W7l1ayt5N4C7d0rICuTk4T2Ixzz7VvRr8wqp4d0k6XpxgIwxlkc85zliQT74xWqkXOaI00nclyuIBmpUTHWnKoFLWhIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN7At1aTW7/AHZUKH8RipqKAOa0CV309YphieAmKRfQip7yB2jbyW2sSDz+tXv7MRdRmu43ZTMoDpjgkdD+VWPso7sfyri9hLY6PaIxHsRJMs+0b+4JyCPWnw2aiHypCXQE/eHPXOa2RbJ6mlFvGOxP40fV5B7VFBF2qATn3NQ6gu6xnH+wa2BDGP4RTgqjoo/KrWHfcl1UcTbaNLe3b+ZB+5893DN0xuODXYwW8cQUhQXUEBsc4PX+Q/KpqK6UrGTdwooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure represents a parasagittal section of the lower right abdominal wall depicting the separation of the musculoaponeurotic lamina into the anterior and posterior inguinal walls. Familiarity of the anatomy facilitates the preperitoneal approach and iliopubic tract repair of inguinal hernias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2692=[""].join("\n");
var outline_f2_40_2692=null;
var title_f2_40_2693="Linear IgA bullous dermatosis of childhood on genitalia";
var content_f2_40_2693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis of childhood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tense vesicles and bullae are present on the vulvar skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2693=[""].join("\n");
var outline_f2_40_2693=null;
var title_f2_40_2694="Zolmitriptan: Drug information";
var content_f2_40_2694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zolmitriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/25/2454?source=see_link\">",
"    see \"Zolmitriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F236070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zomig-ZMT&reg;;",
"     </li>",
"     <li>",
"      Zomig&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F236071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mylan-Zolmitriptan;",
"     </li>",
"     <li>",
"      PMS-Zolmitriptan;",
"     </li>",
"     <li>",
"      PMS-Zolmitriptan ODT;",
"     </li>",
"     <li>",
"      Sandoz-Zolmitriptan;",
"     </li>",
"     <li>",
"      Sandoz-Zolmitriptan ODT;",
"     </li>",
"     <li>",
"      Teva-Zolmitriptan;",
"     </li>",
"     <li>",
"      Teva-Zolmitriptan OD;",
"     </li>",
"     <li>",
"      Zolmitriptan ODT;",
"     </li>",
"     <li>",
"      Zomig&reg;;",
"     </li>",
"     <li>",
"      Zomig&reg; Nasal Spray;",
"     </li>",
"     <li>",
"      Zomig&reg; Rapimelt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F236106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F236074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Migraine:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial dose:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Administer at the onset of migraine headache.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nasal inhalation: 5 mg (one spray)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Tablet: 1.25-2.5 mg (maximum: 5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Orally-disintegrating tablet: 2.5 mg (maximum: 5 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Second dose (either nasal inhalation or oral):",
"     </i>",
"     May repeat in 2 hours if the migraine headache has not resolved (maximum daily dose: 10 mg); controlled trials have not established the effectiveness of a second dose if the initial dose was ineffective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Menstrual migraine, prophylaxis (unlabeled use):",
"     </b>",
"     Oral: 2.5 mg 2-3 times daily starting 2 days prior to the expected onset of menses and continued through to 5 days after the onset of menses (7 days total) (Tuchman, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for concomitant therapy with cimetidine:",
"     </b>",
"     Maximum single dose: 2.5 mg (maximum daily dose: 5 mg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F236075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate therapy at the low end of the dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F236076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, zolmitriptan clearance is reduced in patients with severe renal impairment (Cl",
"     <sub>",
"      c",
"     </sub>",
"     5-25 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F236077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe impairment: Initial: 1.25 mg (maximum daily dose: 5 mg);",
"     <b>",
"      Note:",
"     </b>",
"     Therapy must be administered using oral tablets because doses &lt;2.5 mg cannot be achieved with orally-disintegrating tablets or nasal spray. Patients with moderate-to-severe hepatic impairment may have decreased clearance of zolmitriptan, and significant elevation in blood pressure was observed in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F236043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zomig&reg;: 5 mg/0.1 mL (0.1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zomig&reg;: 2.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zomig&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zomig-ZMT&reg;: 2.5 mg [contains phenylalanine 2.81 mg/tablet; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zomig-ZMT&reg;: 5 mg [contains phenylalanine 5.62 mg/tablet; orange flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F236029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F236047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as soon as migraine headache starts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: May be broken in half to achieve a smaller initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally-disintegrating tablet: Must be taken whole; do not break, crush, or chew. Place on tongue and allow to dissolve. Administration with liquid is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasal spray: Blow nose gently prior to use. After removing protective cap, instill device into nostril. Block opposite nostril; breathe in gently through nose while pressing plunger of spray device. One dose (5 mg) is equal to 1 spray in 1 nostril.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F236046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of migraine with or without aura",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14308798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term prevention of menstrual migraines",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F236114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       ZOLMitriptan may be confused with SUMAtriptan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F236104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Abnormal taste (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain/tightness (1% to 4%), palpitation (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (6% to 10%), somnolence (4% to 8%), pain (2% to 4%), vertigo (&le;2%), headache (1% to &lt;2%), insomnia (1% to &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 9%), xerostomia (2% to 5%), dyspepsia (2% to 3%), dysphagia (&le;2%), abdominal pain (1% to &lt;2%), vomiting (1% to &lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site irritation/soreness (nasal spray 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (5% to 10%), weakness (5% to 9%), warm/cold sensation (5% to 7%), hypoesthesia (1% to 5%), myalgia (1% to 2%), myasthenia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasal discomfort (nasal spray 3%), throat pressure/tightness (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Neck/throat/jaw pain (4% to 10%), pressure/tightness/heaviness (2% to 5%), diaphoresis (&le;3%), allergic reaction (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Amblyopia, anaphylaxis, angina, apnea, arrhythmia, arthritis, ataxia, atrial fibrillation, bradycardia, breast carcinoma, breast neoplasm, cerebral ischemia, confusion, coronary artery vasospasm, cyanosis, depersonalization, eosinophilia, erythema, erythema multiforme, esophagitis, fibrocytic breast diseases, gastrointestinal carcinoma, gastrointestinal infarction/necrosis, hallucinations, headache, hematemesis, hepatic neoplasia, hypertension, hypertensive crisis, hyperthyroidism, infection, intestinal obstruction, ischemic colitis, mania, melena, MI, miscarriage, myocardial ischemia, neoplasm, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction), pancreatitis, photosensitivity, pneumonia, pregnancy, psychosis, pyelonephritis, QT prolongation, seizures, serotonin syndrome, sialadenitis, skin neoplasm, splenic infarction, syncope, tardive dyskinesia, tetany, thrombocytopenia, ulcer, urinary tract infection, urogenital neoplasm, uterine fibroids enlarged, vaginitis, vasodilation, visual field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Events related to other serotonin 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptor agonists: Cardiac arrest, cerebral hemorrhage, peripheral vascular ischemia, stroke, subarachnoid hemorrhage, ventricular fibrillation, vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F236050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zolmitriptan or any component of the formulation; ischemic coronary artery disease (eg, angina pectoris, history of MI, silent ischemia);  vasospastic coronary artery disease (including Prinzmetal's angina); signs or symptoms of ischemic heart disease; uncontrolled hypertension; symptomatic Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist; concurrent administration or within 2 weeks of discontinuing an MAO inhibitor; history of stroke, transient ischemic attack (TIA), or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F236033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration; nasal spray contraindicated in patients with cerebrovascular syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual effects: Rarely, partial vision loss and blindness (transient and permanent) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Drug clearance may be reduced leading to increased plasma concentrations; dosage reduction of the oral product is recommended.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (eg, SSRIs/SNRIs or triptans) or agents which reduce zolmitriptan's metabolism. Concurrent use of serotonin precursors is not recommended (doses &lt;5 mg can only be achieved using oral tablets).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Elderly patients are more likely to have underlying cardiovascular disease and hepatic or renal impairment; use with caution.  Cardiovascular evaluation is recommended for elderly patients with other cardiovascular risk factors prior to initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Zomig-ZMT&trade; tablets contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for treatment of migraine headache; not indicated for migraine prophylaxis (may be used off-label for menstrual migraine prophylaxis) or for the treatment of cluster headache. Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.  If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered;. rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F236100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F236038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of ZOLMitriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: May increase the serum concentration of ZOLMitriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F236065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Limit use (may have additive CNS toxicity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F236040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F236053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using zolmitriptan in pregnant women. Use only if potential benefit to the mother outweighs the potential risk to the fetus. In animal studies, administration was associated with embryolethality, fetal abnormalities, and pup mortality.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F236080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9738958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F236052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zomig Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (6): $308.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Zomig ZMT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (6): $337.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (3): $186.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zomig Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (6): $337.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F236054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ascotop (DE);",
"     </li>",
"     <li>",
"      Heng Li An (CL);",
"     </li>",
"     <li>",
"      Myslee (JP);",
"     </li>",
"     <li>",
"      Zolmiles (BG);",
"     </li>",
"     <li>",
"      Zomig (AT, AU, BB, BE, BF, BJ, BM, BR, BS, BZ, CH, CI, CL, CR, CZ, DK, DO, ES, ET, FR, GB, GH, GM, GN, GT, GY, HK, HN, HU, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, RU, SC, SD, SE, SG, SL, SN, SR, SV, TH, TN, TR, TT, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zomig Rapimelt (EE, FI, IL, SE);",
"     </li>",
"     <li>",
"      Zomigon (AR, GR, UY);",
"     </li>",
"     <li>",
"      Zomigoro (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F236032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries and sensory nerves of the trigeminal system; causes vasoconstriction and reduces inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F236049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.5-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Oral: 7 L/kg; Nasal spray: 8.4 &plusmn; 3.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted to an active N-desmethyl metabolite (2-6 times more potent than zolmitriptan at 5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 40%; mean bioavailability of nasal spray compared with oral tablet: 102%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.8-3.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Tablet: 1.5 hours; Orally-disintegrating tablet and nasal spray: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~60% to 65% total dose; 8% of total dose as unchanged drug; 4% of total dose as N-desmethyl metabolite); feces (30% to 40%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(11):1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2694/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2694/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuchman MM, Hee A, Emeribe U, et al, &ldquo;Oral Zolmitriptan in the Short-Term Prevention of Menstrual Migraine: A Randomized, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2008, 22(10):877-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2694/abstract-text/18788838/pubmed\" id=\"18788838\" target=\"_blank\">",
"        18788838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10233 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2694=[""].join("\n");
var outline_f2_40_2694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236070\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236071\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236106\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236074\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236075\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236076\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236077\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236043\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236029\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236047\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236046\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14308798\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236114\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236104\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236050\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236033\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236100\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236038\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236065\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236040\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236053\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236080\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9738958\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236052\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236032\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F236049\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/25/2454?source=related_link\">",
"      Zolmitriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_40_2695="Fosaprepitant (intravenous aprepitant): Pediatric drug information";
var content_f2_40_2695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosaprepitant (intravenous aprepitant): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"    see \"Fosaprepitant (intravenous aprepitant): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/55/6004?source=see_link\">",
"    see \"Fosaprepitant (intravenous aprepitant): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5634805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12822224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Emend&reg; IV",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F13313140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Substance P/Neurokinin 1 Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F13313149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"      see \"Fosaprepitant (intravenous aprepitant): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.:",
"     <b>",
"      Prevention of chemotherapy-induced nausea and vomiting:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Single-dose regimen (for highly emetogenic chemotherapy): 150 mg over 20-30 minutes ~30 minutes prior to chemotherapy on day 1 only (in combination with a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist on day 1 and dexamethasone on days 1-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3-day regimen (for highly emetogenic chemotherapy): 115 mg over 15 minutes 30 minutes prior to chemotherapy on day 1, followed by aprepitant 80 mg orally on days 2 and 3 (in combination with a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist on day 1 and dexamethasone on days 1-4)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3-day regimen (for moderately emetogenic chemotherapy): 115 mg over 15 minutes 30 minutes prior to chemotherapy on day 1, followed by aprepitant 80 mg orally on days 2 and 3 (in combination with a 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     antagonist and dexamethasone on day 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild, moderate, or severe impairment: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dialysis-dependent end-stage renal disease (ESRD): No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild to moderate impairment (Child-Pugh score 5-9): No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh score &gt;9): Use caution; no data available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5657664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg; for Injection: 115 mg [DSC] [contains edetate disodium, lactose 287.5 mg, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emend&reg; for Injection: 150 mg [contains edetate disodium, lactose 375 mg, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5657515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13313150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Reconstitute vial with 5 mL NS; further dilute in NS to a final  concentration of 1 mg/mL; administer 30 minutes prior to chemotherapy; infusion rate is dose-dependent:  150 mg over 20-30 minutes and 115 mg over 15 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F5657554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in sodium chloride 0.9%;",
"     <b>",
"      incompatible",
"     </b>",
"     with solutions containing calcium (eg, lactated Ringer&rsquo;s solution, Hartmann&rsquo;s solution) or magnesium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Incompatible:",
"     </b>",
"     Dexamethasone sodium phosphate, palonosetron.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Granisetron, methylprednisolone sodium succinate, ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13313146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Stable for 24 hours at &le;25&deg;C (&le;77&deg;F) after dilution in NS.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13313141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderate and highly emetogenic cancer chemotherapy (MEC &amp; HEC) in combination with other antiemetic agents (FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5657514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosaprepitant may be confused with aprepitant, fosamprenavir, fospropofol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Emend&reg; for Injection (fosaprepitant) may be confused with Emend&reg; (aprepitant) which is an oral capsule formulation.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F5657530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with aprepitant and fosaprepitant (as part of a combination chemotherapy regimen) occurring at a higher frequency than standard antiemetic therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, eructation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (includes erythema, induration, pain, pruritus, or thrombophlebitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, alkaline phosphatase increased, anaphylactic reaction, anemia, angioedema, bradycardia, candidiasis, cardiovascular disorder, chest discomfort, chills, cognitive disorder, conjunctivitis, cough, disorientation, dizziness, duodenal ulcer (perforating), dyspnea, edema, erythema, flushing, gait disturbance, hematuria (microscopic), hyperglycemia, hyperhydrosis, hypersensitivity reaction, hypertension, hyponatremia, miosis, nausea, neutropenia, neutropenic colitis, neutropenic fever, palpitation, photosensitivity, pollakiuria, polyuria, pruritus, rash, sensory disturbance, somnolence, staphylococcal infection, Stevens-Johnson syndrome, stomatitis, subileus, tinnitus, toxic epidermal necrolysis, urticaria, visual acuity decreased, vomiting, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13313142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosaprepitant, aprepitant, polysorbate 80, or any component; concurrent use with pimozide or cisapride",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13313156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe hepatic impairment (Child-Pugh score &gt;9); use has not been studied. Use with caution in patients receiving medications metabolized by CYP3A4 as decreased metabolism and subsequent elevation of serum concentration may occur; the effect of aprepitant on orally administered CYP3A4 substrates may be greater than that seen with intravenously administered CYP3A4 substrates. Use with caution and monitor use closely in patients receiving docetaxel, paclitaxel, etoposide, irinotecan, ifosfamide, imatinib, vinorelbine, vinblastine, and vincristine as they are known to be metabolized by CYP3A4 isoenzymes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Chronic continuous use for prevention of nausea and vomiting is not recommended because it has not been studied. Fosaprepitant has not been studied for the treatment of established nausea and vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13313143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Immediate hypersensitivity has been reported (rarely) during infusion with fosaprepitant. Stop infusion with hypersensitivity symptoms (anaphylaxis, dyspnea, erythema, or flushing); do not reinitiate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fosaprepitant is rapidly converted to aprepitant. Fosaprepitant and aprepitant have the potential to significantly interact with many medications; increased serum concentrations of pimozide or cisapride could result in serious or life-threatening adverse effects. Concomitant use with warfarin may result in clinically significant decrease in INR; patients on warfarin should have INR monitored closely, particularly at 7-10 days following initiation of fosaprepitant therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Efficacy of oral contraceptives may be reduced during treatment with fosaprepitant; alternative or additional methods of birth control should be used both during treatment with fosaprepitant and for at least 1 month following the last fosaprepitant dose. Contains polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. Infusion of polysorbate 80 containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5657546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP3A4 (moderate);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5657545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Astemizole: Fosaprepitant may increase the serum concentration of Astemizole. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Fosaprepitant may increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Fosaprepitant may increase the serum concentration of Cisapride. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Fosaprepitant may decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect.  Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Fosaprepitant may decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect.  Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Fosaprepitant. Specifically, diltiazem may increase the concentration of the active metabolite aprepitant. Fosaprepitant may increase the serum concentration of Diltiazem. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: May decrease serum concentrations of the active metabolite(s) of Fosaprepitant. Fosaprepitant may decrease the serum concentration of PARoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Fosaprepitant may increase the serum concentration of Pimozide. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terfenadine: Fosaprepitant may increase the serum concentration of Terfenadine. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TOLBUTamide: Fosaprepitant may decrease the serum concentration of TOLBUTamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fosaprepitant may decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13313145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Aprepitant serum concentration may be increased when taken with grapefruit juice; avoid concurrent use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5657520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5657521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies for aprepitant. Use during pregnancy only if clearly needed. Efficacy of hormonal contraceptive may be reduced; alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least 1 month following the last fosaprepitant/aprepitant dose.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13313178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate hypersensitivity reactions during infusion (anaphylaxis, dyspnea, erythema, or flushing).  If reaction occurs, infusion should be stopped and not reinitiated.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13313147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosaprepitant is a prodrug of aprepitant, a substance P/neurokinin 1 (NK1) receptor antagonist. It is rapidly converted to aprepitant which prevents acute and delayed vomiting by inhibiting the substance P/neurokinin 1 (NK1) receptor; augments the antiemetic activity of the 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     receptor antagonist and corticosteroid activity and inhibits chemotherapy-induced emesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13313148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Fosaprepitant: ~5 L; Aprepitant: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~70 L; crosses the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Aprepitant: &gt;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fosaprepitant: Hepatic and extrahepatic; rapidly (within 30 minutes after the end of infusion) converted to aprepitant (nearly complete conversion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Aprepitant: Hepatic via CYP3A4 (major); CYP1A2 and CYP2C19 (minor); forms 7 weakly-active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: Fosaprepitant: ~2 minutes; Aprepitant: ~9-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (57%); feces (45%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: 62-90 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13313151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/55/6004?source=see_link\">",
"      see \"Fosaprepitant (intravenous aprepitant): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosaprepitant may cause dry mouth. Fosaprepitant may react with many other medications; report all medication use including OTC and herbal products to your physician; avoid the herbal medicine St John's wort. Due to potential decreased effectiveness of oral contraceptives, alternative or additional contraceptive methods should be used during and for at least 1 month following therapy. Avoid grapefruit and grapefruit juice. Report immediately any pain or burning at infusion site, swelling of mouth, difficulty swallowing, difficulty breathing, or flushing to your physician or nurse.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cocquyt V, Van Belle S, Reinhardt RR, et al, &ldquo;Comparison of L-758,298, a Prodrug for the Selective Neurokinin-1 Antagonist, L-754,030, With Ondansetron for the Prevention of Cisplatin-Induced Emesis,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2001, 37(7):835-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2695/abstract-text/11313170/pubmed\" id=\"11313170\" target=\"_blank\">",
"        11313170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lasseter KC, Gambelle J, Jin B, et al, &ldquo;Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007,47(7):834-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2695/abstract-text/117525168/pubmed\" id=\"117525168\" target=\"_blank\">",
"        117525168",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marbury TC, Jin B, Panebianco D, et al, &ldquo;Lack of Effect of Aprepitant or its Prodrug Fosaprepitant on QTc Intervals in Healthy Subjects,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2009, 109(2):418-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2695/abstract-text/19608812/pubmed\" id=\"19608812\" target=\"_blank\">",
"        19608812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Multinational Association of Supportive Care in Cancer (MASCC), &ldquo;Antiemetic Guidelines,&rdquo; Updated April 2010. Available at file://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2010.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Antiemesis,&rdquo; Version 1.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Belle S, Lichinitser SR, Navari RM, et al,&rdquo; Prevention of Cisplatin-Induced Acute and Delayed Emesis by the Selective Neurokinin-1 Antagonists, L-758,298 and MK-869,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 94(11):3032-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/40/2695/abstract-text/12115394/pubmed\" id=\"12115394\" target=\"_blank\">",
"        12115394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17060 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2695=[""].join("\n");
var outline_f2_40_2695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5634805\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12822224\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313140\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313149\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657664\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657515\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313150\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657554\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313146\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313141\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657514\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657530\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313142\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313156\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313143\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657546\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657545\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313145\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657520\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5657521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313148\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13313151\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17060\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/17060|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/55/6004?source=related_link\">",
"      Fosaprepitant (intravenous aprepitant): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_40_2696="Zones of adrenal tissue";
var content_f2_40_2696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Zones of adrenal tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 543px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIfAgoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAozXAfEDxRqdheCw0NVEoTMkpXJUnoBnjpXATS+LdUbE19eMp6qrlV/IcVLkehQy+dWKm5JJnvjOqDLsF+pxUBv7RfvXUAPvIK8Hi8GaxdOGlErH1JrTtvhvqDqN+QD1BajmfY1eX0Y/FVX3f8E9gfV9Nj+/qFov1mUf1qP+3tJ/6Cdl/wB/l/xrzBPhjPj5nz+NWI/ho6jkrn60XZP1XCr/AJe/gejjXtJPTUrP/v8AL/jTk1rTHOE1GzJ9BOv+NecH4cPtI+X86qS/Di5HKAD6Gi7BYXDP/l4espfWkhAS6gYn0kBqwDkdc14hcfD++QfLG5+hrP8A+Ef1vTX3W01zCR0Mbkfyo5mUsvpS+Cqvu/4J9AZozXg8HiXxdphGbuSZF6rMofP4nmtex+K2oW7hdU0yORM4LREqf1zRzETyqstY2foz2GiuK0z4l+HbzCzXElpIf4Zoz/MZFdZZX1rfRebZ3MM8Z/ijcMP0p3OKpRqUvji0WaKKKZkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFZ+pa1pmmKTf31vARztdxu/AdTXNzfEjQPOSGykuL2ZztVIYTyf+BYpXRrChUnrGLZ2lFYmheJLDWJJIreWP7RH9+NX3bfxHH5Vt0zOUXF2YUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDD1a1so7k3N2g+fAzjuKqDV9LtQBGi5+lcf8ctbuLOKwsrOZonJMzleuBwB/OvP7XX559OWWVgXU7Xx69vz/xqG7M9jDYKVanGUnoz2uTxZbJnZGPzqpL4yVRwgH414rJrz8jceKgk1yRlHzGjmZ3RyiHVHsk/jN/4SKoSeNp1Y5fivIZNZlPAeqzapL/eOaVzeOV010PYz44nH8eaX/hPJVGTg14v/akueSaQ6o5HXrRcv+zKXY92svHnmMA6A/jWxF4ntJhiaMfzr52sNUlM6qD1NdLLqksEALkg07mFXK6d/dPY2m0S+4YIrGqN14V026BMDpzXjyeIJRJw5wPetmx8VyxkDzD+dFzN5fVp605HU6h8PlZSYiCfYVzjeF9U0mfzbGeWB1PDRkgitzT/ABlIMAyZ+prftfFEM4AmCMPUijQn2mKp6TV0cxY+MvFOk4W4K3sY7TLyf+BDmugs/ivBwuoaXNE3cxOG/QgVpH+yr1fmVVJ9KpXPhbT7n/VFTRqYSeGn/Ep2fkbth8QfDt5gfbDA5/hmQg/mMiugttTsLpd1veW8o/2JAa8qvPAinJirHm8GXkQIj8xR/smndmbwWGn8E7ep7wCCOOaWvAodH1y0H+j3N3Hj+65pxn8VwjC6nfADtvNHMT/Zd/hqI97orwB77xZtOdUvj7bzVC4m8TuMSahev7GQ0cw1lEn9tH0YZEAyXUD61Vn1Owt13T3ttGvq8gAr5vOk6vO2ZJblieeWNXbTwjqFwuJBMy+hyaXMaf2TCPxVfw/4J7Rf+O/DllkSanC7dAIgXz+QxXO33xc0iJytraXc+O7YQf1rjbH4e3UhUmNx9RXR2Hw1XAMwC0XbH9WwNL45Nmff/FvUpwy6fpkMGeAzsXI/QCuavfEXirV9yy31wqt1SI7F/IV6vZeAdNgAMuWx1HStZNN0TTEz5cS47nmiz6jWLwlL+FTuzw7T/B2qahIpZZDnuc10N94NutA8O6lfqB56W5CEdVyQGP8A3zmvRL7xXYWakW6px3rl9V8ZG5Ro3ZfLPBXtRZF/WMVX0UbRPOfhhqE9l4ysBExxMxjcZ+8CCf5gGvpodK+f/BenWC+PLGZZVSAOWVD2bBAH05r6AFEDizRWqR9AoooqzzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8a+Ntm+pX8P2FPNubZP3sa8sVPIIHfvXn9tpN7DoV0JYHjkuJY2VXGCFQNkkHpnd+lewePvD8OpawtyJJ4blUAWSFipA/OuRHgSzknM139pupW5Jllzn9ankvqexhsdKnSULXsebT2sMHNzeQIeu1W3n8lyasWtgk+PJiupx6pEQP15/SvU7bSdH0zC+TFER/dT/AAq0uoaXECIyXI/uqV/mBTtFHQ8xxM/hVvkeYJ4b1GVf3Om7Ae8so/kOan/4RLVm5K2cY7gKx/rXqMMyXBGySyhH/TWYO/5Z4/OotaNxa2oe2na6c/wRGNAPqT/9ej3V0MXicRJ2czyu58Jaqg4Nu3/ACBWBqNjPaSiG6g8qUjIxyrD2New2G+4jka9llRhgqkLCRj7cDH61heMNLZ9GmuLksBEQ8aEDcvOOSPrRaMuhccVWoyu5X9ThfDNv5moxKRnnvXU+PtObT1jDDAIB4rO8Fwb9aj2jI3V3/wAYLQIlvLjIG3PFQtj06+Ica8UuzPFnIDdXA9dhxSxyMR+7cN9DXtaaVZSW0bl4VJQE7tqkcVk6j4a0m6H717Yt2PmKD+eavkXRnHTzWr9pJnmUV1JGRyRV+11Z0/ixXRXHghDn7JedOinEgrA1HwzqVoxIiWZfWM4P5GlyM7IZlQnpPQ1bbxE8eBvPFbVl4uK4zIeK83njmtziVJIj6SLjNEckmNyfMPY1PqbqFCt8LTPZ7PxidoxIa2bHxjGeJCDXg6Xkq8cirCanIAMMc9aLmM8spyPoa38U2Dj5wB+FXE13SH6lc/SvnL+2Zl6MaQa9ORgsRz60+Y5nk8Xsz6SXUdGc/ej/ABAqVbjSWGVMX6V83x65OT94/nVlNfuAPvHH1o5iHk76SPooXmlpjHl/pTZNc0yAf6yMV87P4imIxuI/Gq0utzMT85x9afMJZLf4pH0Dc+NdOhztkXOfSsq8+IVuvCE/lXhUmpyMeWP51Ebx2bkk++aXMbwyektz1e/+IUz7hHJj0rl9S8WT3BJeRj+Ncb5ksnqacIJGG5xtX1JwKVzshg6NLVI1LnWpZMjzDiqJvJJG6k5qKOKJiViMlw4/hhjLfr0/WtzTfD+oXK7jClonUMw8xgPpwB+tNRbM6mNw9LRO/oSeGre4n1az2MEYzoFZjjnIr6fQEIobrjmvCfBPhy0h8QWs9xPLc3CSAq0hUgc9gDXu4qlGx87mOJeImna1gooopnnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzuvK32zcuTwBxWbtbByB+P/AOqtLxA6R3O6RlRQB8zYx+tYwvNzkW8E0xHfywo/M4qbnVTTcSYx558tSff/APVTWUY+ZI/zNMa9mT/XWVwg9UAcfoc01LyKZgFuNhP8MmUJ/BsUXNLMGtYWJ3QxuDyf84pPsUCD91aQKfU//qqd1YfxZB9hTBvAOYlx7tigLvuQEGJs7VUdsEAf41xPxK1JYtMW2Zl8y4YAKGzwOSf5V12t6na6TYtc3yxqoBCjqWPoK8x0/S73xlrE+pXp+zabH9+Uj5Y1HRV9TT5rHRh6SqO8tIrd/p6sd4Hi+yzi/nXEWcgnoa77xxLFr3haS4gIcxjnFcPrlw2sXP2LR42j0+2XYrAccdKk+G2ptb6pcaRqZKJcKYiG7E9DU2sd9Wcak+dfFHW3l29TsPC9rb6t4fsLieNXlVNu/owxxjOa1BYSQP8AKsVxCT9yQAMv0bH8x+NYfgotpupanodxnfDIZY/dT/n9a7A4xyMD8qpHl1rwm4rb9DA1Wzsp7V1hsrdbwD5EuMxg/wDAh/Ssux0m9kfyriyltOOJIZt8Y/Bia7FkVxg7SO+ef51SfS7UsSsSIT3jBUn/AL5osEatlZnOXmhyxqwvYEuIR/y0jHzY91/wrJfwbpl0pkhiUE/xRsRj8K7b+yk/vXJH/XzJ/jUUei20cwm+zytKOjNKzH9TTuwvHe+v9eZ5te+Cp0bNvNuUfwyrnP4ism40C6g/11juA/ihfp+Br2plBGCDn/aT+tQmFHOCAT6L/wDrosmawxdaG0meGT2MA4ZLmMjrviOB+VULi2gUDy5lP4EfzFe+SWEbfejI9yKzdR0m1kjbcqH6oP8AClyo6Y5nXXZ/I8Rshm6WMj5SRXTalobQ2olUALjOegrDe2NrrDwj/llOUHuAeK9e162jXwhE5APmKh/UVFrOx6E8c1ThUS3PFJAikrJNGuOxYUkQjcgCXfz0RS38hXtVt4b04bXW1iRiOqx/1xWlFolso+U4H0Iq+RHFLNaz2SX9ep4na6bNP/q7S7k/7ZbR/wCPEVo22hahKQYbCJfeefH6Af1r2NLCGMfPjHsSTU6JAqHYJD6Eq3+FCUTCePxEvtfceX2nhC+ch7i8jj/2LdQP1OTWlH4K09F8y/UuR/HPIWz+oH6V1bWmpSMT/aEQjP8AyzSEg/gSals9NlifzEVDL/fIDN+pNF7bIwbc1ecr/eZWl6EGXbptpHFGP+WzpgfgOprpbXw7bBV+1brhxz8xwPyHFQTw3JIFxfXCr3wdn6oKSLTbZiSQs3uVzn67jRdshrzsQ6dJ4ig8R20TafbR6f5mN0I3YHuTzn8K9PFcVolpbRX0Qt28tg2SiSbR9CAcGu1oSObENNpJBRRRTOcKK821r4j6k/i/UvD3gvwpP4iu9LVDqEpvUtIoGcZVAzg7mI7cd/Q1X+I/xch8CeGdB1HU9Du21HVMsdN8wLLAqpukJOCDtyo/HORQB6jRXnfjr4kyaDfeE7PQdEfxBceJElezWK7S3BVER87nGOVfPJHT3rnZPjvYDRoH/sWeHXZNUk0htPu7qOGOGeMAvvnOVCDcBnGSe1AHs1FeYar8TdT0Hw9DqXiDwt9lafUYLGFYNSS4jlWXOJVkVeQCpBBANX/EnxKh0TxXr2iNpskzaV4el19pRMAJFjOPKAxwT/e/SgD0CiuO/wCE5j/4VT/wm32F/K/s3+0fsnmDONm7Zux+GcVlfDX4h6n4zuoDN4ZTTrCe0F3HcjVre4Yg7SoMSHeuQ3cDHQ80AejUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKAOJ8WQv/bKTCWbKp8g2hkX149azkv7xC26OKZemQTGf5Vb8aT6nBqu6ztLe6h2D5C5R8/X0/CuTk1vWowc+GpeP7t2T/7JUaHo04SlBaXJ/wCz4EuPtA/tCIhskK4fn866Ealp0kQScSnA/wCWkLE/yrl4tf1aRW2+HboN7yk/+yimNeeI7jhLK3sVPG6U9PzNLRbG8qc5/F080dA11aYb7F9r+XqFyqD865nWfEsMTNFDd3N1c9BDbthR/vP/AIVBd2lui/8AFR+I/MPeCH5uPTjis+bxBpFrA9t4f0o+cwwJ5vmZvoOgpNpbm1LDdXr/AF3f6CR6Tea9MlxrlyYLGLkKMnaPT61pT3cmtLHo2hxfZdKgGJGHX6n1JrnW1HXrWBY76JnspjkwkAMB6g9Qa6XwepsLmGFJ1fTrw745SPuv/dJ7GiMlLY2rJxheHTb/AD9Td0/SbGwtVht4SFUYyU5J9ScVxfjnT1tLmDUrb5WibDgY5XPtXqsmmyMMZOPaQr/KuP8AiTZ/ZtCcYJklOxQZCfqattWPOpSfOnHcp6m91cz6Z4l0xUaYoI5kZgobsefwrXtvFM7ZN1pFwoHU28qzfoMVz1ho95qNpaaZDJIkEEAkmbGPmY8D8qkl8CXkSn7PqDqPQof5ipu1sdVR0W+We6/L7zoLjXtC1Lbb6gzRODlRcIyEe4Pb86uQafbGNX0+W3mi/wBsBx/30DmuCvdG8RWELDd9rhHJVlzn8DWTDfs04jRDpmoA4DwsVD/Ven5AUubXUqOGjPSlL9T1orDGubnTj/vREOP6H9KYzaTJC3kRWpnx8sc37vJ98jNcAnirWrfEVxf2QkHH7xOT7nAq/b+Kbmb93P8A2Td56qrMjH/voYp3M5YKrHf8zYt2vmvY45NH8qNustrcEBf8a6KS0uYhuim84Af6uXjP/Ah/9euNh8QaYsmNT0uWyOfvqQ6D6stacupeHoygMkEjsMqqBnJ/ShEVKU7r3fwv+rN23uYpS0attlHVAen4jNFzG3ltlmPHcmsj/hJNPtkyLa7WMdxBxR/wlOnXNuxhFw8nTylhJf8Alj9apMydGpuos8s8SJt8Z3Cr0ZkP44FemeJpRBoWhwE43lM5bbxu9a8w1eWSfxY9w6bPMddqE5IAwOcd69D8VSltb0W0WJpRbQK7qpGenvweSKTd3c75UpKjCL395/1950C6zp6kLFPG5HHyyb/5ZqyLydl+SwmYHpkqP51irqljG5F1ZTWzH7zS2hI/NatW19prj/Qb6ON/9lygH4NRc4pUrfZZfR9RPKaXb8/37jb/ACQ1SutQ23Bjng0sTLwV+2nK/XEdaNpe3B+49vdAd1YA/wCH6VRktLaS6kuJdGHnSHLMJc7qV2TG1/eX3f8ADliJLoKGaxjMZGc21xvP6hf50+G+gEpilMkMvZbgFc/Q9D+dTQ306KIoNPCIowMyYA/Si4+0zqVnnt40P8KoGP5nP8qd2Tvv/X5kjLKfmUI3sq9Kau9mw8IYew/xWqUVn9nKtbyS8fwtISp/DGKtLNKpw4YD/ZGf5mqQNdjX0yI/a4yEKjr6f0rpRXM6Pua6jLCTGf4gP8TXTCmcdbcKKKKDI8mufCPjLwx488Qa54FbRLyx18xy3VrqbyRtBMi4DIyA5U5JIPrx0rP1/wCFGu+N/FsOpeNNajtrWDR/sKLoz7WaaQETkiWNgEYMy8EkgLyORXtNFAHgcXwa1/UtO+HOn+Jr6wmtvDRvIbp7W6mjklhkCCERsEBBUKARkcAcnJrqPE/w2gsvC1hoXhDw14dvtGjmkmurHVpJA0jsABKkwDMJBggk9jgdBXqlFAHz5bfBDWY/AGq6bbXthp99Nq0OrWGnpLLNZ2hjziMuw3ncCckD+Eda2V+Hni3X9W8Ya94mk0a01PVfDs2g2drZyyPEgcZ3yOVz97HQHgn059qooA8V03wZ8RT8NrjwXqbeEhp39kPp8E9vPcmXfs2oW3JjHrgfQVe+DngHXPBt5bjU9G8F28cVgLR77ShN9snI2cuWQAhiu5vfFeuUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQz3VvbtEtxPFE0rbIw7hS7egz1PtTNStBfafc2hmntxNG0fm277JEyMblbsR2Nc3o/wAO/DGl30d+mmLd6kjBxe30jXMwYHIYNISQc85GKAJvEHjnRdD1E6dcNe3GpBQ/2WzspbhyD0+4pA/E1YtNeu9R8Oz6jp2haitypKxWN+FtZJcY55J2jk9fTpW/RQByGlXvji8v7dr/AEbQ9N0/cPOQ38lxPt77dsYXP1NJ4p0DxNrN3Mun+K/7I01goWK2sQ0w45Pml+MnPRfSuwoNAHhPiTwZrejebL/bGpapHGu97q5l3yH8OwHpWNpFp4j1SNn0ya6dEOCzfIM+xJ5r2vXPtz3jR25gjiIHztlm6enT+dcJd6pHFrjaZJpl9qDKw3SFtqj1IXGMflXPK99z2sNiZqmoq2hysGheK5bmW3EkhkQAt++HGfXnrTpfBerfu5L64CxO4RnaXcFJ+nvxXexW0Ed5q+n28v2JrlV2FeCMoASPeqUmkx+HfD/2Ke9e4huLldwk4wucsAPwzUtPubLFVL2T3t0OOuvByW19DFHf20yEDeFJeQnPICrn+ldto9lpmj35aW0WxVo9sMsvOfUlj0PsTT9at3vFt10LUbKxiAxJMrDefQDH496nufM1GybSbaZLkrHtmvJRuAPsB1NJRSdzKdWVRLmfqZtn4ei2XtvFPJqInI/eS9Ij/e3dz9K5yGNvDmpz6Tqw3addnO/srdnHpXfXjXlzpM9rp7C0v4wAMjg/T6+tcF4ispbbw+qa/dBr8vmKNTuYL3yfrih+67o1w83N2k9/v9TfvEvtXsho6XQj1C0YNvZuJY+zA96wNXlN5rlpYSTvcW9lkSOe4UZY/ofyq1p0WoS6PYXcd1DaajBGYw8zhfMjI4Bz/niqNhZGyiuhcXllNeysMRxzAhlzkrkeuMVbjeVzWnFQb12/Pqzrrq+1LTdLtP7MsXmvb2QyNhCVQdgT24wOfSt25lnfTbMXiCO5kkj3IpzznJ/TNU9I1m51GFlghtredPl8iVyWXHfoMj6Vlx3ltqd/dW11qMr38KFlMSeWkOOu3n9TQ2cLi29Va39fcbd7daqNZVIoY4tMQAvNIV+b175FeY+Nxb6v43tVsNrgyKpZRgHAGee9dHcS3qaXptwsc+oS3C+a7Xb/ALqFRjPtzmuf0eT+0PFd3qJjCQW8LuCg+UtjsfTJ/Spu3JI6sLDkbmuiNnRtI0a5tYZ9WQtPeXDxQKq5JAOPy4zWlP4C0O7a4VY3jSLjfu4zjJ61b0aO7/s+xT7Db2ojiCC7lkBYgjkqMdT9a0LqASaTc2Ml19nZMlpT/ED3puzOac25tpnlniTQH8O3kIsL9poZVDKvUEE4xWq+k6xL9pj0SaCyt4pfKkd3EZZsdMjqOaxrx4Y9VghtpXuLeCRXeRjgBQc4/H0rqvD89hqolg1WZo0N09yrA7UlPpn1HpSg20ehU54U03r8v0Ofm8HeIxBd3Dagm2EMX/ensMntVbSYdUu9It7eG4LXV3IynB4WNSMnNdF4v1ny7O3FtLLHJcPIRbhcl0bgZHrjP51hWVvHFp1rBdOsN0EkiKzZCNubd94dGHFOLbuKDnKm2zD0W0z4rt4EOVE4+ZupGep/Cum8UQR6zNrmqSM7RWpWKIq2Mv6flWZpui6lpuoS3UlnIwOTG0JEg9uRVzSdOur23tbOMXgeZ2kuUdSqocnkA9Tt4p6qNjWqo2VpdLX/ABf5FrT01Oa10/SYb+5iK23nyNGxOCT8oJ+nNLPpPi+EER38N2uMbZ9rH9Sa6Xw3PDa2WqzkQ/2rKxCW8h24VRhVBbAPr+NbQmmSTSYruOFZ7hJGmEAOBgA8H8as8+tVlGdkeV3dxr2lEz6tYWrxk8lEVc/98gVJNqOpSXDJY2m5cBseawPPTvW/4r1e01Lw07JZ3dvNLJ5SRTrhm77l9R0q14M02VtVb96FFraQwTHaMF8Zx9RST6XNVWmqTnJHOpP4gyGbTSf+2xH/ALNVmPUNbXONJcc9p3/+Kr0C48O2c373akUhOfMjO3cSe+OtRtpjWoPm2i3aDupww/xp2fcw+tXOH/tfXVGW0u5xnqJJP8amHiC/2hXtNWjb0jkb+orure106aM/ZzJHJj7m8q35Vh6bqMUlwYXW8gctt23cQZc/7wOaNuoKtzX93Yl8JapNd63axuNXiBf7swyvQ8E46V6sK5LQwI9SSOaAxOc7WHzK3HY/411orRHm4mfNK9rBRRRTOcKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKDRQaAOR8S26R3s17cahdQRKgyqvhF98Y61hafqKagJv7M1jz5EU4DQruH44Ga2PFcuotfyQ2thBeWxUB1d8Hp71ztulxp2+S18LxwzOCMxzL3+grCSdz1aMb01ff5D9au7HRNJjkuYJr2S7cEuW5J9d3anaTBJLr6m+kkuLc24ezEqj5Bn5gfU9Oap2Ooa+lhBax6XZ/uUC75nyMjv1FUtV1C7EitqfiK0symcJaxBmGeuG7fnS5WdCpyfu9fW/4K5q20IuvEFxDNoghtQxCzc5cjqeDitJUmhfVLTSzHHcAK8e8ZUZA/wNcK+vaFKu271DWNQI/vTMo/IVQn1TwvyV0G8c4++Zm5/SjlSNPq1R6NP+vVnWz3N5oulNLrl0DqOcQGI7mY+mMciuY1G5NrOb/WUFxrUoDQ25+5CvYkevfFZdpr+kWeoLJBZS25/gMhLbT681taDDYS3rx6tbS3F5dPmAl8RzL1B3fpj9KVrao39l7Jc0l/X+XcgstCn1TF/rU7mCb5kdcYZv7o7D6mmt4JnNrKZFgW4AzHHE2SR65BwPxrq2nsLbV7bSruD7VO5CLbxj9zbgj0PBOOpqPVr7StL0650i9LmZZeLe2GGmU8gEjoORzUct+pl9YqXtH8uhyFvq13aPHDriyhIeIryE5li9N2OGH+c10MmuXttp0qpaaey3CEG+J2BlIxkqOc/T8qw74SXlsha1Kp92Cwtj8oA7yN1NVodNnvNWtrXWpZQCBtiUEqi+w+lU5cqtLc39nCSvNf1/XyJtU15ZbSK0jkkvxGoXafkhTHsOTj3Jqtpus6k18NLlkBilhKooXGAAeB+RrvY/Cliq32nQOsNw+x45SAX24Gf1B6VxHie3bS/EtpJZMXWKQAS7cbyRhseo4NLmkpK+wqVSnP3II6HVNZsb3QdMee7kTyFG+2QYLOOCCe3T0qpcSXfiC5R50fPl7I7OBtrMvq7H7o/U1WlOo6i0o0vToILaIl5JfJUsxHuRmtDw3cRXtpfWl5ObQykGV1OGjcD/0E/lTsm2Q4qnG8d1+FzZg0i00zQp5prXzrxFMYhjQ4jJ7KPx6nrXJ3+m3OjWfn3SRrbXI3SW8hP4dOh56iute/h0rT7R7y9uEZl8qKXbhpQP4iD25HWuT1G6n8Ra3seQz28RAQsmC3PC+nPWplrJW3Jw7m229uv/ALWn6aE1TT5PMeW8vTsSeY5ESbcnGf4sDrWh43vLSy0ufRYLNkjiCkSsOGJB7nqc4qHxBbT6BPbtIrXGnzqC20/NHIMfMp7HvmsPxPrravaWlqZhcmFjiUDDMDjG4diMVb10RcIOrOMlqv6/4Yx7ax1S201Z4bmRFYhVG7Aya6rxDp0uhpDLBqbzSb8H5j8hABIIz6Gta608LF4W08AbpZVncey8/+y1neO9Jt9Pm2W8rtPeztMd7DhmPQe2BTqX6FOv7SpFdHc1dL8PT6nLqkx1K6glS5KIE2lCNqnJBHPU1n6z4b1rS4Wu1vLS5jj54txE3PbI/Cuq8NeZdaFqEts217mWTymPbACg/pVP8As+70jwdqY1S7adthZfmJCDHQE+9OT7HGq04ztdbpWscZbajCvk3kdgbiZEDtlydufTNbPhrXbaGxubFdoSfeSS3lzKW6n5uG9iCOlM8KRzT2MKaekf2z7EwYSDgZk+Un8M4rZvvDNvJpFut8sYu2KrK0eAGJ68dKluSN61Sm3yTILZ7PStCkgt7yed5HTb56lQmWHQ4xx161uHVb2TWre2sobaeyKAyTeYCR9MH+lcbe6D/Z2rxWdkbxd4GJYgygZ+nBqW48NarHdLGJY7gyAsDKqngY9s96SmZypUpa82/c63XL7T7dnGoxO/7xIoxGp3liM4GMVLJEkF0iLeyxsYzIBIFYBR15IyMVxButS029Sx8qFro/MqRhlJ49VPoKnutQv55GhvtOuizRFWUTOco3BHJPBxT9ou5m8K9kztv+Ek03RrOPU9X1a1TTt/l+ftJXceAMjOK6jR9b0vWoPO0jUbS+ixktbzLJj64PFeffDu4Q3q2EMNxHagH9y6goB9Sua7Wy8I+HrHWF1Wx0awtdRAZfPghWNiG65xjP41vCXMro8zFU/Zz5WblFcXqPhnxHFf3F54f8YXUImkaU2eo20dzAMnO1SNroo6AbjWnquratoujWM82jzaxdkKLxdL2jyzt+ZkSRgWG7gDOcVRzHQ0VznhjxlpXiO6mtLP7Zb6hAgkms7y1kgljGcZIYAHn0JroxyOKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKDRRQB5T490HVbzX7q8tbryYCq/8ALTaBhcE9K4f+wtVuIpp7XUZJBCTvKyZxjuBgV7H4muo4Ll47q3le3kG0sg3Dp3HUVh6fLZxxOukWErq3Un5VP4nn9K5pJ33Pcw+KnCmlY860O5vtW0a7s57h1aOVY2YHnDHGasnwlJZapZWksHnGYb2l/wBYVHI78CmaRE9vq+twkKp8gsQOgKPj+leiXEvl/aY4tSka7SMyiIhMquOAPl6fnSfvRTZ1Vq0qcrR2Zk2/hOygjvFIe4aMbkB4yducYHvTNJ0G3m0QPe2EUVwXUfMvONw7fStp5I7OO2mW8WKS4Iys3Ilbj8vwpweea8nN1MkVtbYJVB1O3OSaXJHscTq1GtzjPEHhmyvNYlsLezNvGsPmefzszx+Vc3YzXXhp20/Wbd59KnIbn70Z7Op7GvU5XS5ghuY7xpbIviRcD5geACcZ64rkfiFp+oXFlfSXYhNspAtmTqq8/KfyFK3JqjpoV3JqnPb+vxJrnULqz0hGivreK2fkXuzdO49Mf3veuRtoLvVp3t9MhlWR/wDWTN80r57sewrf8LWKahouhNPypaSE8/xAEj6ccV0WiQTWWmySXtglldxyFESIZ89D2PJ/OrlfoW6kaDairs85tD/Yd81vdE3No5wZEblCD95T3Ir0PS/Ekz3UFncSWnkOMR6iW/1gwMDGMBvUE1cuPDthcaQ1vFpYiWQmTLSEMjEdc8/lXmOl2bQLqUpk8y0hKqE7PITgCkm1ox3hiotvRo9LntZNRkv7U6bND5SF4Lwy/NI/bketcd41W5F5pq3AjS3zGI0U5ZRkZz+Oah07xNc6SGjutOuLcAfK1pcMuPqr5BpsV9Za7qenxG9k/dONsc0e185zyRwRz7UrKWzFSpSpzu9l/Xmd/bJcXGk31rpUiQzRzEKze/zdvrXNa9ol7pa2moQtE+oFSJ4kHyOP4vwrV8M/Y5zcSzzNBc3FyyQujlWYLxirl7LNpi6nOUe9uYFRU8zklGPPSqmtbnOpOnNpf8OcYt9ceI7V7WKVoTCu4xv8xiA67fWtrQfDiPobSy3K2ayxkQbznGertyOSO3YGsNEFr40jls0VYmSQzAnICbcn9eKs+HtV01tUWGeGPzAf3cd0ABjtsbt9DkfSiOqv1Oqqpclqei3OrjtxHY2tlZyR37Wts47fOxwAPTse9edmyJ1+K3ktvs9zvAkQHPYf/Xr0i0vhLqUsV29rbWqjMIPySBu3PT17muM0pftHxFkeVzIglJ3HHIzntSS95EYZuPM32uafjKe6i8QRmwimmGn24DiGTYyDAGQfwPFZVvew6mYrtftN3qBcwRi5YtsOOfyGamml+161rV62rR2EYnEbq3JlUc4AHPf361Y8J2oiv9LmIKpNfzPHlcbgYzz+lXd8xUbQjrul+lyR73XreAqmnokUYx+7klAA9ccCqWsJrMtg4vYyIpcDY0jhSeuDzg/lXZWumvph1BWumu7i95VDxsHPzHn9faop4YNUsEh1gLNbRPiO4t5Dt9MtjpWb5u5hGvFSukcr4f1FjekwXElk7IsdxGsYdlVejKT1X1xyM10U32KPVre0vZb68mlGYpjyiHnkflWb4n0e2tNRs7vR2Kzr+8xGQQijGWJ9CPzqhdeK/JlVLOG9WMd4SoA+m5TVbr3jRw9t79PqdzPJfRXcNrFJAwdCwkkB3cew69RVMvDFqiwXOoSSag/3Nq4VO+MDjn+lck3igO8c73GrRSoCFLpC4UHGeNg9Klj8TIZhK+pSmYDgyaeuR+INGj6maw00v6/yOunNz/aW2KwtpLtEBFy7YAUk8YxntTbaJxe3TG+hubx12yQ4wFAzwO461zVt4lZb9rlbzT3kkjWNzMjx8AkjABPqa1dNvrOG6e6gtLZ5pcl3huc9+eGAp8pMqM4rVf18zX8BRWGn30ttFcP9okckxS/KwwMYHr9a9BFcP4SvRcatK80cwkkY+XujGFUdACCe3P413ArWmrI8zF39pqFFFFWcoVwj/Di30+RpvCGs6p4emJLeVBL59szHqWgkyv5ba7uigAAwAM59zRRRQAUUUUAFFFYutadrF3dJJpeu/wBnwhApi+xpLlsn5ssc9MDHtQBtUVyv9ieJ/wDobv8Aymxf40f2J4n/AOhu/wDKbF/jQB1VFcr/AGJ4n/6G7/ymxf40f2J4n/6G7/ymxf40AdVRXK/2J4n/AOhu/wDKbF/jR/Ynif8A6G7/AMpsX+NAHVUVyv8AYnif/obv/KbF/jUvgW+1C8stTj1W6W7uLPUJrUTLEI9yrjBKjjPNAHS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVnavrmmaPpj6jql/b21ih2tPI4C5zjGfXPGKANGg1yug+PdD8QalFZ6K99eeYCftCWMywKACeZGUL2wOepAqDWvEPiiG/nt9G8GS3kMbbFurjUYoI391HzNj6gUAUNdmmi8aO8ks32ZYVCxJkhifXPH61DdRifSJbJppbCSTOHwQBk569PbrU1zqF1JbY1yG2t9UBBlt7SUzKgDAjkqD0HpVW/W/v7y2n0y7gNiMb1J6+vGK5paNnq0tYxex57pEZj8QX8SysypbSR7+7fPXoX2W1nvmv7WKY3k8IjDSAoAMAZwe+BXA+HYg+uarLFgKZI4x6fM2T/KvRxc3Ul9Mk0HlwwOhSTPDA5BpR+FHZim7q3b/Ij1G10qeK0TVwsckBHll325PHQ9+3FMEs7atJIlpK+nTR+W5wOSO+DzjHFK1tItnNDLc/bJ5JfMU4zsGQce3Sp7qJ2v7W+S+8q2iGJIicKeP50zlT6XM3zrVrUafaJ9isjJ5Zkl+Uu2eijrnPesjxFbwR6DdC7u7uRvOaKENKxBwe9aktxpf237NeMzt5/nWwCt8xPJAOOeag8RJLaabfSmeLMxLm2dc4J44PY1EtjaGkkcd4K1FrfSL62Jw9pcLcr3zg4P6V6xaRefbi6WdZZpI8pKOVGR29q8b8JObWK81WaAyxTuYUjzjeatTaqyW7RRaPNFCDwHvWMYJP8AdGP61pdJK51YnD+1n7v6HValdX1pZ31jDfNqd5M/IiyfLXHO45wvPGKzfCumfadStNOnAjWzBuXwc+ZKSPzAqomnapeQ263l0tlbSHasMa+WrH8MZ+tR3kN94R1GNZWdrWTlZVOWj9WUnr7g9ahSjcFFKLhFrmZ2FpZXaW1zZai0N5dTP8in59gPViccfSuJ1mxi0TxtpkJz5KzIc/U12+nXlvqemy2VvcJbz3KEx3SZKyjv1OQ3qM1xOtWD6jcQWNiXuI7Afv7xhtVQCT6++BQ42kiMO2ptS0/rc63RBpHlRRajIsV1Y3UrIrEjdliQfccipddup7ue5Fmrx20kaq1xJujXjORzyR9Kwo21jVZZItHuFjiZfmdQNzds7vTrWTc2uuQPKsl7LcFOHRzvGKcpRTswVFOd3LXsdRo3hpZoZViaUxzY825kTaZAP4UU9F/nVW/g8P6nJqEH2aRBZR535xuI46djmqnh/wAciwi8nUN8YT5Qp+eM/Ruq/Tke1aetXFz4g0lv7FsYxBMwMs8bA8+/Q/pRKKkvdE41Yz9/Rd7mVoEOoW2gt9hjaY3Ds0UcmHCRjjdg+prEttfmF1Ii6Pp00w5LLbKP5V28TXg0rUhpgSOa1CW6r6RquSefXrXJ+A4BNrWp78HZA/X2IqlfmsbU5KXPKS2HR6lqRt476Kzs7KCRzGskdtjByRjIHsan1SPXbW5xqCPdxxgS4BIKZ6EMPun61tQmez8I27XXkrZiUsmIhIclidx3cD8Aa07PUYIytxaanbXksgHnQyTDJ/3T2x6VL5r7mUqzTdorqv6Zh6br+nSW08GoNIqzHMnnw72Jxxl0xn8c1Jd65Jp2lxrYSRx6eSVH2WMmV26sAWJwffGa29M8N2moz3V/LI1zHMzbYZIgPKPoPp7cVx/h5beSGa2uyNtrfCWRW4+RxtJ+g6003fVEx9nK7S23Q+BrzX/L0+NUton+cR7wWc92ZurfyrrtP8PpbadLaCOP7dg4kYZDe49KmTSNO0vU/wC1YmeWSVfLt4VIxnHRfwHWn628On2v9pa0zyn7ixIcKue3v06mo5W9ZGM6/O1GGi/Uj0vQ4LLSWXVxDOVBLPIM4Hpk1Ql8P217o+I7NULr+7kj4dR6478Vp2tjY6jpK3cUBgEi+Yu49O+TUE9tFJqtnq9xFeRi2j2omUEYyDyefc0+VdifaSu9dTC/sDSIrRbIG5udRZSAFDKRnuQeABUOreFba3sWdVkW7AGPN2mMn/fxgfiRXV/aTDefaZoin21fLjki/ebSAcfpk1X0rT10y1vQj3d084JYyKMA880uRGirzWtyL4Y6IbTURczzxecFYCKKbePrwSK7zxTqd9pGktdaXo9zrNyHVRa28iRsQerZcgcVkeH5dmsW9vbxIbdrZpGlAwcggY/nUfxb03xPrHgi703wTcW1tqd0wieadymyEg79rAHDHgZx0J6HBropqyPLxk5Tqc0jH+H3xasfFkPiC4vtOl0Ox0VxHc3d5cRmHfkgqJAdpIwOhP3h6iuk03x/4T1PR7zVbHxBps2n2ePtM4mAEOTgb88rk9M9a8ti+G/iy5+Fj+D303w9pcNmYLi08m5klW7lSQOwnyg4bBORnnHYUniP4ceLPF0HjTUr6z0vSNR1jTbfTrawhuzKh8uVXMkrhAM4GBgHjitDlPVdO8eeFdSg1Oaw8QabcQ6apkvHjnVhCv8AeJ9ODz0qbwt4y8O+LPP/AOEc1iz1FoMeasEmWQHoSOuDg8155rnw88RJ4j17VPDEmmWMt34ci0y2cjpcLICxK7SMbRgNzzjjil+FfgTxFovxAvPEmvqqLd6Ulo6yapJfzGUSAkl3RcAgcKOB0oA9B8TeNPDfhe4toPEOt2GnTXAzElxKFLDOM47DPc8VlW3xAsr3x3p2gafHDdWN9pL6rHqUdwChVZNm0Ljkd9278K8y+Md3J4S+I2o6zbyWFzJrGhGx+z3cVx5keGYZiaOJ1Oe6EqScHIHNO8D/AAz1u70nw/PeEadC/g6fRpQ5KzwSzMWB244wGz1BB4xQB6zo3j/wlrV5c2mk+ItMu7i2RpJUiuFJCL95h6gdyMiqg+KPgUmbHizRj5MQmfF0vCnHPXk8jgc815xpXw58W3h8J2mrWOjabb+F9NubKK5s7lpHv3kg8pTjYNin7zZySSfXi/4S+FN/pmpfDqa/t9LeLQ9PurbUAPm8x5B8u3K/MMk9cdaAPSL/AMb+GdP8P2uuXuuWEOk3WPIuWlG2XPZfU8HgdMGkfxx4WTTbHUJPEOlx2N8HNtcPcoqS7Bl8MTj5e/p3rxm2+EHinTfBvgBbaaGXVvDbXontYL97YSLPKzAxTBDtYAjOVwenbnV0D4U6jHd+EJLvTLC2sdO1S8vrqzlvWvDtmiVV+ZkAZt6kngAcHrQB6xF4t8PywXU0Ws2LxWttHeTuJlIihddySN6KV5B9KybPx3a3Xj258PrFELKHR01gal9oGxo2fbjGMAY+bdu/CuB8c/D7xXN4k8Yt4ZtdHk0rxLpUViWnnaE2hjjKABVU5BB47fTHMlz8KtZvptRSW6treK78Hw6CsiSMStwhBJIx9w4xnqRnigD0fQfHnhTX3vF0bxDpl21ohknEc6/u0HVzn+Ef3unvVew+JHg3ULLULuz8SabNbWCh7qRZhiJScAn2JOM+tea/8K78U67cWkuuaPoVjFpWgz6RFbQXjldQZ0CfMyoDHHgEgckE/lS0T4e/Eew8Oa7b6fqAsd1rDb6baX2oi+kh2SKzBJ/KXy12Aqq4ODg8YBAB7T4W8WaD4rgmm8OataajHCQsvkSbjGTnG4dRnBxnrituvKPhH4H1zw74w8S63rSJEmqwWypG2pSX0wdAwbfK6qT1HTgdBwK9XoAK5XwD/wAzH/2Gbn/2WuqrlfAP/Mx/9hm5/wDZaAOqooooAKKKKACiiigAooooAKKKKAKOty6hBpc8mj2sN3fgDyoZpvKRiSAcsAcYGT05xiuf0Sx8ay6nBdeINY0iC0QnfYadaMwk4OMzSHPBweFGcV11FAHJa38P9D17VJ73W/7Qvllxi1lvphbpgAfLGGC4OMkHPJNb+laRp+k6ZBp2m2cFtYwZ8uCNAFXLFiQPqSfrV6igAoNFBoA4PV7+ePxRew/Y4/KCIEkwd0jEevTA5/Ks5jplrfR2d0N19MpfjIXPJxwa1dbtrh9WnmguFe7i6IyDaFPQf/XrJW7sZr0PcWLf2pGMHam4g9OGrmluetT+FW7dP62OH8OrIZ5fKUF3vUwG6EqARmvRL+O6uYCl2YVtsjzFjzkj0z6Vx3gGITXLlh8yXTNtPb5Frp4bV9LtdR+23glWdiUBIBGeAPzpL4UdWIac9Nye9+0Wl3p8Om2/+jMcOV4AHvU3+iyaxMjJukijDYxx/wDrplxKmmWUJmnmbeVjUL1LY9almTzLSGSGPyZg4EeecZ6/pmmcvRfmUopZp9H+0X9ssNyG/cxr1znj864z4kEQILhkkivJ1wwLZQgDGR+f6V2WtnVo57b+z4RMf45GIAX6A1xfxQZ7jXtJs93zN5YYD1LH/EVEtdDqwyvUT73Oo8OaVDFYWdnOkebW2UYbGDKw3Mf1qxb6Kljotwl/5U1zIDtIXv2Aptjewxwwrcp5smoXD7UI7DgfoBU8jGzsru7trd3nWTy0VVLkDIFXJJsxlKfNa+/9fmJcPYXIs/7ZtpYprdgUGGKluOmOvQU3Wk+2JdLf2ZkUxH7Ki9c4/n0rQvnmxaNIVR2Rgu44HmEcfj1qvaWt5DpL/wBsXCtdeYWiZTyD/CB60muhClaz/r5Hlklpe6LqFpZyhlhumTdAP4WPTHv1HFbdzZ3+okabp0ZisImLSY4DsOpZqseIWibxrZASPM1uVkdn55UE/wBe1ab3Wi3fhm1hvb91kYmUpb5d9xOTkAHnnvSSbjZHoSqytGVtX/Vzk/Dt/N4c1z7HLxA75iZzgRt3XPdT/gfWvR7KJLppV0yL7JCx3SzEZZ2PUDPTHrXJeLIdLvNOihS2vYpEGwPKipkdedzA0vgS/v8AT28iUi4hHylFdWYqOhGCckCqim9JGdWPtYe0joy34m/sZtPuFs7WMzQME83+dY2m6TdXGj6bplg5gmuIXu5X3kYBY7R7cYrb8bXFldaZGNNMbJKzSSFRg56cjseat2OnpPcyPHdLbLD5MOOMskaDpn3zUxVmwjNwpL9fuOKmuNX0e2liuI5WZwYxOr4cf7J/hYfUZqx8L23ajqYkLFzA/JGCeR1rr9atWvjc3I8lYpEIgFxxvbZjIHrgGuN+G7H/AISK4jf70kLg4+mf6VUG+azNYzVSjN21tqCfbp8fZLeBgrsnmFGmcYOPungdO2KLKLW7u9WBH1DIJxthWNQR65FdN4WeztNK1O6uDMjW900ZMLFWbPIHHXrW5NJcx6hZQWV7Mv2pSxE43lQB1weamSlfcznX5ZOMYnNzWniyFI40vbr522gM6EfyrBew1TTNWWKRo3u5x/qjGp3j8K7y4lt11lLS41O8k1AHC7EAVCRnGAMdKvxIWuGuJbKG4voCY1nAC/nnp+FKz6MzWJcVqlr5WPPoNSfTZs3OjiJ0J2tBLLEwz7EkVfsPFslzqH2WSW8hG0ybZfLl4HfJWuvkRruzuRdSJJDcrsaW2cHYemOa8/0exjj8S6w6MzQ2dp9mVpep3HaM/hmqi5Xsy4ThVTco6r5ly88bPIs1qw1JYGUoXigT7pGOPkouvE0V9a/Z7mS/ktzjKtbhf1Cg/rW9N4enfxBa7LWL+yFiHmuzglmx2HUY4qbUbC2tNGkuLHSlvZnkIiQLkYJOCfbFF59jP2tDS0fyM238TQWv2ZZJkWKJcIjwsAB7kN149KdpOoIuqPei7Nwjk/ILoEDPYBlH862P+Ef0/wCy27S2ot7mYgFEc8NjJHX61gx+HdO1pL9tODIYWZAzqGV+OoOMii76oSnRknujvvDk8dxqQe3MsQKMWidOG5HORkfka6sV518PPD50rV5ibgOY4yuxZd2N2DkjtXoorem7o8rFqKqWi7oK8TtPjmtzommTro2NTubwQy23nHbFCSoE27byCXUDgchvSvbK4VPhf4fTw7ZaQguFW0aMrdjZ9ocRyGRVZtuCu5jxgV24aVCN/bK+363/AEOCqqj+Bjx4/srT7b9uEs7pq8mlQRWVq7uzqgcKRk5OCeRx9Oahm+Kvh2LTLW7xfM85m/0UQYmj8o4k3qSAMHA65OeM1dXwNpEOox3BursTHWJNaVTImDMyBCuNudmO3X3rNPw38PXUzi01C7S/tbmeZ5oZYnkjM53tGyshXb0IDLketaL6q97/ANf0iX7VbWNex8eaNf6lBZaet9dyzQRXKtBaO6CORSyszAYXgfxY54rnNZ+LNiuiatLpFvKNUsBBIbe9j2gpJOkRPysem7oSDnHFdDonhTRoptTltL2e8NzappdzmZW2iIMpGVAKv8xz6dgKxIfhBocdnNbNqGrSRyWkVkNzxApFHMsygYjHO5QCTnIJ7804fVVL3r9P+CEvbNaef/AN6fxzpUOpX1sIr+SCwcx3l7Hblre3YLuKu/sOuAQM81ST4maD/Zt9e3CX9rHaW0d4UntyryQSNtSVBnlSfxHcVan8CafLf6jMl7qUNnqMjS3unxTAW9wzJsYsNu4bhjIDAHFZ7/C7R5dKv7G6vtVuftdpFYCeaZDJDbxtuWNDswBkdwSfWoisN1v0/wCCN+16Dn+IkR8UWWkRaPqipdWslwLia2kiKbX28xsoO3uWJGBjjml074h2UmmaSxhu9R1C9szemHTbVmKxBtvmFSchc8AZJJ6Vta14WtdU16x1drq9try1ie3/ANHdQssbEEo4ZTxkdsH3rIg+HGnWlvpyabqer2FxZWZsFuraZBLLBuLbXyhXgkkEAEZ60J4ZxV1Z/wDD/wDA2C1VP+vIt2Pj3Rr3W002H7WPMuHtIrl4CsEk6DLRhv7wwe2ODgmuel+KNvH4PivYIn1DV5dNn1FY7W3cRIkZZQ8m45VNy46k8Gt2x+H+k2Wtx6hHPfvHFdSXsVnJKGgjncYaQDbuyck4LEAk4ArNHwo0ePTLaytdR1e2SKwk0x5IpYw89u7M5R8oRwWbBAHXvVR+qp636fr/AMAT9t/XyLWk/EXTry+03TGgupdUngtpJ1t4sxwNMiuM5OcYbJIBAHU9a6nRNUg1ix+1WqTJH5jx4mjKNlWKng9sjiuUl+Gejz6rpl7c3V/N/Z3keRE7R7VMKhUO4JvH3QSAwUnJxzXV6Jpv9lWP2b7be3v7x5PNvJfMk+Zi23OBwM4A7ACsq3sbXp7lw9pf3i/RRRXMahXK+Af+Zj/7DNz/AOy11Vcr4B/5mP8A7DNz/wCy0AdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUGig0AcZrEL2urXtxawyySz7R8zfKMDqKyPtF3Fpdo9nB5l1NKBJx90HO4n6Vq38upnxRcRtEn9mBMhz13cYx+vWs+0lvHe6a1aBoElZUVwefXke9c8tz1afwq9uhxXhAM2qTRFmRWuGDFWwRlB0P4V1aK8T3QvLOKRC+yCNTudx6knpXG+HVMmsXQlym27XO1iD82Qea7+1msyrPYlWET7X9alfCjrxOkr+gls0rokax2twY25BkyYvbp1qC9uA9obi/umt445fLVYhghs4HPU02ygS0hmksiLW05LTyEsznPUZ7VYikggtPtSE3Nqx3ksMtu6ZH+FBz7O6FaGfc0M19J5Spv3KNrEe5rzbWZbS78baW1hlo/MXJPUkEd69OtxdMzXMirukGPJPZe3PrXnHi6SM+NrAwx+UYnUBcY+vSk90dOD1m15He6Zd20WkW8vlNLMqZ4Q5GevJ7VLFKtjPMIZRNLtM0sOeTnnK1Ri1G5h09bC0szLeIduxzhSnrn6cVow2y2uojZEkk0kWMscMqjtnv1qnuc0lZu4ajc240z7dfReehUFLcDPJ/mamikhEVtdGDykYbdrdVz0xTrbzbOARS24lVScFO3pwazdX1O5t0sLuK2EqzSKgXBIjU9c47/oMUEJc3uo4+OaBfFGqzwoXS1iZkGPvEsFxn8atR+GtYurd7gTCBT8whjGzcPTj+tZmiZludadvvPLAD9DIM12tpHJaa9e3sl8bi3dMJEgJxjoPTj+tSleKO+tN09I/wBbf5nK3vheMHTWgNxcx3UmyQqmPK6Zz156/lVTxJ4ZFgHk066KrG4RCxAdm6nb64r0DTrW7hgIub5YnndpFiVVG0sSSATyetVrnR0vZoI7m3jK2Z3rJub7xwegPPQdaXJ2Mo4uaer0OK8JAa7e3MWpDZcQx75CvAlA6Ej16V1ejW0TW1rbzWJlN2rzSXGMbFLEqCfWuR8EK/2/xHcKT8sawIfdjj+ldzdOUkOnW+on7QsYf7NsXiMYyAcenqe9WneKbKxLfNyr+tP+CMae2uLe3e4s5ppbYlI3YfISSF3Z/LmvO/B0wtvHMAdw4aRoyQeOcj+teji5Dfai99A9rLGqW9qqgMrY79zk4rzG6Edn4rSaMoVSQH9390EHJApL4kXg1dTh3R3ngxZI9b120Vo1HmiTDpu65HqPStc+WkEuq3NwscyuOXG0IBkbP1rBjt2n8a3kMNw9s8o80MncKen/AI9XStbpctdRokM9uWBdJQSN2M5q5bnNWtzc3dIfHJFM0V5FZQCabhJwQ3UdcjqKjt7J7e2msp3W9WXc8pL7X+bk8en5VHBcJPbpcWc6PDZvhooVwoAHI59Ac02CKwh1CW/t2nnuZzjknaue3pipMrNXQqTQaZpcMltp8v2XzMRxKMsScncfTv8AnXJ+Fozdy3RI+e61BQR/sxru/ma6oXjwPeWcV7G9xHE0nlvGTsAHQY7Cuf8AAccqw2c4i83PmykDg5L4z+Q6UR3N6fuwk/67nUpLpmoXl3YW0x8+D/WiMkbTkj8ehplpctbabaedd2tvAyhIy68tx7mm3cbWlhfNomlbbqYMx6Luc9z69ajuLLSb+1043e+Q26/u41Zs54yCB9O9M51trt95NLFKt/Jf3F8nk2o2KHXbGCcZJOfoKsXF/Jb2SSCOGVJmCIYWyCW4B9xUN1BDeWtxa6jC8FtK4YYblhx1x05FLanT/NtbGykjMVoM7N+cEcAc8560Ceu/Q1/C0MEF7cbbeSO4lUPK7DIY9ODXTiuBi8LnxNYCDxXzNDKZYJLG4khMZ6AhlIOcHvmtnwt4ZutAupCfEms6nZNHtW31F0mKNkfMJNofoCMEkc/StobHBW+M6WiuHn1jx1pc8n2vwzp+r2u4lZNLvfLkVM8ZjlABOPRq2ta8W6NoMOnv4gvF0s3oJjFyCACACVZhlVI3DqfpmqMjyj4maf4o1fxnda9pGi3csfh0wixJJQyspEkpSPbmQNkJx/d71avl8QJceJb7TrPWrS0v9ZsZLh7e2cXP2MwL5hjGM7gdoO0Ejn0r2Owv7TUbZbjT7qC6t26SQSB1P0I4qxXcsbaKjyrTT8n+a/E53Q1bvueDaNba9YWBAg8TW2iT67qM101tA/250ZVNuxGN5BOckDGcZ4p2p3XxAWPw81yusz3f2KIXFpaRvCDKZDljMitHu27dyyYAxxnNe70U/r13dwX9f1+QfV9LKR4T9g8T6NbeMo9GTXRdza357ERErJZsU3SQttw0pwQdpyAOgNaGjR+Lr6bw9YS6n4ghspr69We7Fo0UscAgVow5mQn7+5QzDJ7cgGvZqKTxt1rFX/4FgVC3X+rnktrJ4uXx0sbnWWcaw6uHj/0A6ZsO1g2NvmZx0O7Oc8Vl+HV8eQWvh28+063cajqGm6gLqC+jxDBOi/6PuBUbCzY5bk17dRU/W9Lci/pP/P8AAfsfNnlvwil8SNqNwNen1do3tEaSG/tpFEdwG+YrI4AIIJ+VMrxnivUqKKwrVfaz5rWNKcOSNrhRRRWRYUUUUAFcr4B/5mP/ALDNz/7LXVVyvgH/AJmP/sM3P/stAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBooNAHn3izTdKufEcUmoNM85IEaFzsH4VTl04XVje2Fu/2crNlSOqjsRV7xT5Z1nzLmwuW8pwySxkFTjpnn1rJ1OC3uZJJdTLQ3Bi3xxxOVKhcnJI6muaW7PXpN8sbM5LwzBi9nkLfduosszDoCxJP4V3ckdo9rc22nW4DTgh2RNg5GMk965v4cwfupmYFt1wSC3P3VA/mTXT2l/fS6vJbyWLRWqqSJT3PaktIpHRiJNzfkEKR3umLazWXmxodhViACV4zSahcC1itomtJFh3rxGN2AOeg/CneXPcaRIthIkc0jncX/AIcnn8akjkRb21sXl8yeOMuxPX0zQc5k6vPbvdpfSai0cMKHEJQjnrn61wWnRS6lrF3rcpLxWzhU/wCmspPCgf57VveNNXvns2tJLUQtPMEhQnlhng/n/KtrRdCGnWcMUCi4NiC+0cCWduST9BgUo6u/Y7IS9jC73f5GVYeLJ7nUlsNcjS0nVsW9wB9xv7p9q66GS5ub37SsQR4V8to2PLdyRXK+KtAn1KwguLmKNNSckFIz97GSPxAqn4Y1yS6jOj6rMYLsIY4Lg8bx/dampX0luROnGpHmp9NzrtGtbbSbnUJ2nkU3DBzFJ/D16ep5/lSWVw/9oTWC3LJIF83bsG1QecfrTLPT1sLaK3NxJcTtICkcgH7vHU/Sr10AmZ41gYykJJLGvLAcY6/hTOZ2u+p514aTdfazHIN2URyDxkCRe30rvopr8Xd5DLBHFpyoPIcYGTjp1/pXH6KxuPE+pMYTA89s7BD9CRXTaneLpp01jA97PdNtGWxtHHQY96UfhR04j3ppW1a/r8i1cw2d1e2l5cyPFc23yiIEfMfp1PXtVHxCt7faI8+nXBtmV2lkO/BCqDxx/Kr2qz/Y2ur2C2M91GqKqAckE+31NZvin7FFY3vmgLJKgAU5wXIz/KiWzMKd21/X9bnPeAgY9LupFXzZJ79QoJxu2gn+tdnM/kyzXLaelvPMAklwCGIHTJI9K5XwGBDo+ms4JHnSSnaCT0ArobGEQJc28NzJcy3BLSGVSojB7kU3okjXEJc7/r+thyywMZokspYPsbqqzMmPN5xx65H868+8b2aafrkS28At4iquFznk9T+lejwRyxray3E63ttECd8YCgH+8RnnArgvHlgba2tJVmmugWYtO4xnJzgd+5pPdGmDklVSNyYH/hJdCnVyi3MCqzDvlOR+YxXQRX58++Y27wwwsIhuBxP2wBjrXPTS58MeH79VzJbTKjc4yNw4P5muomSVby1u7tlMYyCi/djJ6N7+n41cjKstr+a+5j4njklFpHbNbQEb2yoXcfQf1p0RvFS6+3+QkZkAt1B7dgfU1UdL5Zr+W7eNrHBaJQfmB7c44/Oo54i2oWlo6zzsY9/2gsf3J7Eds8VJhYsXs1uZb6IC1Goi1YuQp3BMdz+XGareAlUaXAAeRAp6dMsxqzPA50m/l8xWcwyL5pjG5gAcZNZ3geCK60iDzkB228YH/j1C3L09lL5GrY2uo2+sX15f3gNk5PlxbjhR2PoOKsaTLHP9rnt0BzKwDYxvx/8AXrP0++0+41maxijkaSDI3M2VyODxn1q8IZY72dLOURxsBIwIzhj6fzpmUl0ZBpf2+xtLqXXLhHLvuVVOQueMCo9RaLR9FEtvZRvK5UEeXnJPc45pI1sL+7uLKSWSa4QfMzdOPT6GtC2luvnibyT5R2s7Z5460Dejv/wDV8MIrIs/2cQSyRguvcexroKxtD3mR2Z0YFeNorZraGx59Z3mwpk0Uc0TRzIskbDDK4yCPcU+iqMjH0zwzo2kTX02jada6dPeqFmktIljLYzg4Axkbic4+ua52LRvG+izxjTPENprdjuAMGsQbJlXPOJogNxx/eX/AOt3VFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK+Af+Zj/wCwzc/+y11Vcr4B/wCZj/7DNz/7LQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKDQBxeoyPe3uqQM2xYnCqSuMcA/jXF+KtW0w6bI80p/tHyvLUFWHU8npjoK7HxCLy41s2qmOOyYFnI5Zh6e1cB4s1NtUkg06KPyQLgxqp4yOACf/AB6uWfY9rDRvZm34fsLyHRNO/s6aJJNokm8xM53fN/IitiS7u5L5bIRCFym/zwcjAPOBjrVeQXa6MraaP3ryDhf7uccZ9sVeu28m9tJ3ICkGMknoTz/Sqe9iZS5nzPzKV5DDFbPLp9y8biUCZkfr65HrT7izS3vIZrKSMXYRspIxJkBqrcPYaNYvE12hF1P1dh8uTz+A/rVXxasEds2ox3ahkiKqikHdkYzx9ahuyuVFXaVzAgupNc8Sy313CBHYLvRA275icIOg78/hXata3Nrpu60vDG6rukyobnqTzXKfD6wMttHM6kCeZp+f7qDao/Mn8q6mG0h0eznDytI9w5ALHJZm6CqWiSNcQ0pckegoFs+oR2dxJJLfNF5yyEcL7j0rmNf8NWtzZ3Go/aCl2zGQAnnPoB612C/uB5htGe5SPaHUDJ9s9ayvPm0+Wxjt7BrqS5YPPLj7oPvUtXMqc5Rd4nO6D4qlsdltr/mbwMRXigZA9G9RXU6PZW9raTmKWS4iuG3+YjblX8ByP1qnrOnveyS21taRSgTLlmOCiEDcR+Oa5298LXFlNcS6RdmOOEZch8Ad+lHO18Subfu6uz5W/wCvkWNGW6v/ABVd35SREjgdTuXGeCK6DT7gvpsSvd/6SIPNSMKAVU8Z98Vy2l6rqttqdrb3V2JxOQAowQVIPPH4V1Nhc6baW5ldVe7CiN9ilm9lz2+lOLXLoOvFq3ytYnzb2t/b26XUy3dwmck792PXP41zvjEwRaLdx3LvPqIk3BwuMDIGeOBxW3515Z6eu2KFCgAZmOWjQngHB7ZrD+IJuY9IEcQH2JhnzM5LsQamWxnRX7xf1/XoT+G7a6/sKwGnyLFdfZ2Ku3QZf6HsK3obmKGWe3vZ1aaRAWdOrHGD0+lUfDdnC2mW6XMayIlpG2wjdzyelWY7rfpbT3Vr9kZJAIwRgkZGOK0luKq+ab9Qt1t9NsfItYrloWfMkj+n0/8ArVz3jq2mnsri5lvI2tgVMEC44Hr+ldPHJDHezXouJJWlUIqYIVfTnp1NY/iSOZdMvLKOzHlNH5ss4GMtkGoew6MmqiZn6R/p3gC/hTloNsqn07VsS5k019VmnxHNaoqRgd+Dn8xWH8NpPNsNUtzyHt2OPpWvojw2Xh5dSkVpZIMxqrNwuG24HpWstUa11yzkvP8AP/hjU1Se3tNJS5vCblSFCpuwGJ/Sp2ecRoLbdJBKoYg/ejX2PeoopndttmI2RkE2yXjZnPb8Kl0u5A3zS3CyxSH/AFuNgUjgjBqDkeiKWtPM4keK4MVlHbuHi2nLEqevHrj8qr+CTOmlWohEbAwKSGzkjc3A9KmvbiWLwxf+dP8AaJijZZOVAPH3unem+E5fs+kWgMcrEwLygzj5m60o7mr/AITXmbkcrByRZ7XPUgj+dVLK/la/vY/sxLq45VsgDA6n1qlotudNeZ5L2WVHyTF5bZz6/WrNpdxvp9wxmWCeUuVDnawznHHX0p3MnFK9tSzbW8dnJJNBp+2R+WKvkn86qu8d7o00KzeTPODv8zjBPY/y4qHQyuj6OsFzfNcyFjtYhup6AZqxftqEEumQadArxE4nZsYVRjv+dAuv9dPU3/BlqLKyW3WYTbF+8Pr0HtXS1jaGoEshAAOO1bIreGx51d3m2woooqjIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV8A/8zH/2Gbn/ANlrqq5XwD/zMf8A2Gbn/wBloA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAoNFBoA4rxNdJbaqjKxabkeUoySvrXn2t3Ud14uSRUKJawGUhhyTj/FxXZ+IZmsHv7i0tvNvRNhs5YsD0+gx2rjb0GfxldM6bP3UaMv+8UyP/Ha595pHr0/dpN+X+R0+lRa1ZKsUrW91bBBsbBR/oe3FSxwyahPPDq3lkIQyQp0x2Oe9Jqiak+r2Ysm22kZBk4HI7/pVzVYnkEQt5PKuC2FkAyVHU8d6W4X221M3TmtLiHUEksgsUTGMhvmLCuS8aTWumaEdNiQrckgnuAD0AP4iu2a1uXt3X7ckjqd3EYAJHOGxXFeO5JLzTLOaS0WCWZwHfIO4ZFQ10N6TXNc6jw3bwxadCJDtW3t413ZxtYjcefxqzc2UL6jYXZkkljDEAs5YAkcYz+NMtbOK+sNQtpCyo8mwlDyMY/wpJhBDZRaVYuZJVAAJOduD1J/CrluZt3k3fUu2kupf2xcpcRqLEAeU2Rkmobb7e0MhiliW3wWi+U78dge1RXc+pqqiUQQQb1VnVss2SB36CrF5Y3DahYy286x20IPmLj7w9qROnW3/AAxnapcWun6ZZi78+VrhiDJG5Vj3OSO3PSr9zb2kW2Bh/o88JSQZ5x2P86aJZTCtvb2/mgMQsxxtUetVWkm03SFngge9vZ+WbGefekUtbJb/ANfccw0duvjfToLRHjt4wQu8cnC5710lvcLMq2EETfaV/wBI34+U4boT7isZy0vxBtXlQq/lFmH90+V0rpbI3g0xGjSFAU4fkt9acfhN6z0jfsv1Ktxc2Qa8eCOWa+nTbJFjPl8Y+bsBXKeNPtcenwwTyhoVZAhDkknHPHp9a7iIXEF9BFbwo9kY8yynqT9a4zxfcyzpYwm32wl1fzem9iMkfhUsWHfvo7DSYJDGPKm8kLDGrfKDwF/TrU6xH+0IRdS+ehUmMkDG7/8AVUANvIl7bTXCwKwVMlgpxtHTNNFrCYbLTbaUvGv7wyBsnA9D7+1aS3OeWruxVN2I5rW9aB7i4J8mOM/dXuTwOlV9UIEL6bcTXM87QMxZDsUcHGcVKrRt50sVs0EsEgSKRs5k56c9jVu5eSWG5T7RarOIzuQLkgY785qeg72ZxPwtATVbqEkYKOv6Guk8Mu66PMmyERpNId8hyB8xPI/+vXM/DBSuvz5+bKuT+RrorJ7M6RPa3LSqsszE+WjEnDZ64x2q/so6cU71GvT9S6EktNV3E/aDeRc4wuNvp7Yap4ICYwtt5AWFiWt1wct6E+v4VnWNwj3tq8MNwLC1jMau6HJJxz9OKtWctlpULras808z5C7W5JPH5VCOeSfz/r9DI8WXLnTr2cSeXCYxEtuM53bgTkdOxrotCjECJDjGy2iH6E/1rlPFV9DPJHokYLXvmpJMQOOc8frXU21vJLd3ciTyRhXEYA6YCjtTj1ZU/wCEl/XQb4el1FrKaXWQqPvYoMAEIPXH40l9fWWmWcd1fIcSyBVwoJBPP5YFF/BNczR2j3T+W4LEqoGQO2RSXmnxXcsNtczxTGL95HG6KSO2cUGVo3uy9qKxS2WwoGL4CDpz6j+dUbmSbTUja4vmaH+IsgyoAyTnvUFxE/2m5gnvmjnaMCKYgAJnrtHTP60joLmW2051lvo4oiJZJTjd05J79O1FwStp0Ou8KyRXMZubeZpYpEBU5OCPpXQ1geFYhBHJElukESAKio2Rj8qm1vxV4e0G4jg1zXtJ02eRd6R3l5HCzLnGQGIJGQea3hsebX+NmzRVTStSsdXsIr7Sr22vrKXPl3FtKssb4JBwykg4II+oNW6oyCiiigAorFsfFWhX/iO70Gy1S1n1i0QyT2sb7njUFQS2OmCyjHvW1QAUUVn3us6dZatp2mXd3FFf6j5n2SBj803lrufb9AcmgDQoopsjrHGzuQqKCxJ7AUAOoqjomrWGuaVb6lpF1Hd2NwC0U0Z+VwCQcfiDU0t7axXkNpLcwJdzhmihaQB5AvUqvU474oAsUUUUAFFFFABXK+Af+Zj/AOwzc/8AstdVXK+Af+Zj/wCwzc/+y0AdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcH4ok1FNUkXR4rZ5iN0huCQoHQYxznivPQbtfFt19tkRZWCb/ACvu53L0z6ZruPEN35+r6lbSQ3UcewRh4lyx5PI9K81uFktdcdRb3ESrbHZ55G9gpTnA/wB01hHWoj10uWi79l+h6ZIPJaOC71KQvIfl+UKT+IFOtbT7NqLM0sku5Pl8xi23nnrVe6isLi6tbmVxJcwAbUQ7j+I/GmyK2o6lGk8TwxRxlsE4LZIwOO3FR1GtUVoYbaxuZ4YLpnlvZfmOchR3HpXPePIbmK6hM0wNp5iiGMD7oGM5ro/tEV/aahAbXyktm2q2ereo+lc/43igttOtdszT3EcgEjSMWbmktWvU0Tabb7foadmlhPDeNeAlRcFRgn0zzWnp1vBbXFzFZKqq8KyIfrkf0rE0CK2vX1m0uCPJaRZM/dwCMA/pW3ZQobt0sZAscESQhgdwB5OPfgirmrSI5rx3IbSO9k0wR6soEjzKNu/dxn/61PnhtTNLbCe481UMgjMp24HtmmyCXel5Jei4SF/9WqbQMnHryamuTbmSS6js5nuTEUDBe351BV9SU3N1Fe2cVvbFrRxhmHROM5piyFJ72AyskEJ8xinX5ucfrUdnqE76fHJMsdlFwoeVwc/0FRQxpbTXlpfFp1uyXR1GSwPGOOmPWmKxgI0a+OfOibfF5DEMTnrGf8a3bb7JI1hLJNcGS3jAWONDtJPcnH9a58wRWXiORY0ljijtWCiTBP3OvBNdc9vcNY2YtJlhKhS7EdRiiPwmtWSukuxBCXuZZ5pHlgtIjkQY+Y8Zyfr6VzXihxd3WjLEsiQs5fy3GCK6MTG51JprExpCqlHmlHyuw9BxkD1zXJLqLXniaS7u5Ue2hPlxlUKA/mTQlzNIiD5Ly7HWrNLGmrTWsAmnjlwiY5PyLxUcCXLNpd1JbQx6hIr+YoGwYwOv+HvUvh9ZSl3JBIuHm3HeM5+Ud81IolW6W9mnS5jBZMQjiIfmc+9XNWZnGSe39aDrqC8nubaf7RFItsxZ4EHU9P0GayIdNg006jfNevO80blECcqCO+OfxNael2dro0dxcm5WTcCzEDBI/OsLxDq01tZtbW9ptW4hMrvtJwGOMZHHH9azeiuawTcuWO33FX4crsv7mUgjbBI/PB6f/XrU06XVBNZW9pDmxlMrTS4BxktxyfpWf4TPkaTq05UgiJVBPuf/AK1adtFcwLo6zXkotLhSrRhQoD7cgZHPr1raUeWCJnVVSpK39aGxCz3Gly29syrcR/u+eRkd6jtpZZYYII3Wa4gwXmx8gPp7n6VnyLP9juX1BEgT7UI4OQCYsjqffmrWvW05jtJ7G4S3srYmaUL1kAwQoxxg9KyJVvvKU0kNx4o8y6WKCOzUNLIP434A5rT8P30c7XdsGzKrmQN/fVjwR/L8K5DTIW1S4NtNKYkm33lw/cKvC5/E5/4CaoaBdLb3uTL5yRM21sldy9wPyz+FNO1k+pt7NTi0nsd7BZR6NZQhpzJJ525nfGSWPzVaS0tItTk1IyjzpIwgLP8AKF4zj8hVP7dBHrdpZxWTSiWLzPtPXaOcdvbrmpka3s01G4aJfLiYscDnpzQc7v16j5b6JbO61ARNLGg+UActj0/OmXM8sumx39tH9nuHj27JhjaW6Z+hp1nePcW0N1bxAR3HHlSHG1uec/hVRJoNVvr3T5WkkmhH3iMIG9h7H1ouNR122Ov8I+Z9jxPcJcyhQHkQABj34FeOftPa9pzX+leFJrS3tp9RjV73W5rA3LWVpvYFY9qsxdircDp7bty+y+E2DWrYAVgArKBjBFb1bw2PMr/Gz5w1TV9AsR4N07S9f1jQPhilhcKl9Y+daPLdq+Nsr7A4J+ZugDMT1qPQr/xb4if4XabqeteILK21OTV0muoHMFxcW8aBoHkyvDEDgkZwcjk5r6MvbqCxs57u8lSG2gQySSOcKigZJP4VykXxE0eTTLnURb6stnFbPeJNJYyRpPEvUozAA8EEAkZFawpTmrxVzBzjHdnhr+KdWi+H/h3T9Z1bXFuZtXvrFNUl1Ka0VEiPyfaJY0aRyc4UcZOcnAr1j9njVNW1X4cRya/d3N3eQXlxbia53GRkV/lyWAY/UjNd9b6rZTWguftMSR+Wkrb3CmNXGV3c8ZqSTUbGO+SykvLZbxxlYGlUSMPZc5qeV9h3R8w6RG3hDwV8RNRkvPEchPi2fTxJHftb7UDxn7RJKqMwz/G6jJGAMdahsPEniWPwT4wtT4wmt4bbU7MWuoXNxcyK0UiMzxrclPNVTtGHIAHqN2a+o7XUrG7imktL22njhJErRSqwQjruIPFQjXdINn9rGqWH2Xf5fnfaE2b/AO7uzjPtT5Zdguj5usfFmsz/AA506d7/AMRadocniL7PqerfbnvHS1Ea/NDOVDiEsD82Dg55OcV1cOtzR+LPh5b+CfEOsa3o90+sb5Ly4eRbh0tlaNHdgC6q/wB0n35Ne3TX9nAcTXdvGdofDyAfKTgHk9CeKyNL8W6Tq9vplxpMzXttfu0ccsa7QhUEneGww6emfw5oUJNXSByS0PDPBuuPf+DdVnPi/wATXPxFbSdQe40l5ZAsM4jfbiHbtjKkJtIxkn8Bb8E+O7nxPr/g21stVv7yBfDEqaqrLIEa8WNQ28sAGcNnkZ6+9e9Jq+mu1yqahZs1sMzgTqTEP9rn5fxqJtbszJpwtm+1RXzskU1uyvGMAkknPTjHGaOSXYOZHy1Zavc2Xw1+H2ix3mraRcz6fdSJcx6jPZwl/ObCbYo2aSXjIU4GD3zUkt/Jez/CbxF438Q6zpkc+m3tvc6jDI0TRujME+YKcO4IBPVgBX0s/ivSR4kt9DjuUmvpUlkPlMrLF5eNwcg/KeemK0LXWNMu03Wuo2c6bxFmOdWG89F4PU+lN05LVoSkn1PmXXfF+sN8SPO0XVdZtHt/E0djcafcajPKXhaTBb7P5YijiI4X5i386+qKKKgoKKKKACuV8A/8zH/2Gbn/ANlrqq5XwD/zMf8A2Gbn/wBloA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigApByBng0tBoA4DWdQhOrajHBcKkoGwMVyokGf1HHFee63MX1iyinuvtN35bRySBNowQxA/UV6JrVxA2p3pimgWWEFV8xgFDnk/0rzvxFLcyXWjpdFpJkkLGUJsQ89F6fyrGGtRep6r0oN+X6HWyvJZ6dbT6bZq80qqzkLy2cdauX9w0F9C8MbTSCM+ZEmN2OPX8aq6G12dIs2kvI082NTHGyDKjA4HrSyw3ItbyOxk26kzAmVwMsM/4cVM1aTRVN80Yky3SXc8dslvNAXPmyCRQuQO3B55x+VYXj3TYotLu7xGcu7oSCeBjPSt6aF5ZbdJppA1vHvkaMkFie36GuZ125t7/QtU2WrwmJtnmy8kjPJqb21NIxbWmwvh1IZT55VZHks0YAjuvBP610Om3MM1qs8UZSCfKuCMbWHH5cVwuh376aLSFGX7Wi48pxgMDyUz2NdnbalDqOnvdlTHaxcNCR82R1DDt2rrxdFwlzdGcODxEaseTqiaOOytIls7Mh2DgsituIHvSa0sU6QTrfi3EDhmHHzDPTFQaY8YurhrAIiXMYkhO3ADYxg/iKe8Fy9lDbXuy5uRIJGKjooOe/euM79pXuSiGG5tBFe2crRM5kUYyBk+xpNMuBcNqN3HE7zQO0McbDBAUdAPc0+5g87U4Ls3r28MK4aBjtBPr6VJaIWv7i6s0CRSKA28FdzD+KmiG9Di5rq6uddme8gaCdraT5T7JXWzw2T2jQxFftKxLIyBj04J4+lc54hZx4vXeyZNnKPl7/ALtq17nUNP02ztr7yxJqM9uqIo6sMDr6CtFH92rdyJVF7VrbRFHxhKHmsbfT5Ga5lTakSEAbT3rktVs5jZObf/j2t28vzFziWU8kj2GMVv6RpjQxSW+xnvZE3zuOfIj67B/tEdq1PFdnZJo8LW8jgQoPKto8EHJGWIxn8aU4ulF9x0antZpL4dhPDt5BJoTw3MzxieILvVSccbSePcVb0iPTtGt5Vs7lJZ5iqjGcE9Bx0rM+H8htbPymVmPlOcdc7Xb/ABrV0e8uL61vbu6IjtCGCbowuMfhniqrK0iaDvBrzBtQjtdfTTBbo5MYZ2YfM2fT255qn4rmkg0e5hjmiFuJAI8jLsBglR7CtZvO1S2je1KRZTa0rDJI7gH0rD8Swo+gwsVhnWJ9kc0TZAz14/CsXrobxsmmyCzyvhC4A4M0yR5/D/69dJa2l1dTXkGpRJ/Z42rAnfj+IEc+lc/dQkeGLCCMlTPdBQR2+6M1rst0+pxWF1eXMi+XvLRKIxjpgkc/liu3FLlSR5+Dk5uTFk+yxLdXV9JJJYW7bIldt3IxkjuefeqnieKGBLW0snaH7ScsoY7Nnckf4VrabaW6WUljNEhjt5SAH5GOoP61lyCLVNfuC2GjRhaouew5cj+X41zQjzNHVUqcqbX9dibRbD7LDJf+UJIbtdkkeOVjHC49RjOfrWP4osVNtBqOlQLDbW+FGBjcM9foDXW2NvPZTX1xd3ReBiTHHn5Y0H/1qztQ0gaxp1j5tyUgjRmKqeHJxjJ9qmp72pdGSg1dh4av5LmzSC0jVgqhhI54RTyFx3xyPwrQt3Nks8eolWikbd5wHytnsRXI+CLgx3M9oJNkiMQpBB4bOT/30CfxrorPTv7LtNPsZ7t5oxKctIQOeoA9u1VLZSXUhfFKD6Fq7vSb20S3gaS3UliVGOQO2fr+tW4HRGd7eylDyHczbQMn3Oaqpfte6pd2P2KdIbcArcspVS/ouev1FR6pe6kItO/su3815ZAZTxtVB1znp1/SpDfRHR+Dmmc3rzr5Ts+fK6lfx966YVlaEcpIT14rVreGx51Z3m2ZPizRY/EXhrUtIllaFLyBofMUZKEjg474OOK83k8B+Mb231KC/wBVs1gm0ZtNS3ivJ2gkl2hVlMbLtj+VeQueST3r16uK+LmuX+geEhc6ZOLR5ruG2kvGQOLWN2w0uDxx059a7MNVqKSpwtq+pyVYRtzS6HJ+Jvhz4kvINetdLudH+zazYWVvMblpQ8cluMfLtUgqeeTz7Vq3fgPUn1PxCiDR5rTWZ3n/ALQuAxvLTdFs2xjbg7cfKdwxk8Gkm12bw4tjp+k+IU1+fUrxbdLjUpkdLQ+Wzne0QGd235VOD70zSfiFrGtN4dt9L0zT/tWpxXTSNPcOsSmCQIWRlUllPJHH411c2Icbq1vu6f8A2v4GNqd9d/6/zM6L4W6rcaNqlrc3OmafLNpVtpkSWAcxy+TJv82XIU5bG0gZwpPJq5qfgXW766s9QGm+FYLi3E8RsU8z7O6yRqnmFvLzvG3pt+7gZHWs2w8Ya/KHGsTwShPF6aVGLaUxOieaVKsABujAxjPLc5p998WtQ0651Y3+mW0aW8c8lrbjzGa4EbYDLMuUYc5bpgZ61pbFOWln/wANb+uxN6VtTa8P/DVLLX9KudYWw1WzsNDh05PtMe9xOkrPvVWBAADYBzkdKzfDnw21bTtN8M2UsmlwDSLq4eS5tGcSTpJGyq/KD94Nw4JIAUcnpUWueNNXuIJ7CSW3hvbDV9Nie602VjDNHOclBnngAgjPOR617DXPVrV6avJ7/wCX+UjWEKctun9foeQw/DfVx4Vi0R4fDsX2JY/JuolffeFJVfbONvyq235gC3zYPbBuaV8PdUt9U06/mnsICur3GpT29qzCOBZIfLCxZUbjkAkkL16evqVFZPG1Wmu9/wAdy1QgeLaX8LdZtorS2uE0Fre1068sS8ckqvd+d0aTCAg+uGOOoz0rU8K+Adb0i1SO7/sW6RdRtLiOGfdIbeKLO5llWNC8nPyBlwvqcmvVaKcsdVkmn/XUSw8FsFFFFcZuFFFFABXK+Af+Zj/7DNz/AOy11VeeeFtP1e5u/Eklhrf2KD+2LgeV9kSTn5eck5oA9Drz3Xfi14f0rXL3SobXWdVuLAgXr6XYPcx2h9JGXgEd8ZxyOoxXS6fputwXkUl5r/2qBT88P2JE3cf3gcivLPDCeK/hrrniyxh8IXviG01fVZtUs76znjXcZcfu5SxG3GBz7k0Adhr3xZ8PaVqQsIIdW1e8W3S6ni0uxe4NtEyhleXH3QQQfXFLf/FnwvbaRoOo20t7qMGts6WS2Fq80kjJjcuwfMGGcYxmuQsYfFXgTx94p1ePwld67aeJFt7lDZTx77edEIaGTcR8mWOGHGB36DlLH4T+KYtP8AQTrcWVyur3mo6hLp80YOmiUJtCFsg429g3JP1oA9VHxf8ADT6RdX8MOsym0uPst3app0puLV9pb95HjKjCnnp261Vg+NvhWbw5ea95Wsx6VbBCbiWwdUk3vsGwnhueuOlYvwu8L+IPD+jeOdF13TZLjU7t5pk1zzd41QMhC7gWJRhnGOBz7EnD1jwL4kn/AGVbHwtFpUja/H5e6z3puGLkuec7fu89aAPQ1+K2jf2HqmrTaZ4ht7LTVR7hrjTJIiFYkblDY3AY5x0znpWto/j7Qda8RW+jaPcSX1zLZJqBkgjLRRQuMoXb+EsCML15HFee+G4Nb0bwp4pWx8GeJpr65gSKC01rVY71J2O9ccvhVAbLdNwwKi+AngfxD8Mde1DQ9QsYr3SdQgiuxq1uqr5dwFw8LjO4qDnacY78biAAe5UUUUAFFFFABRRRQAUGisjUvEuhaY7JqWtaZZupwy3F1HGR9cmgDmdamhfVL0wtb+fF8gMhwA3NcJqk0t1renWt5PDPcRKzu0P3RycD8sV1Gr3On6jbyXPh6ewfz3LpcZBUj+8PWuVaXzfE8u90eS2tMMyLgFiByKnDLmrxXmd+JajhJNdv8jpbFrWSLTkJnNxaRj5FiYA8epGD+dSXgS+Ek88slpDBlWIbBP1x2qZL6WK/tLKO1Zomjy83ZeKrstrm8tL8lkeTfgA8g89qxqO8mzoopxjG/ZEdjIbJ4v7OU3ltd5cFmwVIAzknr24rF8X30lzexabMqLAo8+dY8khR2J9+nTvW0sls8M0NsXtooIikZ2kEdyRnrxiuZ0KKOSe3e5dWN05Z5JG/5ZRngZ9yK1w1Pnnd7LVmWMq8kLL4paL59SxqOixzaU0iPnVFIkmQ87i38P8Ah9Ki0S/mjklkUE3cKgTQsf8AXxjrx/fX9a3b++0qK4At7iAzTTJvIcYAB6k1g+IYk064Gr217vkM56KduD2BHB704V25vn2luKphUqS5FaUdv1X+R0VzdWP2FLm7ZltfvQog6AdDx3q3b4jhubrT4zM8yK8YLctx71m2dxDDuW4hD20iia3j25Kk9VA+prSVXM0b3kwtlYbIoY32/me5qK9F0Z8rKw9eNempIivjL/ZNvNdKq3ysHWM4JJ/u8fzqzqSQ6lY/Z5pXtSwBIPGP6VC6tA17JDDJdXURAjDNk4IB7/U0y8meeCwjvYcPI+51OOMdj+JrI6OqaOSv4lfxja2kEvnlYTGHz1yuP61NaaVOmoCK0zcXfTzHPywqOAf8Kj0mdrnxp500KQ+RDKdkZyAApA/lXQWpaLQbB7ayFy904aRj2B6k16FKXscMpW32/E8qvB18a6d9kr/ci9a2r6HHIQ8ZtFTcS335ZPf+VUtTV9NsP3NkJGnjJnm3YCDHQfiavT6bbTak0eX4hDbPMYhTkjIBOO1ZPiy51C1sIbSRYnjmOwSIcNkdMj8q4WpVJW6s9GLhRjfovyRX8FwSK1i4cK8sUzAkZ43iugWO0vdReCa5aeWDBMBXCA+uOhqKzjNjdWECR72S0PT1JGavJ5cVy6wxQR3UoLnL5Y++K6MXHlml5HJgajnBy8x0EkcJe0kwEUYU9iD2rnvFn2W20eG1s1UJ5wyEHA61pK81lolxJtN1dq535X7xz6CsTxdIz2OnTSwCCZjl09PaueGskvNfmdk/djKXk/wRa1GORdL0BYUEkgkEioTgE7s9fwrZS9vCT52nsk54Uhwy49z2qrdukf8Awj5kOFC7umf4TVtFjiurm9NwZBKAFQHIAA6Aeua7cd8SX9bnm5brCTf9aIyo5LZEN1qERmuboOXG3KoEHQ+g7fjU3hzSoVtcTRhiU3MCOMv838iv5VQ1hb9bGaNpFiS8uAqKi5cKxGRk/jW2p8lIpFuRFJK2FSTo46KMfTHSuaCtTcvkdlaXNVjBPz/yIdMthd2czX9o8MQY7Y3csGX1xUFzHaaXYWsxtGmeSRYwgYjk9/0qe9eS5055r26+zWS58wQjDOOmM9gfbFTJI8UMEap9pRzmEnAIHv8ASsTpuzmPsUdv458uNAsUikhO3IDYx+BrZupIJ9RntbW2aOeyaObzMYV89V/Wqd2wHi/TJzNHK0iMpKfdzhhgVv6nNNHCQlueoLuCD8orS37perMbtV7d0v8AIsTS3siFYYUi45Z3yfwA/wAaW3CwWKs1z5capks2MLVG3tb0+IJ7yWcfYWhVI4g3tycY9c1BPaRalorWUlzLAhkOWQckAnj6VBVuh3HhqPZDKfMaQsQdzHP5VtVheEyi2Zijd3EYC7mBBPH0rdreGx5tb42FRXNvDdW8kF1FHNBICrxyKGVh6EHgipaKoyMiPwzoMenSafHomlpYSNve2W0jETN6lcYJ98Vbi0uwiltpIrG1SS1jMUDLCoMKHGVQ4+UHA4HpVyiqc5Pdi5V2Mw+H9GN3JdHSdPNzJKk7zfZk3tIn3HLYyWGTg9Rnii18P6NaXFzPa6Rp8E9ypWeSO2RWlB6hiBlgfetOijnl3DlXYzIPD+jW9mtnb6Tp8VosonWBLZFQSA5DhQMbgQOetadFFJyb3YJJbBRRRSGFFFFABRRRQAUUUUAFcr4B/wCZj/7DNz/7LXVVyvgH/mY/+wzc/wDstAHVUUUUAFFFFABRRRQAUUUUAFFFFAGdr+qpoumS3slpe3gQgeTZQGaViTgYUfWsXQPEWu6tqcSy+ErzTdKcMTdX11Eso4OP3KljycDkjGa6uigDj9W0zxrf6jcfYvEWmaVp+79yIdOM823/AGmd9ufouP51pXPh+e/8OwaZqWt6o86ENJfWkotJpCCepjAAHOMDHSt6igDl/D/gXQ9C1FdQtEvZb9VKfaLq+mnbBGDw7Efp6Vam8HeGpruW6m8P6TJdSuZJJntIy7sTkksRknk1vUUAedeIbdnY21lHNaRRScCBVXgHoOeBXE2UjXGv6tM6MgO2JgxBI+bjpXY+KNQs49XIl1KW2EMpLxpG53n0JAPFcjZWsy2tzqSI7pc3cbgBTnYDya3wVGaq80l0Lx1eDw6hGSvdaHbm4mMY8q1fGOCxA/TrWfNPJZaPJc20DXFyWy4bjB7k+gFQyXKXOppeKdRaKNcLCkB2k+tUtakuLiKYmC4isMeY8bqFkc/3Rgng9a5lha0nblOt43DwV+ZMzdV1G71uEK2210xTtnlznefQetRpqscl9ZWgtUsTbDFnK/CsMfdf2PrVyLSnvNOgmluoIpnXdBASAkYz6dz60viSzTUtPllhh86aNhGHBCjAHJ+nBrSVZYd+zirpb+ZEcM8XH2s3Zv4V0Xb7+pauLpZFmvbqOKM2TgmJx8yk8H689CK5xHk1vV5ZJ5nl0+3l3AHjcx6IB+FQ6ffw3dtcWmpySKisIY51GcgHO0jvjAra0CC1jeG30ybfHFI7FpR96TA5P4fyraOHpwn7S+lrpdTnnjKs6XsGrO/K30/pmZrVzcWt1Z3j4ngc9FOOAc4HoR2NdTDc6dqnkXF3+8eIhoJFJG/04Hf1FZ2oWrXVrcGVLb5ABGIz8ip1Lj3zXP8Ahq+WytpLiaORbdp/3LpztxwzY7jPas6M/rClCr6p/p/kb4il9TcatD0a7+f+Z3jT3a6hK1vbkJMFO6RhkYGCQuc+lYeraj9jmnhhMV7PdpsjIYmQt79lAPQVLe3wmvYJrKHzNVdPLEm4iJE67s9MHrVSK0lhhuJ7bc8uC092Vy7HuqDsP8n0rH2Dp61dF+fp/ma/W1VtHD6tr5L1/wAjP8LlLC+u7e9kD38sJOAOAOmAe9dDZSx2vh2ykj+2TElYXSKRvkPfI7AVzhtFTxZawRlo2e2dgzHJB8sNz+VaVrqU2lExXUuIp1EiTJjgHjDj0/2uo967Kk4V6EUly66dtDhpwnhcVJyfNpd99dbm9aW8VveagtiogYQDLk7vnOTuOfqPyrkrZ5r+9c3E5uRYxkhgOGkbhR+ZqbxHqAgtEtNMhKu4EQwxaVnJ5+YdQeOe9WNFWDRpYI71mkZcyXDRKX2yHpux0AGaxw+Gmm5yXw7epvjMZTlFU4u/Na/p/wAHsPttTvLe+zeDdcWpO5OpMZxux644NdFAsE90urx23zPGArtKAMepHT0rDvtMVhbPpVybi5RWkabIIZck4P8ALFRaPdRXcT2gOYpDmS03bcHPJRv120f7xFRek1+P/BBf7JNzWtOXbp/wDqUkuWvXAEaq6BgevtxXK+NG3XNlH5/m4Y5wBwR24rfiv7FZrSKEmHy8x+XL8hUY7569O2etc74pgghv7FLZ1K/MxIYNyTWVKlKNaKkuqN6lenKjNxf2X+R1N0xWfSFRd7R2m8D1IUf41DEJ5ms5LuBIrjLMwU+gwP51Zvo5v7Tskt2VWW0C5YZwCF5xVC3mjnvp3tnllubMmOXzOFYHqF9OlXjXea9DLLFak/X/AIBjf6QNXjgvplla2zMWJwFdzhR/M/hXTTf2dLNaySyRPJb5MYV84JwCcCsPw5PFqEl9fuCUllaTBGcouVX+TVoW91aXumT3VvbNGYGJGVA+Ydx/n1qK/uRjT+f3m2HvVqTrediYPHPBNbT2U0kLO2VKAAjdkdT9KGuZHupFis22Rxhf3jhCM+nX2/Ko7xo76Szkb7QqwNvIEZwTiku3t9QmmgWKeVGjEcjRjbjByOSRXMdljH+yxW2uaDDHEyIG3FmIO4k8nIrcngtrbVb3UHuJ3eaIReUVOxQPTj/Oa590gtvEmmW0KSLHbox2vyejHr+VbhlvhPqTagixaeFWODOCSeQW459K12pL1ZzyfNiX6L8y5G8Cypp73TfaDFvEWedvTOajnS9t9Djj0VEE6EAKxHQHkc0rabbw6jLq5LyTGIIin7qjGOPrUuYLRIhc3RhknP8AfwGY+n51ka37HXeGi5tCZQok43BemcVs1jeG4hHDKQznJH3mJrZrojseVW+NhRRRVGYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcr4B/5mP/sM3P8A7LXVVyvgH/mY/wDsM3P/ALLQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQaAPGfF39t/wDCRXUNrdswdmkSNUXhc9KwLga9HbB57i72ucBUAJzXoermSPULyZUjt1DHfLIc5wewB/nWPbz3zRiSzntZrIsSXKncMnt2qHiqy0UrfJHo08Dh3FNwT9WzmV0zW5wVN3dhNgc7pAOD+FYxt7o28lxC95iM8SFyyg+/tXo7pFZMHu9Ql8+YgAuflPtjoKe0UrSrBNOfLdSQkQ29PcfWoWIrp3U395r9Vw1rOmjE8J3tte2qTTrGSDtdSMmB/wD4k9frmpfEdybez1ICGS2VMbJFPyy568dK5u5tL3S9dE2mwvHJMdptXYOZIz64Jx7f/Wq34kntkureKK5nuDDhhZ+aWijftuI649M12zpQxEFWk+Xv/wAA82nWnhKjw8Fz9tfz/UueGtLFrBAJIlku1tmuXVh1eQ8DHsBWZatcWviHbJAYnuRv8sHhSOf5ZH40llq81tqxk1CdkYjCTleI2PVWA/hP6Vfntrq41oNJtW4vPlT58hYwOWBB7kgf8BrRJTqRrwfu2/TYylKVKlLC1Faba/F7iahdpqMtvpGjl4YSSJp3GAinqOepH861fEttGuhQWekwKsduQCG4KKAck8/41yepWZ05TMnnFEmMUqsT8+Ofl/D9RW3quoy3Wi28jmCVEUmVygJkTacMo7e/TB4rlqxhKi3Rva+t9/I7qMqsMQliWr20fTz+ZJ4WmjbSbmCdilskhYEddq4yAfTJrcV44Ai21ytvbSIHG/Dbc9MZ6Vj+DEe1063NzauVniJCqoPV2bkfQil8RjZpUyPC1zdyPlQqbdn91V/DiqxVKrdaXskZYKvQipNtK7f3GMbsjx19seWS6gs1Yu+FHDLtAGAB0qxfS296qS2kduVVNjSyyFVRO25ME7u2PbrV/wAKWR0XQ5rvUoj9pY+fOuMnnhV/I59s1S0FLW71i4SVGENwgEak9lJPUd/mFae5Hlw81eyv89zP95PmxcJWTdvloh2l6zb2UFvp9vaNPzsju5Vxuf0x2B6Dmrmq6ZYR2S36SzW5m4243YP41V8bQ3NtBtihjjtIcNAUxxjBPv2rdsJrbUNNuv7QQJFGwlcOcAZGSf51E5yxFJz6xf5l0qcMJXjDeMl5dDn0kvtI1KGK5kXypiqiQHDYPA/3voc0mpXmnxu1vbqGlRjsaCAh8k/3s4/Q1JqQk1K8i1B4JhYRjZarggyEA/N7Ac81atb+2vLKTTrvejSL2UByQexHDfzrVRm6S5rOXnvYxlOn7dqLcYdbbXLMOq3N/ps1ta2qLqlmFLCVRIxQ9xnGea5y+vtTe6hh1Ewr84+VYkVh/wB8jj6Vr6XqEA8aXdxYedLElkRIfJYMSMHGCBknB6Vl+K7VIdbiu4CzJdASgn1JPFVCpWjUpqWl3rp5kujh5U63Lq0rp38vuOl8YpqL6pC+nRJMIrdSV3srdOxBrN0y+urjzdPlD2M9xlf3y+YGyOSGG0569c11gBfU22tjdax4I9xXOGwtdH1K2NxcJHFD0aRvvMcnp25I/KlOU5VVTtdegqUaccPKrzcsvXch0m+stJu5dMhdLqNAsZ2OA6jHTaevOTwe9bc13D9nMUPk29orbC8hxk+mO341yt9otvd2EcKxIdWB4WVsCRf7yk8H8DUd7Fq+hwWtxqiJcWkZQMjNl09gw5OPQkiorKNWryTXK+/Rm2GdSjRVSm1OPbZrudv5NxcXULpcPb7B88IUMHHqDUNzBfSQTNp7LFO0w+aReNo47iuQ1Fb2RptStBaR2CHaHuED9wDjPPXin6XPrd3C09nZ2k0QbbmIeRz36YNZTw9GEnF1NfRm9PFYicFUjS09UWjL9o8bnIB2KI2/QH+v5V0KXdnNrdxYC2V2gjEjPjIBPb8jXKWt3Jpt7Kb+0WzuywczNMJPUcgknHJ5q43jaNXaNr7SznjO18/oa2eElUhFUmml+bOZY+NOrKVZNN2t6I2Z5bK0hht7y4khN0x8pFZiByMfqRVt7RLi5g+3RQyywHdE7j9fTPFZFt4htJvJDPplx5f3W81lYH2ytasl9BdyW7CW22rneouFJIIxxkjmueWCrQ3idUcyoT2kXT480Hwzc/ZPEN6bNpQHilNvIYWHp5gBXPHqK7LRtY03W7P7Xo9/a39tu2+bbSrIobAOCQeDyOOvNZXgq2tLfSGt7SN1t1Y4WQlsZ9yTx+NaN1oemXOl3enSWcSWV3nz44R5W8nGSSuDngc9aSi46M5qklKTcdjSorj9M8Cx6RqNvcaTr/iCC2icFrGW9NxA6/3cSBmA+jCptfm8aWupSzaHa6HqGmYUrbTyyW9xnHI34ZDz0yBTIOqorn08Qy2Xhp9W8R6Xc6Y8TYlt4v8AS2UbgoYeUDuHOeBwOuKXw94y8OeI22aLrNldzd4VkAlH1Q4YflQBv0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvgH/mY/8AsM3P/stdVXK+Af8AmY/+wzc/+y0AdVRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUGig0AeYa5qaS315BP9hMBkKndcYJ57jFU7i8s4tMkgs7vTYmxlVMzYzn6e1UvFXh+yk1+7WNPLd43mJVQRway7vwsI7i0jhzIkv3yI+F6VTrYfb2b+866eFxTS/epLfY6WfUrKWFPMl0yR15AaYkAj6ismTUJdQ1CMDWLKyIUoVgJJYE+p6H6VSPhfTI9QMM0hI2jD7QBu54z+VZc/hh7TSpZbmFFkLYEaj5iPUEU44rDw19mKWAxU9PbL7mjc1OwvZZHtdPmIiztllUjc5xzubrj2pvhjStNQG4tp0vFVzGz7SvlP8AQ9frSeENSd7dklYedb/LKDjMkX8LfUcg1rm30/T7e9j06DzJbpi7RoSwZyMZPYdqjGRbkpt3T2Ly9qMXTUbSWj/4c53XPDkKLeXFpdee8j72hxuxnr36VT0HWBYzw2OpEoyN/o104z5R/uMPSuwu5Lvy7BdJhhlhLhLpGwCqYx/j+VZHivw7bX5ZYpfKuF2sCwJDKf4Tjvx1+lZUK0qErrVPdHTiaEcTDleklsyxfaY95bGZD9o1BiN6yuMIh6lO2OnI/wDrVhaallZajJa6jPHPpiEt5kZyEP8AdB6YPpTNDnNhqcOmaq/2iyZ9gik5KHtg+lXLqwl1C0+33UZlTzDb29tCMLEMkdh7V2U3Tor6xTu09LHn1lXxElhKqSktb/5f19w+/trbVLW/vv3kjwzbYwhGRGQNpBAzjHpWRouiRalryrp/mmK2w8kskh6/3cZxnNaekaRMzXGmTu1mUQESBhwhPQ/rg+hrp9KsLXT7G5s7FxCiISJd2S/HMhP+cVo01fEKTtulr+JheLSwriua9m7L8CG08SSPf3VveWyxzx4DwLksy9N68c9sj8awrpp9Pmk1ZrdTPcFvKgYkbI89fYt/SmaKTe68l7FNvtrJWUTyHHnPg8DPOK67UILy8sYZrPylebBm385GOnI6CsZSlThGtb3v6/Q2hCFSrLDc3uL+t+yZzsurWeraMfMlkiW2wZ0kXdIo9F6Zz0z/ADrPu9WutfuCdL09LSONN3nT/M2FHUKe9aeg2iDxNfyxrGLRYdj5GV+9/wDXroNT02K3F1ejCgW7RhQOBkU54mUKalTVubVipYSE6rhVk5KOiMnwTd3GpWcgvZXmNtdOqO3cbRwfzrN16LT59Pe+SJoS0hXYD8r4/iHp+FaXw+UxaQ0rADzp5JMd8HHQd+lRauseo6ujn95ZxfKEwV3t2X8TRWozqVIJ+WvbuGGxFKjTqW7uy79vUboa6gdG2Wt0sF2kfmNLIOVU8hTx6Vi6pqF4YoJb2O0vy5+R1Vk3YOOxHp6V2GoWMhv7CKFZoxIjrLNCRx3wcggiub8TaXJYrEFlgeCFhtCoEYZJzkDgnp6daqGIqVMQuXa/4BLC0aWFbqfFZ/f+RbiutXMBaO0hhkMQbLyO5Cj6tg496wdUhkutHTU7uYzu0ohSMrgKemQBx+Vdlrl4dLXTLhEEnmWqjaVLDGBk4FUY7uPxBPbxu9uIbNxPJFGjoxA7c++OlbVvaSrLklZO2l9f8zmwzpQoPnhd66202+4bd+GtZtJVezv4pE2DMEy5TH0IIrMv21OO3P8AaViZ7IMC6LMSgweo5OPpxXcXV5Z6rbSp5xjSRdpzlSo/EVDYafY6dpxtVZ7iGTOQfn3Z69BiuedbEupt+B1UqODVHV626P8A4NvwMKLW4tO0uDMaXNjcFigVRuBzkqQSBVAavqV83kWVqLW2fiMZEa5759fwY/Sp00mC01uSGC8RNOkHmKjuu6KUdDjJ4wT19a27mFbprVp0kl8g5D2mHVunUdR0rWvCo0qlOKTe/f8AHQww1SjGTpVptpba6W+WpiWHhNZrj/iczlpQSRGowhHqp/wANT6bplhDb3B1EW5dTiNfODH0xjPrWrPc/aL1xdxvHZx42rsJLnHJPp9KZp1zvku45Y3ELfLGqxYwOeen0rglQrSd2mepDE4eEbRkkZ8mg6XNfpYCwCSGLeZ1c5DccY/rmmXHhrTWmtktoQZGfbL+83FCPr+NbUV20dgtw9m41EoFbMZP6jsKhmuR5tlFAiPGT+/MsTBvc5/Ol7GrHVJg8Rh5Oza+djt/Bemw6bp8sUAIy+ST34rk/iP8WI/AV1P/AGr4Y1ubT43SJL+EReTM7KG2plwSRyOn8JrsvCkdvDYPHabRGHJwpzgnmvKPHXhjx3q3xYt9dOi6brOgaSAdKspr/wAhVlIUmZxtbcwOcfRfTnW8nrLc8+aipPk2PTbrxv4e02DTjr2rWWjXV9CkyWmoXCQyqGHRlJ4weD2yDVjWfGHhvQ5TFrGv6TYyhFk8u4u40fYxwG2k5wT3ryfxL4N8Wza34q1GPw3pWqyeK9Jt7WRZr1V/sqZYSjqCy/Om47srgkqOB1p9v8JtRjvrpb2Kx1GFPBseiQTTYYm6UEZAYZUeh9KCT1HWfG3hfRWtF1fxDpVmbqMSwefdIvmIejjJ5U+vSrz2WjTTw641vp7zRRmWLUCiFlQqcsJP7pUnnOMGvCtZ+HXjifQtD0RbaCfTofDq6fKkF8luY7oAjMjmNmkj5GFUgdc45J9W8KeH7/TfhJYeHrsRjUodJFm4D5XzPL24z6Z70AasfjDw1JZ3F3F4h0eS2to1mmlS9jZY0bhWYhsAHBwT17Vh+IPip4S0fw5Drg1W31DT5btLIPZTxviRvXLAAAcnuBzivP774QX7fBfw/ounWmnWviLT7i3vLtYisYvTGXJjaUKcn58gsCMgZrJvPhZ4hvvDXiCSHQjBqdzfWF6kGoarFctctCX38pGqR5VlHfd3xQB7Vpfi6x1TX5LOwuNNudPFiL1L2DUYpC43lT+7U7gowfn+7kY60Wvjzwjd297cW3ifRJLey2/aZRfR7IQzbVLNnABYgA9ycV5tqXw+8QeI9W8RXjWFp4fi1XwwdKjgjuFkEM3nM207ABtIxkgfxEc1X1zwX4n8SfCbVPCzeE9I0S+j0+3toLmK7ST7S0UsblRtUFEPlkjcerDPQmgD07xv400/wvoWtXvmQXt7pVsLqawjuFWbYTgEjkqD2JFJceP/AAxYR6euta5pemXd5bx3CW91dojhXGQTkjjqM+xry3WPA/jTxRL451LU9JsNNutc0WGxt7ZL4TbZEbJ3NtAHrxke5qH4ifD7xtrxuNOhtoJ9Lk0aG1t/KvUthHOiYbzv3ZeX5vugEKPbJNAHtd94l0Kwuxa32taZbXRVXEM13GjlWOFO0nOCeAe5rJs/HOlJpN7qOvXul6Va299JZCRtRilRip4yynCue6H5hjmuQ8L/AA4uIvH9hq2v6fp93Z2vhu005DKFlKXUbAsVBHHGfmFcjqXwu8QrorKNMlub5PEF/qdvNYaoltNAku3YwLoytnBDKcEcYPWgD37SdTsdY0+G/wBJvLe9spgTHPbyCRHwSDhhxwQR9Qat1yXwq0rWtE8CabY+KJLWTVo/MaY2yqq/NIzAHaqgtg/MQOTk89T1tABRRRQAVyvgH/mY/wDsM3P/ALLXVVyvgH/mY/8AsM3P/stAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBooNAHm/iGR1ku5buRbe0Rslk+Zjz3/HtWX9te502SfT78PGpCMfKww5H0x1q94kKzalJYzzwETOSsbKckfgapWto1vbz2dskFtCvMkmS3UZ6H29a5Xue5BJQRajIFy1mbUfZVQMZWHDHis4Q+Vp0t3p8ZnvPuAMS4XnkKOw+lWYd01lAsd6Lm2ZvLZtuCacZYf7YFrCJI5NmS6Hg47YpFLQ4rW7a60e6ttQ2+UzfMVU4/3k49a7Hw/frd6cPKIdlXKY7r2/wqvrsUcumXT3SvNMpMcYHGDnqMdK5Pw4xtbryJEdGB3KuSpI7p/UV24ZqrB4eW+8f8jgxsXTmsXFabS9O52mjC9vLaRtXt47a6VyqvCcZXsRzkU2J45NLngjluEmk3IZ1VmbPTOar6xcSWtvbS6ZDNdRSMBIFlbKKcDp161ce1SPTLmwnLwwNGT5mDgKevPryRXJKLi7M7IyjKN07pnGa/p8thptq8ks08kfDTOpBbHPc5/Wugk1CTRrd3jkhit7xvPiZjkxg9VCdzn8PWs24tWuNPstLSVjaA+WtxKcF88cfh2rV8RSaRb6tYwPJ+/sYxGTIu6M57EdvrXoYOnJQkprR7X7nkZjWjKrHkeqVnbt/VzEhjn1TUoIbhbiC2nO/exy859W9uOB0FWoNF1GDVrjT9PvV+zqiuyTRhl+YnsRjtXTyTiaO2e3W3SZjtSZjuRR3wR1PscVR1y2stJtxdypcy3TNzPHJtdj7n09q5K3tYzvNtM78NHD1IKFNXX3u/dnLeKNHWB4oZNQeTUBhlAjIC88YxwPpWhba9qmkQ7dU02bCADzEnaNW98YIJ+ldCbFriK3vBGuoRjEiCXCyqOvDd/ocfWqPjWeyurK1+0zGBGY5VhyfbHfGO1VQlXfuw1XnsZ4uGFSUpqzXbf7i61+9/o1vHo1qkElyDKxYAkj1OetZMWp+IJY59PtTpskkXyyKsasy/UZrTkuGsAGtrmxjt0URxic7NwAHQ/jVe3lWG8uW03S1XU5+ZmkcBRz1z1IzzwK0xFacKjjF2Rjg8JTqUVOau35v/NGBPpt0mnHUb+a5ku3fy0igj4ixnOAOnTtU17LrVnbwQX8Mt9buwaORWKzKRz1HOcV0Vu93Z2LtDe2t4YgXmU8fN1PI6fjUrJO3lam7+awAKwj5VVT1x6t7mso4mrGXNzanTLBUJx5XFW8t/69THsvElkF2XVzqcIHG2b5/wA2Az+tY2qxPf5u4XFzk7QIF3LGARxkdCe+cE+9dJqFjo9/qK3txJKZNu3yNp54x0xn+lc9rmlTaTOl7p4ezRsgHzCHz9FPT8a0WLvbmVtU9DF5c1dwldtNWl59n/wDtZLuL+ytJdpkikELQEs2Npxxn06CufurK5nW9uRvDi1EXmjgyNuUkjBPYGtMWl5/wiv9qPdF5gqnJUE/nXParp2qT6hE9rfTT3UaiZJAeAvoMmuvEOnTqxqSv8v68zgwca1ajOjC3Tff+tCe40do7xobHUryKMW/2jKTuQBzxnd7GrNmJdU0/Sra9lZ4pfM3s55bDYHXr0NVLbXtTtbaVZNKZiCVZgxRPQ/LtbH54qrYza9BZm+str24PMLoDH6YA6jmuWM4JtOpo/X+kdlSjVkoyjRs1vsv+HNXStA0zUop1WzntljbaGbq3vyOtZz6FZxW808dyVuIWKhY3MYfBwSuCM1fsvF8F1FJa6rbS6c+PmKktGfbjlfzrS+3QvbW8eliEQocFUAdcdvf17Unh60FzU3dd0/8i44uhOXJWik+0l/mjMtbG7a1hlg1WfdJgCIXDkjPr83pVwaTeTu6DV3eROoErkqff5q0Z59OF1ZmFrZp2kwWUgFRtOc1Ygtre0muLtJgxfLFQw+vFR7TELRt/iaezwjV1GP4GDNpN6tm8pvp96feRZHzn0+9Ra2mrR2izrqlxCrc7HkbP65z+VX2uLnyorgACaZ8vEsoOwcADGcZ96JVuFkcWknn3kcoDF2BwpGQMHgdR0qXVrreTNFQwz+zH8Dt/Ay3f9ktJeyvJI7ZG9ApA98V0lZfh4EWR3cHPNalaKTlqzzZxUZNR2Oc+IGpazpPhe5u/Ddj9u1FSoWIIZCFJ+ZggILkDJC5Ga4bTPiitnpr/a7h9V1B7tbWO2ezNjNC2wsRMCWAAAyCuc9MV6Zrmj2OuWJs9ThMsG4OAsjRsrDoQykEH3BrH/4QLw1/ZzWR00GNpxcmQzyGbzQMB/O3eZuA4zurro1KChy1I3d/61/ysc841HK8WYVz8Ube00PS9UvNF1CKHUPMhiTguLlSQsJH+3glW6euK6Hxf4mbwz4ZXVbrTpppC0aPBE2REzd3fHCju2D24rAsNM+HniKVNNtrix1Sa3hmjWBr953RXP7xgGcndn+P7w45FddqWgafqWlwafeRzvbQFTGVuZEkUqMA+YrB84J5zz3p1PYxlH3WtdfTp1FHnaeqOGsfiPf6j4i8O29lpdrJpuowTyzSx3SSlPLcKWVgQMKPmIK5OQBgg0zT/i/aXtre3Y0a9Szis5b2GXcD5ix9VbjCMRyOT9c11kHgfw7A2ltb6f5T6bI0ts8c0isrMQzFmDZfJAzvznvUMfw+8MxRXUMenOlvcxyRPAt1MIgr/eCx79qZ9VAq/aYV/Zf9N+fawuWt3/r7jLu/iFcxJaJH4buze3FtLfLbyXMSkWyBSZCwLDJ3YC9eOcVSPxMtYzqmoRreXNmljZXNta7EUs1wSFUHrknGckgY4rqfEfhjw7qGnQnW7dFtdPhZVla4eHyotuGDOrA7No5BOCBzTW8IeGtQtLkjT7ea11C1hgfy5G8t4Y+YguDgAdQVx25qYzw9tYv+n69huNW+jOKX4k6npL+Iptd012+y6hDaRW8bqUtQ8IcmSUL93PfB5IFdv4Z8SS66LKSPTmS0ubRrn7XHOk0IcSbPL3L1JHzfhg4PFV4/h/4cjgmijs7lPNmE7yLf3AkZwu0N5m/d046896v6R4U0TRru2udLsEtpra0NjEUdsLCX3lcZwSW5LHnPelVqYeUfcjZ/8D17hCNRPV6f15G5RRRXGbhRRRQAUUUUAFcr4B/5mP8A7DNz/wCy11Vcr4B/5mP/ALDNz/7LQB1VFFFABRRRQAUUUUAFFFFABRRRQBm6/q8Oh6c15cQXlwgYII7O3eeRiegCqCayNA8VXmtajHCvhbXLGzKktd36RwhSBwNm8uc9OldTRQByGpXHjuTUJ49J0/w7BZK5Ec15dzO7r2OxEAB9t3Ge9aN5aeI7rQLaKHVbCw1kEGe4jszNCRzkLGzgjtyW7VvUUAcx4f0bxJZ6gs+s+K/7TtwhBt106KBSx77gS3HpmqWseD9X1K9nnHjbXbSKSQskFqsKJGvZQdmTgeprtKDQB5MtvawTwLKNT1G8tsp9qmjw0hBPJ6DP0q7GktxLdJJZTeTKgBDMoJOMHv6Yrkde0GafW71opVjKy5bEhGNxwP1qifDN0jSlLw5jYLIQ7cZ71fNhPO/p/wAE6lSx9tHG3r/wD0G00xYbN7aC0mjQ8j5gefXrTdOinaOOW+0+WO6xhiNrfrmuBbw/qK3otBcuX2hsiRgPzpsvhrVI4JnM7SiPOUWUknB7cVPNhPP7v+CU6eP6uOvn/wAA9AnieK98xlhW0dPnEjqp3DoeuMYrm9YudNXVIrma6s4/KYEiIs7tjpyOKxP+ETmEEU91IIxIQMEsxXPtVu08JBLmBoZ4pLY/6x4gAVojXw9N3hBt+en+YPCYqqrVKiS8tf0RqeIdRgka3l0/T4JopAdshB69xgd6x49T1Oa5S1isLdJX+6DHg49fmqLS55tP1e4093JilYPFKOgkHRvoehrd1XUbGC4hub6Bk1GJeF+8R74Bx64JroqVatSCnSdov00+ZyUqFCjUlTxEW5La19e2hjR6TfX/AIktob+bfKjiR8NkRqOfoDwK29S0yPVLbdNayL5s5lMsJBYDkY56frXKTz6o8bX1vE9tCZNwc8l3PQsfTtgcV3I+z3YsZZJpm8k+dGEQsJAw4PAPvxWE2vYuMZczvqdNNSWJjOUOVNO39dzlHtdS0yW5OjieS3QgukqjPIzgr0P161paZrr3cB/0dp41AE1k4yV7bo29PY1vDe82oABonuhiEsMZOwD+dcfMH03W2mtCxmjQW64GPMkIG4ge2CTUYes78lTWPn0NMZRgo+1pe7PS1upt6r4kkjdLaC3f7QR+7tlHA93I5/AVzt7ZTXCahJqDvLqMcKsMgBVBP3QO30ra0K/jmujqkrqsiHyLsEdFP3X/AD4Ppmt3W7ix+wXYMsIZo9rMWwB6c+vt1rXFQlNqNFe7bSxhgqlOlzSxHxp2d/0MXT3t7/StPFzYG7do0eNc4AYKFOT6cVPdyz2Orxand2gSNk+zlIn8w56g9B6VQ8M6paQQQadF5glDkwyuCqux/gweRntmrRsrOC+tY7GNjcXFwZpVdslAo5z+JFLG0nf2sdn+ZpltdJewno1ffsSwW6WdndfYNFuFFyCHzKNxBz6njr0qpKttq2k2dpqf2yCS2IEgiQnJAxjIBroWN5/bCBQfsYj56Y3fzzVPZNc6XetZM4mlnbayHaSA+Ov0FcJ6aa6ixajbSarb+WzpAsbIWkjZQTkYGSOe9UdeiubkvaPKJGeVpo+/lx4wM/rWxfymLTxFNELiZ0wUxlenJJ7CuKDtKj6dpIYxM2bqeJSdo9F74H+NbU6d/fn8K/qxyVq9v3dL43ov8y1N4xMP2bSkT/iWbvIkmxwT0yPbNbulRyJbTQy3c0QtsgBAv3O2CRk1jXGj/wBpafOkSxC1tk2QtwNwHr7/AF6VH4Wuri5AgjYy3dupVEb/AJaxdx74/p7V3wrLGQlSkrPdHnVMNLL5xrRd1s/I6GJlOmyNGzXdmzfOko2yZzycj3ontLjyEto7u0sYmYEQqMs/OcFie/sKju1vZtIljs/sdrFghiQQY+549aldLW5e2ubiGQuNoV4zuViOR069PSvLlFxdnue1CamuaL0Kmr6ZBdajBLeI0Py7dkYLeaeeh/xHasa88LyRSebAGjtv7xOHU+uB2rr576AX9t5hZECsA7oQu44wMnv1qG0Sewk1K4vZi8Dyb4wTwBjt/LH+NEZODvB29AklOKjUSfk1c5doNciaSJ2edY1DiSYq6Y9iR7UzzNUW2FxLHbiDsxiUA10k0dpb2lq97ZrKZXVSNoO0seOPrVq9toTHJbSRs8M43CNexBGcelbrGV0rKX5f5HNLAYWTu4fn/mc75WvW8SyQR26Zx92Nc1DLPrsN6scrW5nlG8qbdSWFdNPJcyCNlij8mFsuqSbn4HQf4U5lt7i7iu1hlkmRcKdpUAfjgdzSeLrP7X4L/ISwGGWjh+L/AMzs/BBlbQ4zcIqSk/MFXb+ldBWT4ZYvpoYqyEk/K2Mj8q1q0UnLVnnzioScY7IKKKCQASTgDvQSeKeEvhprFv4eW61aWSPVLCDUU0+xj8sbHnDDcZVY7sgggEjbmrt14J1O38P+E1/s+81NIYt+s6a2pHfNcGBUVg7vtwjA8Agc5AOKvWvxctnl1NZ9KkVbSxlv45IbhZUmSMgMoYADPI6Fh71M/wAUxbC8jv8AQLy3vFjtpbS38+NzcidtsY3A4Q565zivWlLFuV3H+n8/P79bnGlRSsn/AF/SPPvG8GqeH9M0q38UXR1C6Xw9LbW8a3wR4b0scShSwMhClFyu45Xpzmte98HeLLvVLC9dNQmjFnYm1kguY0ksnjjXzFYSMCMsCSVDZzgit/S/iJqlvdajDquly3V2+tHTbWztpI8x/uQ+3edobnPJI61rv8Rli1TyJtHuUs4ryDTrq585D5NzKoITaPvKCwBYH6A1bq142Sir/wCfZf1clQpvds4n/hA/El3qHiSOexdra+tLxUnvrpTIZXB8oK8cnzLnHDouB61FqfgbxHcaZoMUemX8Vjb6b9mksor2Jpbe6DZM6lpAnzcYIYlQOnau3tviZDPqNsraVPHpd1d3FpBetKvzmFWLt5fUD5SB3PtWXB8ZLV9MvtQfQ71LWG0F5C4cESJ5iptY4wj/ADA4yRjPNJVMXdWgv607g40e/wDX3DrXwdr1xf8Aiq8uJryDUJLOCPSbh75tqzfY/KkYojYzvJ+YrwfmWsJPBnihtF1CCz0+602GYWCfY/7RVneSOQGeYOHwuV9wzY6A11d58TGsLfXBqHh69gvdKlt45IBKki7ZwSkjOmQqjac9ccdc11ng/Xk8SaDBqcaRIspZdsU6zLwSOGX6dDgjuKxlWr0lzSirafgk11+fz0NFCnN2T11PL9Y8C+I4bXWbHRIpxpH9rxXUNmbsE3Fv5WJFBZ/7+DtcgHFdV8OX1LRjaeG7qwvdqQy3ck13cIzW6GTEcfybgcnfgbuAvfpR4j+Jdto/ii40ePS7q8+yNCt3LEeY/NAI2pgl8Agnp+NUb74ot/aGuafZaTsvNPjuWjW6uFjkkMSk7vKOCUOMjBJI54py+sVYcsoKz1/DfcS9nCV0z06ivOtC+IOoXsXh22n8PTy6nqunrfFbeeNUVPky/wAzcL82QMlh05NFt8UrJmjuLvTbm30m5jvJLS8Dq5mFqGMuUHK8IxHXOO1cjwlXt+K/ro/uNvbQ7notFeaH4qxWlpcT6xotzZhNMi1WNVmSQyRSyiOMcYwxYjIPSnQ/FDfZRs2gXhvpNRi05IElXbI0iM6ssjBQR8hB6YNP6nW35fxQe3h3PSa5XwD/AMzH/wBhm5/9lqz4J8Sf8JNplzcPZSWNza3ctlcW7uH2SxnDAMOCPeq3gH/mY/8AsM3P/stYTg4ScZbo0i1JXR1VFFFSMKKKKACiiigAooooAKKKKACiiigAooooAKDRQaAPK/FT3StcqRb20cj7TKWLE89MYoJm2ra+TEWuFJMgOFxjqR1z0rN1vXbG8nkjmu7m2xJnEtsrLkHrnFRp4g09ZYGbW7dhFnlrcgkEdMA1f9n1Xqv6/A6VmtFJRaat/Xc1Ibkywzra3ZZoPkZjGMZ6VFehLKSCOK0W5llILux5GT16VAPEXh+OGVVvrdBIDu8qA5b/AMeqofF2mwxrHFJqV4yjAIiCZ/4Fj+tJYCp1aRX9q0r+6m/68jZaJ3vrkQtvniiXy45GJAJzz/T8KrXSCDTd2pNH9qLLlYxlsbh/COtVW1CPVdKNxYLKbndsKTSFgv1GRVWS31vydtxerbxjG+OPC4UnGeOf1qamHhQt7R/cv1HRxlXEfwYpW6t/puS/2NPceILSeMPLbo5kXzE2gDPCjPJq/Fp+nSmR7kxm/wBzZ844Ibtwa5fXNJhsVnkF1c/bYAkivk/MSeApJPNaF7ceIDLDI10iLJhI2Owbjj+daJ0JUmtUk/67mUlio4hS0cmummnzsazaK0egzWpYXUsoOGU5APUVD4anjt7WOGCeC5aNSjRJKNw5JGM9etYqXt9rEc1hqd1tEMypLxg7Txk4x0OakTwzbMFjuJHlRJCTJGNoWPBxwffHSk1Tw6TS5lJFL22Lk+aSi4Ptf+kdTbW6RW0sMwZpZmaV1uAMgewyc4rDKC5u1urjZ5Vyjw2kCn5tuPmYHpuPfNZBsv7F8QQLZFGbzN4+bdmPHG70PJqeXWDZaoralZCyXfvSWJSQD6lTwePTBqlCFSnaHu3fXqZudSlX5qnv2V9Ol/IoB/7B1W3uILd2sXjKOsrD94OhBHrnmtW5s49X1GbdeQ2sCMUiiHUcenQVWeyXWLnTltsXKC7LtLA2UCMw4x1HTvXRqbuCwto7e1jn8wv5m5c87vqKmUalLDuE9Nfw/wAjaE6NfFqpT10v8/n1MK58LvHp0cbSq9+znywmdpXtk9vXNQ2GranZ6hFbX+RIxEYnIBI/2SO/1rrFt49P1OEQqqC5VlK9cMOc1y+o2Nz/AGxo0M7mW4VhI53bsck9aywk5QqKC2e6N8fCNWk6j+KKun1/4Y1L3xdp9sWgMk8zDgyRW+Qf1FUP+EytVgWLT7G9mKjCx7REP/Zvyq9b2qtoMMlraxTzLIVbcgyQCc/rVyeysVEbCIQtLHskhRcsAR146EetXVrcknFQV0YUcL7WnGcqktTJPia8S3K6zpkcFncKVDRuWdAe/PWrKoDaW66eyW1oGyZ4c7JBx6cgj0NWIrGFbL7AUlaOVjh7gDC/7uO9cffl9AvZF0q+mTaTvRlHzY65Xp+NEcQqiVOsvmipYOVCTq4Z7LVPqjs9UihF0JLONZJTCZSyDcGIIwcdCetci93cWOvR3UaCO5UuxTOMcA4q5rGoqkguLXT3wFVZri2Yo4bAJweg6+lR2sVlrd4s1teyNdqjMsVwPnJI5AI4b68V1UcIqdZOMk7X9djjr5g6uGcZwavaz6aMs6d4nNxeyW+plIXuMqJs/JICPut6H3rqbZY98VnbRmFIT5kikHrk8Z7+tcpBocGo2kK3MscEccZQZI379xPI9OlV7LWr/QbiKz1aOWW0XiKfHzRj2PdfY/pWF1iXyVNJrr3N+WWDiqlL3oPVrt5/1/wTsrK8fUby/tLmxC28LbA7HIkPPbH4/jVdrfT2htjfNtZmxGjueueMUajq8lskAAhUT4ImDdQfRTjn8acw0++WAy2tzIbc5Qrg+/8ACxz0rGWDrR3idNPMMO9pWJkjeOeWP7Q22PDATYYY+tITPBqBluMzb0xGsS8L69Tzn1qGWWHUVvPMMkMeBEpaNgTg5z09f0qa2ktovKh+0DEUO0O3HX/9VZOjUX2WbfWKTV+ZFMQCyluZm8+P7U2C5ACxjrkkH9auHdLdWhsruIwx8Om/7w/rUUDMNPuo7q7hlKsSGMgORwfWpCzSX1o0MsDWez94u5ev+cVHJJdDT2sW90eh+Hf+QcPqa1K8+/4QDRNcaLVRJf2WpqNi3mn3jwuACccA7T17iugstL1jSPDt1a2WsPquo7i1tPqyghRgYVzGFLDgnPXmumOx49TWbOhpGUMpVgCpGCDyDXIaTrfiyPUbez8QeF4vLkbY1/pt6ssK+7I4VwPwNaNx4y8O2uuy6Nd6xZ22px7cwXEnlE7gCNpbAbgjoTTIM63+G3hS2WZYtMcJLbSWjKbuZgIXOWRQX+UE+mMdsVdv/BXh+/8AP+16cJfOtorRyZZAfLjbcgGG4IPO4YPvXRKQygqQQeQR3rw7xZpmra/4/wDGGn6Pb3Ml5GdNe2vBd+VHpzbSWkK7gWJAP3VJ69M12UHUrSfNUatre/ml3MKijBaRvc9MsPAvh6weJ7awcSRXf29Xe5ldvP2bN5LMSTt45479anuPB+g3GvLrM2nq2oLIk2/zHCmRRhXKZ2FgOjEZHrXC3XgvXrnR/G80Elzba3eX839nO184Q2rGI4CqxVCwV1yQGGewrIs/BniOHTkjOm6g2mDUI7m50eS9ij89PLZWEZRyoXdtYqzAMR2rRQ5rv22u2/8Awf662Jcracn9fcdXp/wyht/Gya9JfRmCK5muorKGB0XfICDuzIy9D/CqZIya1/8AhXPhb7Jc2n9myC0uEMbwC7mEaqWDEIm/CcqD8oFcNrGgeLIU1FdC0G4jtNQ0U2cVv/aiFrKUSORks3JIYY2kgdM4GauWngzWZLfxRcX0epC+lijj07yNS2EZt1SQqN+wHcG5YfQjOauXM7SdX7rfo/MlWWih/X3Heah4Q0TULu+urm1k+03rRPPLFcyxsxiVlQgqw24DMPlxnPOag0PwXpeia2t/p8YiSK0+ywwjJ2bpC8jliSWZjtyTz8vvXmel+DPFEGjwxXmlCawi1FZZtPjuFhmvIRGRl8StGCGIOAw3YyccVraJ4K12afwnB4g+1PYWtvdi6WPUGXyy0gaGNmVwz7VGMjI4x06zKnypr2t1/wAD18rfO3kNSu78mv8AXkd5qvg/Q9V1Q6jeWb/bGVUeSG4lh8xV6BwjAOB/tZqOLwR4ej1GW+OnmS4kEq/vp5JFQSjEmxGYqm4Eg7QOOK4r4ceGPEOleNbu91KzkWykSUtcXk6yTs7OCAGjchxju6KR29K9ZrCtKVJ8kZ3Vuj/Dc1glNXcbHP6L4P0PRbi0n020eOW0ga2gZ7iWTZGxBKjcx4yox6YwMCoY/A/h+C6u7q106JLq4SVMuWkjTzfv7Y2O1d3faBnvXTUVj7ape/M/vL5I9jzjwp8LLHSZb9tWuI9TiurNbD7P5TpEkIbdgB5JG64xhgBjgCuitvBGgWy24S0nf7Pcx3kRmvJpSksYYIQWcnADN8vTnpXS0Vc8TVm7ykyY0oRVkihpGkWOkLdjToPJF3cyXk3zs2+Vzlm5Jxk9hx6CsTwD/wAzH/2Gbn/2WuqrlfAP/Mx/9hm5/wDZaxbbd2WlbRHVUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKAPHvEGjRT67clbNkgVGkM4cjL5zgc9MdeKxjpNjaSwLfT3ZF0/7qNT90cdea3te1BmvVMU1o5E2HQyZVUzz9TThqUKqYbWJ7tkx5QjiY4+uQOn1rBYacndRf3HsfXacIpSmvvMe60fTxBcQyPcR3CsURsO4IzwePaoLTQ4BEqTx4dFLZkODKecADNa2oyTTafJam2li80ZeWaRIu/bOagOvWVnapBqNzYKkaBTvdpWP/fK4/WtY5fWlrymLzejBW5vzMbQTdWOrKtzHLDDdjyJVKkf7jY9iK6iJdNkvJ7me7iW8ePyJIpJgu3HB+UmuVvfFlmzxizguNQ8s5R2TYue3qSB7mqs2s69eyNPDbW6Snr+73lfqcHmut0acaUYV5pNHB7atUxEquFptp/JHYR2k2u2unK6gtbkTSx5yCwHygnoeabqF7a2KW8OtW8MU0R3RoG3n6gAVwa32vyXLO+o/vk5EYHAPp14/Kuj0vV49Wb7be26SXUAEc0MnUY6MM/WtKcKE6co0XzW1tqY1niaVaM6/uX0urPT9B8Wr6ONZuLwRXE8dwm2VdgUYP1Jq/ZvHdSGbS3F9IkZjhd22yQg9ip6/Wlksltpbm7trMIbkfNvlDKc9cL3PtVHVvDKQx2txoquWZgGZXxtH94f4ZrjjiU4+zqR93y6f18j0J4FqSq0J+8++z+7/glzw/pRZ52kZWnViJgTkhuoXHp356/zbLY3U8EdpcxpcXKCSZwx3LuOQnWszTvOa+uUu3M01upIu4GZHGOxOBn8aor4hv7GVwwuleU7smRCT+BWtKtCMoxkpJR6X0McNiZ05Tg4OU921r/XoS6VYyaV4usPsqCK7CLJcKGOFG07h784rY1aa+tb5rqPT7Yee2VaKV0Zvb5WGfyrFson1Wa5mtppGkRDK+MCVmHbjqB1rVjvLu1S2XVtMkmtz8wkEeWB919fpz7U7ypJUlL3l9zv0uyGoV5vETh7r7bq3Wy/Eoz6/di6R5LO68+I7QpnxsJHONw9PU1rLepeWNjqVoHe7nZol89srGw/hx0zU2u28f2W6F5Eri5IlUmXYEwoAxgE9vSueivGtrBrWKOGeNpPMMb5QyEddp7fjgn0FbUnOOlZKN9noYVo05pPDOUrbrW1t/I04vEclu0lvdWz2zq5Dvbnj3JQ9D9DV611rTJbR4PtELmVSrBg0cpz3O7IJ/Gq1vfWd3EMJIBcFRJI0bMQF6qQAec8Z7iqer29tm5doo44WI8maVPK2+3OM/zrJwq83LUhzee34m6nQUOejVcfJ6/gbVxeWulad5dy7lXP7sOvIHbAGehrGudcsr+GMTQy3ZizuxGqfiTk+ntU6wrLfWUhkEkQiWGBlAYOe55698jrWndJ5Fle3CRwzQh9rRoCN5Bwc9eAewrKtJYeo4witO+p0YeDxdJTqTd30Vl5Eeh3lo1nM1k2I7uQlWI/1chGNrenTiuf1XT5bLUNOMiqt7JcFg4bJCjB3E9xw1TjTbrSNUt7m3gf7Df7Vnh/55lv6qf5VsXej6hc61DLfBMLGIVZecr1ZvYnAH41vyxrTjiI6W1fyOV1J4anPCSV76L5kOnazYS3t0IYGVpSXdAuHPGC6+o+nIrA1SKW7uINKS/FxCP9ImlY/JGuM4BOewz+JrT8QaJPd3tzc28DW7QEMrocFhz8w9+BVT+17WbRoGuY1ju5dryy7AQwzgFx6HHNOhGniZqdrNfc+wsS62Cp+yT5oyXzXf8AAsX1hBLp8d5Ks8tu22CBeAQuPv4IPUj9ar3ng/8Af2gtrsRmYMQrRYPAHpiun026n1H91LKkDKAwSJQQ6+oPPH0qRTayag0dvOzahbg8SEnI7jn8OlcuJqVlVbk2n6ndg6dB0FGCTXp+dzjdHvdT0LVrvTPtTzs8TbAWztcDPH4Vbf8A4SWOL7Q1+6wNghnlUDk8daTxHozW8kmrWTSJepN53lEdOSTj1HNdCj2+taFHvcRRuodW/unuPqOn41axNaVK6eq3217GLwmGp4jllH3Zbb6Pqtznnt/ExuIkeSMmTlGbYQSO1SImuS3bWm+yaZeWQwo3H5V0UiyfY4RHIbe3tgHE8i5LEDH3fTmmWMDSXJ1O3SC4Zhg7GZN3Y8H6Vl9cr/zfgv8AI6f7PwrT9z8X/md94Jhng0GJLoRiXcxPloEHX0HFb1Z+g5/syIkYPPHpzWhVczl7z3POlFQfLHZBVLVtJ07WLf7Pq1ha30H/ADzuYlkX8iDV2igRz0vhlLTw0mj+F7uTQEiffDJbRrJsJYsRtcEFSSePwGBVfw4PGFrqP2TxC2k6hYbCV1C23wS5HQPCdw59VYD2rqaKACiiigAooooArald/YbGW5+z3Fz5Yz5Vum+RuccDvXPf8Jl/1LniT/wB/wDsq6qigDlf+Ey/6lzxJ/4A/wD2VH/CZf8AUueJP/AH/wCyrqqKAOV/4TL/AKlzxJ/4A/8A2VH/AAmX/UueJP8AwB/+yrqqKAOV/wCEy/6lzxJ/4A//AGVH/CZf9S54k/8AAH/7KuqooA5X/hMv+pc8Sf8AgD/9lR8PUuPser3F1Z3Nn9r1Oe4jiuU2PsbbgkduldVRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBooNAHzpqVzrn9qzJ5sEG+QqoW1Rj7cnnNLeRav9ilmvdQvVhRtmAyqCfTbtrvNXk0ye8E10rFoHLISjAA5+mKS1M/lMWgjcuxk8ssAy5PGetTLGV3pzfckelDA4WKT9n97Zwtt4Vmv0i8yckSxiVS0jhiD7dKu6L4RtoLKS61G3kimQkgbgSR25/wDr100RmuLiS8l8u1WHMSknPfnPbGak8xpp7bfcRTW5Jw0eMFh0H8/yrKVapNWlJv5m8aNKm/chFeiX5nPPo+mzxW8MMrWk6uGfzEPz+3PH5V0G1La52WEUZKp86DjP/wBepFN1Lqdwk0af2eqALuGd5xzj2+tUnFm+n39nbzw2wZmQFWCkHvWSSRq5OWjIvL0iJ5x9hl86c4dSpJJ/PArhdYW40DWmnSPaoYHBOSUPr/Ku8shBaada2MEjTCJlDyDsPX8+OPWuT8c2k63d1cXcm+ORCIk5+VQDj6VrRqujUjUiRXoxxFOdKezX4rY3rN4b+CymMVxLaRESx+UwyjDnaQeoqjeeJ0tbieCJJyCSVtIsDr3Z+qjPYc1N8Ir9YdPvDMFKJAxAboTjgVmeEtjeJdQmIBAMbZPbJcV7mJoQpKpVjHVW/E+ZwmJqVXToTl7uv4EVvL4jVHu7RUgRTu+xxoNpXvnOWP1NaDeKNGvIo5dR06QXcQ2qChwB9R1/KtuGPTbXXLjUG1O3LyjBjaZeP1z2qrcT6fdWEYtbqyS5ikDZdtoIBPBPp0ryvb1ZL348y81/key8Nh4NeynyPyf53OTt70tKyaTYeaudx8wMD6cAEn8c1fW3169lR49OtLfae6M+cf7xruYGhk1CN7d42AhwTGcjr7VHp9jNp99qE0lwGtZn80IQfkYkk/0oeNrbRdl6f5gsvw796Sbb11b1+6xzd7Lrd1aIdR023u4tuVZSY2T8Qf6VRivI5LVFm026dVOUK3jsv/oNdpai5NuW3xCORm2xyJ0Uk4Gc1VgSTQbYxW9sZY5ZDtCuMIT2wecVKxdXq7+qK/s+hd2TT8n/AJmJpviw6WrfZdIjjQk5LMxJ+pNZsksOqa59sISOZ+WhlIAbj+B+x9jxXZ/Y5fs01v8AaBPvX95Dkblz3B7fjWU3h/TrywaCNWjMbEPcSAKynrjtmr+uyek4pp/13M3ltKPvUpNNbdf0RzbR31jeyDSo5fKZyRDIm7oM8jsfcYrasdfuXtLgbpoJUAPkna2STjgkbhz61SEt/ohjkeQ3Nonyx3Ebbto9Djt7Gti3lhu76C/acMsv3bhUGFbshz0H9TzXVS1i5U3zR7NXaOLEaSUakeSbe6dovzMa2fUdTunQrmeIF+dx4xngsSc/THWtDw3ePqICahM9zJavsZm4JRvusMdCDwfrWt9riubwwrcRlzJ5dxthKOwHAG707Gudv4307WZL+3sHitA5jlQHgrkAkcepBrmw1eUp+zqO6lp6HdjMJCFP2tKNpR19e/8AmamtyJb2+ppc2z/JtELl2Ibd0HJ6/T1rmrixN5qKaZZvGHtrdYvmbuBz+ZNdRq99FFc2cmoyCYR4MdtGOp/vse1M0c2U1ndSaY8UkspCnzAPkOc4cH69elVPCShTkk7vT7jKnjo1a8JyVoq++13Y5nTNSn8O6g1jqTFbaM4RgM+QxPDA9Sp6Ee/4V29tcWv2mS5jtHa9ZQrsG+XHruJwB0rN8Q6P58UgcKqRRlljUfeLDAA/4FWTrEU11qVto8DAQWluomAGAXxlifXH9aqnOM6LlXV+XbzJrwlTxChhXbn3XRGnqniW03NHJN54zgxWyAj8ZGHH4CsqLxHJDEYIdOiWHfvUSMSQ3r0rTTRNOXQJp4gWZIydz8crz/Sr9xaafe2CRwNbxS4D8YyPr+dYfXJL+HFL8TrjltN/xpyl+C+7Uw/+EsuxC8c9pDLCwwRvccHjHFTaf4rjs4fKg0wwrnO0SyEc/U107WyLp0UL4kPyqGIznn/61Ma3ePV41W2jNq6csFHymp+tVL3aX3D+o0LWTkvn/wAA7nwdeNfaBb3DxGEtu+UnPfrW3WfoKhdMhCgADPA+taFXfm1POlHlfKgooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBooNAHld+byW4uDewrHbR3KmPkEsuSOfzFTrELK4ubye6LRyYAQgAL6AUuqW8UlyU1K6ysjkLCDsVv6n86qwRoNSmWeR2jgC+WJH+UZGc+5+tcj3PbTuh0MRudMkguI5DHKSxZD2Jz65pkUUEGlSQadbSuqZwOh3Dvk89aZa/6BcXt1PfpcRvlo488r7Dn8KdqMepfZLUaXMiv5geUkD5gevrQV1tfT8BlxfCHTxd6msg2kKYI+SpPqeM1JbNbrHBcQRqLS5wwXZypIznHvUupSRRTQrKola4IR4sZzgdce1RtK8+pJGsbRW9uNxBGNxxxj2FAboq2du8NtJay3huGeUuDj5lTrzXnni7VI9Qk2W6yDJ8vEhycA8n/PvXY6t4giAleGMpcKTC27jC9c1wuj2761rq7Ru3uEXP1/ya7cvoKvXV/hjq/0OLM8Q8Lh3/NLRfqd94F0lrTQjcXK7IZRgMe9Yuo6doIvHe5vXjU/eWNdxb2xkVp/ETWl0+2h0mxOEtkEfy/xN3NULXwWkml/arhzcXO3cFLHDH09vwxXs18ZGgued7y2S7fM+cwuBliZcsGko7t9ysuveGNPUizsJLpkOMu/f3AH9aSTxXqOoRiPT9KhSEjliowB71q+HdH07ULGXzdMSJo22o5Zj/M54NbNq+mzWCxSmMDgMFyBke4rzKmZzl8EUvXX/gHs0slpwf7yTfpZGd4bsrmx0q8u47iMzsS7RovyZA6c/wBK2LtWurWKKTUFjecAooCqWxzgd6juHC2E9tpMRYlD83YcfqapjT31DRtLktpQJ7cLy/HpkH34rzG23dnrwhGCVtEWtQtl1m3S1uHa0uoXEgxyDjuPUVa1K6jltwtoHuJomVhsHGQeeenTNLqCxzXVpA6hpCS59lAwfzyKqarqk2n6jZWttboYpTg+pGccfTrQNLmasSW32aLUJb43QXeCDERhgT69+3HFPgaURXJvID9nuCzbk5ZQfUU+WOI65GXCFjCSPXg1Fp8V/BqNx582+1JONzZ9xgfSgN1cLSGIWslnasJiSTI0ikBQfbHWuWvoJPDM5urNheaVcfLPGGyuf8a6u1kivIL+G3lG52dd2PXuPUVn3mliz8L3dvPMjtnzAcYAxjoM+361dOpKlJTiZ1qMK8XTqdf6uCXds2lNNZxRtKdhifGGkG4HBP8Ae61V1TW5biSO1t40uL9j8sKnMcPHU9mb9BVb4YXAbTtUtmXPkqZIs9QOf/rVa8OadIdEmubQqt7NM+ZD12hugPbpXq4iEKMHWprV2/FXPCw054iosPWeiv8AOztqT6XpL2k07aiFuL2RSYmJyhOOn1rN1fw7PYLFqOlyeVfYy9sPmD+oA7j1HSuqaOX+z7eGc77vjDg9G/vVUvb2PRpUBSW7upFyZHbqPTpx9AK8mNSUJc6evc910o1I+ytddv62MHw5rMeuahbWV0XtbqJ92w8hscgA+nsat6Fu/tnVnuIpZJBIyHEfBz/9bFY/je2Om3On67YIYsyqzDGME9cj34rvIkRbqWaNvku41nAHc4wT+WK9GrL2+H5lo09fX+meTTgsLi+S901pfp5fhYytXeeHQ7iOzs2iQqQxcgbVPUgAnnGauSyJZ6WjKvyAKOBniqWgS3dwb6DUsum4gbhwAeCv0qzb+dGJLRYVnjjO1WZ8DaRkA8duleWe21Z2Y6+hgW0WdI0WVSpQgdycdvrV+OO4KndcDJ9IxgVmXSXEkkUzyIsEDgtDH82e3J9s1JLYu+tw6gLoJCqYK/3vbPp3pktaas9H0EFdKgDNuYDlsYzWhWfoMiSaVA8bBlI6itCuqOx4tT4mFU5NTsItTi06S+tU1CVPMjtWmUSuvPzBM5I+Vucdj6Vcr5t+Mejatq/7Q+my+GSDrumeHY9RsY2cKs0kd2+Y2JwMMpdeSOvJxTIPoCbXtHhku0m1XT43swDcq9ygMAOAC4z8ucjr61BbeKfD91HO9trulTJAnmStHeRsI1zjcxB4GSOTXyLq2jaholv8WoNcl83WJ9Isry+YEECeaeOR1GOMAttGPStvTrnQ5fhP4zj0zV/DN9ejQ1LxaXogspoxuTPmSY+fnA+vNAH1RpWuaTq5caTqljfFOWFtcJLt+u0nFIdc0kafPfnVLH7DA/ly3H2hPLjbIG1mzgHJAwfUV80+HH8Oaz4h+GH/AArCzRdesWgbXLqwtWgiS3EaiZZm2hWZuQOuT9RWDqesWdn8GfHfga5eRPFt34hYQaZ5TGWUG4hYFQBgghGwe/HqMgH13DqNlPeS2kF5byXcSh5IUlUuinoSoOQD2NLDf2c97cWcN3byXduFM0CSAvFuGV3KDkZHIz1rwCx8X6F4H+P3iuTxVqMenJLpVjChdWbc6xpkfKDSaH8QfC3hv48fELUNb1eK0s9SttMktJGjciVfsqNkYUkcMDzjrQB79c6lY2t3b2t1e20N1ckiCGSVVeUjrtUnLfhVuvkD4rX+s+MfHWveMfC9lc3um+EBAlreRTIkULxMJZXZGYM38Q+UHgDNfV/h3VrfXtA07VrI5tr63juI+eQrqDg+4zigDQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACg0UGgDzvVbK3e7F3clR5JJBY4VffmsAazoz69KTqNjmOJVJadB82SeMnngjpXF+Nr+517VbliX+wwyNHFHn5Tg4LH1rk5bAZ/1Y/KuuhlVStBTva4qudRpS9mle2h7CmsIdcYfbNP8A7PKZV1nTOcDg8560n9oaQt3NC+r26RDEiKLlVQA9RkH17V4wdPUnPlr+VMNiv/PNfyrX+xZ/zC/tyPSJ6vrniHT9OEb6NqGklnz5hM6s3tjmi58daF9myL8PdouQEicjdj1xg15QLMr91QPoKVLJieR+laRyR/akTLPLrSKNPWtak1acpBv8tjlnYYLe1dN4Rf8Asa3kuiv77bhD/dJ71z+lWao4LAfjWtqVyPIEacDFeph8HDD0/ZQ+Z4uNzCpiqntJdNivo8g1LxfA07qIY3MrlyAMD6++K7rX9TsbW9UW9oxVlBWWCTbu9cAcE15DdQ+Y54zmqqLNA26CWWMjnKMRXBmGX1MRU54tHqZZj6eFhyuNz3G9jk/s9GjuroCRlBDkA7T17ZqfV7xtH0+L7NCpQfIC3Cr9a8ROr6wURG1O8ZEYMqtISMjpW1aeO/EEOBNLBcqO0kQH8q8uWV4iOyPVjmtB25j1ua/ItYTHEWuZlykTDBB9/QCqbCy01YxqFy6TzsWOHYBm7nA4H1rzm3+IupR3b3E+nWsrldoAkZQo9uDVi4+IFrfENqOgFnAwHjuOQM5x0BrGWCrreLNo4/DvRSPQtTtxbtbT2AVbguFwf+WgPUE1ZlvHihLzWsoKgk9CM/XNcJbfEWwlu1mu7O8jSP5Y0TawHueRzU3h3xtYTreQ6teSRxuf3ZmQkkHrjGcD61jKlOO6No4ilJfEmdQ8NuDHcam2Z5yFjIB+X0Ax0qVo3fUUt5pWlhVN+0+ueM+v41labreh6raWUsupWwkhyyq0wQ/kcelXBfW8kx1JbmAQAeWh35Dj8M1FrGympbMtW15BqcU7CNkNsxUHOCOM5BqCeeCKwP2mTddXERALDJPHt0p4aNQlvFAsMU5zvTGxu5GR3NUvFsVvFZi7eXYYRtC5GDSd7FR5eZJ6I5/4auU8QaoCcqYJh68YNbfhCVf7Ku5nknURTNkKxIx1+70rnfAGFOq3LkfNbv19WH/163/Am6XTL0ARvGZirI2Rngd//rV72Np8uFS7cv5HzGBqKeNb7835m7YmO63XtpNJI/3MS9vb2qSTUVZWeKLIQfNJL8ir+J6/hUNhMiKbexjgyuePtAJ+pxk1FA8aaX9kvWZp8FWUL8xPt/jXgn0tlczfGsFzqHhu43NB5a4ddgJyR05zS+DdUN74OjmJzPYP5bD/AGD0/rVy5QPphtJZUso5U2r5jAufz4FcJ4Sv/wCwddutPu9xhnBjYE9j0Pvg/wAq9LLmpuVJ9dfu3/A8nNoOEY149Hb/AC/E9HRLi4jWRrvYG+YeUoAx265NGm7bWMQS5WZmJLHo59c1yYv/ALBK2l6jKUtHf91cdk9M+38q6NbqxsdLCXF7A6quQzyLye2Oa5cThpYefK9ujO3C4uGJpcyevVdiS0t/7MnvrmeRRFM+5VUdOT+Z5qJIp7VZ5zEjTOcwgjIXJ+77fpTPt+l+WZft1pLOqkqHuVYBsdhnirGg3p1DT83MkEjNnKowPHvzXPY6XNPW56bomf7Lt89dtXqz9BAXSbZVyQFxyc1oV1LY8SfxMKKKKZIVBe3UFjZz3d5KkNtAhkkkc4VFAySfwqesjxdoqeI/DOp6RJK0K3kDReYBnYSODjvzjiqik5JS2E720M7QfHGj60sskBvLa3SH7Qtxe2r28UkWQN6u4AI5H51Zv/Evh2zFheXOo2W28nFpbXCESBnIJ27lzgdck4A7nmuVn0Dxze+EJtFu7nw7E0dvFDBJEsj+aUdeX3oQmVU9A2CQR0rn7f4V6tFpOxo9FluY9dTVo7eaaSSJohHseJnMe7JOCTtIOB+HaqFBttytr3uc7qVFsj14ajYm/FkLy2+2ld4t/NXzCvrtznFZWt+LtG0i0muJryOfyZo4JY7Z1keNncINy545I61wS/DDUV8WXF+01pJbTai2oJcLcSRT25YYKqoQhsA4GWAxjIqP/hWurv4Sh0CS18NLHb+Si3cYcS3KrOjt5g2cZVTkZbLdwKUaFC6vO+3/AARupUs/dPUhrGmGxe8Go2Rs0bY0/nr5at6Fs4BqrP4j0+HW9O0wuzTX8ElzDImDGUTGSWz/ALQxXAXfw0vYdZvL7S00gWw1VNQttOl3LA6iDy2DhUIVsksCAwqTSvhzq+nRaMsN/YiSzsNQgZihZI5bhtyBEIw0anjBIyB05wF7Gha/P/Vv87D56n8v9XPRbbWdLuoJZrXUrKaGIhZJI51ZUJ6AkHjNLBq+m3EkUdvqFnK8xZY1SdWLlfvAAHnHfHSvG4/hP4gk0vW4LmbSVm1C1tITtuJHVninWR2bMYwCoOABgdPetyP4YS22ti+sodJt9niKLU4zGpRltViKmIYTgljnb933pyw9BX/ef1Zf18hKpUf2Tv7XxDp0tj9quJ0so9zri6kRD8rbSfvYxn37irdxqmn2y27XN9axLcY8kyTKolz025PPUdK8y0r4YXSXWlHV10q8trRdR3xuDIC1xJujIDJjgdT27ZrJuPhHq72GkxyzademHSl024gluJI0Xa7NujcRsSPmHG1enWj2GHb+P+tf6+Ye0qW+E9kOp2C6gLBr21F8RkW5lXzMeu3Oat15Xonw91fT/HcWrrPYQ2PntPOqyNO0x2bQQsiZRvVhJ68c4r1SuetCEGuSV9DWEpSvzKwUUUViWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMAwIPQjFLRQB5zfeC7aMtDAhEeSRzk8n1NZbeBY2PINeryKuNxUHFQiaDHRRXbTxtWEeVHFUwdOUryPLz8PoGHG7OPWoj8Oo8n5jivVftEHqKQ3MHqKv+0K5P1KieSv8PAOmfzqJvh+VbjJr143Nt14/Kmi6tSOo/KrWYVyfqNE8gbwRLGM/N+AzWfc+Dbk5wxx7ivcg9s3TbSf6K393mqWZVVuiXl9N7M+fJfBl2uSFBFU5fCN4p5hNfRpt7R+y80xtOtnPAWtFmr6oh5cukj5pn8M3MX3oGA+lUZNElXgxNX0/Jo8DDoCKqT+HLaTrGh+orSOax6xJeAqLaR8xvpT9kIqJtLcdVNfSFz4LtJeREo+grNn8CQEHAxW0cxoszeFrxPn42LBNuwdc5xzTPsTbMbQMdT3Ne5z+AuDsxVCTwHMMgIpx71osVQl1IcMQuh4u1o2TjjPHAqtLZsV2sGK+ma9in8D3Ck/uc/Q1nT+Dp1zmE/lRbDT6IftcRDueVm2fbt3PjjgMatW1hI5wu/B6gsa7p/CVwP8AlkcfSrFt4dniH+qP5VSo4dapIUsVXatqZ2nk6do00Y+/IuD9K5uPVtW08Sx2F7LBG5yyrjBPrgiu6l0O6lXBVsCqTeErhmz5Z5qpxpVY8s9jOjVqUpc0b3OOstc1uzk8y3v2R/7xhjP814q1ceK/Ek6KsmqNkHIYQRAg+uQtdMfCM4H+rqF/CdwD/q/0rm+oYR9EdjzLEbts5i78Ra5d7BdahLIF6fu0H8lqE3d3fahHcXszSSr/ABEAfyArqT4UuD/yzP5UqeFbreMR1VPBYenJTjuiKmYVqkHB3sXroR6lpOJgCwHBFef6hbvDKVVjgHjmvUrbw/dpbbfLbAFY1/4Pv5ZcrD1PrXRenLRtHNTlUg72PPxLKB1PFWbG+u7S4Se2leOZDlWFdlD4Av5eqYX1xWpa/DudeXXLVjOOHatKx1qtU3imezeAL5tS8J2F26hWlXcQOnWuhrF8G2B0zw1YWjDDRxjI9K2q+bmlGTS2PXi3JJsKKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUGgCpqV7FYWj3E7AKvQZ6n0rx6D4kre+J7mwSFfLJPlSK33iOox/I1a+LfiR2Y2lm5AjBGR2Pc/XtXg93LJa3UdzA+2RG3KR2I6V6uGwtqftJHnVa/tJ8iZ7/AC+LWTp1+tVJPGEw6Y/OuK1u4UC0u4D+4vIVmXHbI5/xrGe9b+9Xp08PSlFSSPMnWqqXLc9IPjGYc56e9MXxlP6j1615s142OtN+2H1rX6tS7E+1rdz1SDxrKq8qDz13Vfh8bpxuQ/nXjy3h/vGpBfOO/FQ8HSfQpYisup7TD4ytm+8dpq1H4rtmIHmAfjXiK3xwPmNSrqDf3qzeX03sV9cqrc96g8SWz4InXn/aq7HrsR6SjP1r5/XUn/vVZi1eVMbZCCKyllkXszSOYyW6Pfo9bj/vKatJqkbAdOfevA08R3S8ic/pV2DxbeJ1lJ/KsJZW+htHMl1PdFvImHIFP82A+leKR+M7nuR+VXrbxrLkeYePasZZbUWxqsxg9z14LA44Zaa1rC4PK15tD4zj4zkY9xV2PxlAepI981k8FWjsarGUnududNiPQKB9KYdLjzxt/KuWTxfBn5ZQKtL4ut8DMtS8PXRXt6LN7+yo/Rfyo/stOOF/KsY+LbXbkTZNQt4uiyfnGO2KSo130H7Wibp0mPP3V/Kk/saLuq/lWH/wl8AGTJ+FRP40t1PMv6U1Rrk+1oHQ/wBjQ/3E/KpE0mFf4VH0Fcsvje2Gf3gP4VFJ46gHAckfSn9WxDF7egjsxp8IGOKcLK3A6CuGk8cwKDhiT+FUbjx2uMRlj+VNYOuweLoo9H8m1UdFpUFu8m1EBP8AKvHtU8fSW9s8rscDoBjk+ldz8NNcj1nRlkfb9pYbmZTww/pjpiprYWdGPNIqliI1XaKOyAwOKWiiuI7AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9eu/sWkXM2cFUIH1NaFYPjeN5PD8+wE4ILAemcf1q4JOSTIqNqDaPDdb23bztKeFODn+HPP8AKvNvECosxEa4AOce1dJeztp11dWVwGCrIWUnguOx/Kuemin1jUFgtI8yzHaq9gPX6V9K7KkeLRi1Uv0OguWZPCWhFydxRxgn+HPH6VjNMSa2PF88UU9tp1qQYbGFYSc5ywHP5dPwrnGb0NVQ0potwvJss+acdaQy1VLUbq1uP2aLfm8UomPrVPfS7/ejmF7NF4THA5p6zn1rPElKJDT5iXSRpC5pwufQ1mhvWjfzT5ifYo1Rd9ATThd+/FZPmYpfN/OjmJ9gjYF3708XhB61ied70omxT5ifq6N9L0jvTxfHs1c8Jz608T470+Yl4Y6FdRYD7x/OnrqTd2/WucE/vSi4I70XQvq7Ok/tNsH5qU6o3Tca5vz6PPNF0L2DOhbUmI+9+FRNqJ/vH86wjOaaZjRdFfVzcbUWHQ/rTDqBIxuNYhmPrSeYcdeKXMUsOjaa/ZujUsd1JJIix5LMcAViiQ/St7wmqvPfTsAWgtnZM9mIxn8iamdTli2NUEYuqytcXzIHJjj+XI6E969A+EGrNYaosG8Kkh3KPcdR+VeZpL87MepY5rsfBrFNRtSqncJARj071hOCqQaZpOXsrWPqhGDIGHIIzS1V0ti+n27N1KDP5Var5dqzse4ndXCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKbLGssbJIoZGGCD3FOooA888R/Dq01GUuI4pk5wknylfow5rmv8AhV2o24caPDp9lIw2m4ad5Hx6AFePzr2iiuhYqola5h9Wp9jwmL4H3svNxrUCMeSRAX/9mFSr8CHz83iGMj0FiR/7Ur3GireOrv7X5DVCmuh4qnwKhH39dc/S2A/9mqX/AIUXZ4/5DU+f+uI/xr2Wil9dr/zD9jDseKP8C4z9zXGA/wBq3z/7NUB+BEmTjxBGB/15H/45XuVFNY6uvtfkHsIdjwiX4GXag+VrUEh/2rcr/wCzGs+f4Ja8o/cXmnv/ALzsv/spr6Hoqlj666/gL6vDsfM9x8IPFUOcRWc3/XKcn+aisq6+G/iu2JLaNOy/3kdG/kc19W0VazKqt7EvDQ6Hx5deGNctv9dpGoL7i3c/yFZ9zYXdqubi3miH/TRCv86+06MetarNJdYk/VV0Z8RDnoc0Ybvmvs+60fTbvP2qwtJs9fMhVs/mKyrjwP4XuP8AWaBpgPqluqn8wK0WaR6xJeGfRnyLzjmjJ96+qpvhj4Rlzu0hV/3JpF/k1UZ/hD4SkzstLiI+q3Uh/mTVrM6fVMX1aR8xhj9KVWNe5+MvhZo+maYkumrdvO8gjVC+4sT0AHH/ANYAmuJ8S+AY9IcxpfXEkyQmSZVspJFhYjKozICAx4AB9QfTNrMaL7kvDzOEDH8KNxBxmvU4/hRDc3QtrTXYTJFF5l0WiyLbjIViG69eO2M96pP8LLoWxvf7TjTSVQu15Lb7AB67C+7Hbpn2rRY+h/MT7CfY85DUE8V6JpXwrv8AVLKW7tb+F7dPusEV9/sAjsQfY4NR6X8LtS1NXezuFeJJGiLmIqNynBHJ55GPSn9eofzC9hPseelqQMa7tvhrq/n3sSK5NkAZ3IiCJkZ+8ZR0HJroNJ+C19fWUFy+rRQLKoYI9uSwHuN1L69Q/mK9jPseThq1fDupHTNSWVl3wOpimQ/xI3X+h/CvV4vgYwx5uuKf922x/wCzVp2fwS0xDm71S9k9ogij9QaiWPoNWbF9XqdjxnWPDN1a3XnafHLeabL88UsKl/wOBnIr1D4a+DbhnhubuFoyQG2t1Ue/+Feh+HvAGj6G2bVr1xndse5fZnGMlQQpP1FdXHGka7Y1Cj0ArhqY98rhA0WE5mnPoLGgRFVRgAYp1FFeadoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAENzaxXLwPMu5oJPNjOejbSufyY0x7C0eN0e2hZHk81lKDDPnO4++R1qzRQBjP4X0Rp7icaXZpc3G/zJ0iCyMXzuO4c5OTz71Bc+E9PubJraZ7uQEj95JcO7gAg4DMSQMgHA9BXQUUAUNM0yLTrJraGW4dDn5pZWdhkY4J6VNBaJa6etrZbYEjj8uLC5CcYHHerNFAGZHotsNJOnyl5YmIaRmY7pG3biWPfJ6+tF7o0N3P5jXN/F8oXZBdSRqAPZSBWnRQBjL4dt1OftmrH66hMf/Zqv2lhb2jM0SkyMAGkdizsB0yx5NWqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing of the left adrenal gland showing the microstructure of the gland on a transverse cut. Note the capsular circulation and the connections through the sinusoids to the medullary vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Uflacker, R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2696=[""].join("\n");
var outline_f2_40_2696=null;
var title_f2_40_2697="Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis";
var content_f2_40_2697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Adolf W Karchmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2697/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/40/2697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic valve endocarditis (PVE) is a serious infection with potentially fatal consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H19#H19\">",
"     \"Complications and outcome of infective endocarditis\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, microbiology, pathology, clinical features and diagnosis of PVE will be reviewed here. The antimicrobial and possible surgical treatment and prevention of PVE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prosthetic valve endocarditis (PVE) can arise early or late after surgery. The timing of the infection reflects different pathogenic mechanisms that, in turn, influence the epidemiology, microbiology, pathology, and clinical manifestations of the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microorganisms can reach the valve prosthesis by direct contamination intraoperatively or via hematogenous spread during the initial days and weeks after surgery. These pathogens have direct access to the prosthesis-annulus interface and to perivalvular tissue along suture pathways because the valve sewing ring, cardiac annulus, and anchoring sutures are not endothelialized early after valve implantation. These structures are coated with host proteins, such as fibronectin and fibrinogen, to which some organisms can adhere and initiate infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the sewing ring, sutures, and adjacent tissues become endothelialized over the months after valve replacement, sites for adherence of microorganisms and access to host tissues adjacent to the prosthesis are altered. The pathogenesis of late PVE has been postulated to resemble native valve endocarditis (NVE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17718?source=see_link\">",
"     \"Pathogenesis of vegetation formation in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelet-fibrin thrombi probably form on the prosthesis and serve as sites for the organisms to adhere and cause infection. Thus, the pathogens producing PVE later in the time course tend to be bacteremic isolates with the ability to adhere to these thrombi and are similar to organisms inducing NVE. Unless the infecting organism is Staphylococcus aureus or another highly virulent or invasive pathogen, the perivalvular tissues are less likely to be affected in late PVE since endothelialization limits access to these tissues. Later onset infections tend to be less invasive, are less often complicated by perivalvular abscess formation and valve dehiscence, and are more commonly restricted to the sewing ring or the bioprosthetic leaflet.",
"   </p>",
"   <p>",
"    However, the leaflets of porcine bioprosthetic valves experience age-related alterations in their surface characteristics. These aging leaflets become sites for platelet-fibrin thrombus deposition and subsequent infection. As a result, the infection rates on bioprostheses increase during this later period when compared to mechanical valves [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing prosthetic valve endocarditis (PVE), typically expressed as a hazard function or the likelihood of infection at a given point in time, is not uniform after valve replacement. The risk is greatest during the initial three months after surgery, remains high through the sixth month, and then falls gradually with an annual rate of approximately 0.4 percent from 12 months postoperatively onward for the life of the valve recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/3,5-8\">",
"     3,5-8",
"    </a>",
"    ]. The percentage of patients developing PVE during the initial year after valve replacement ranges from 1 to 3 percent in studies with active follow-up; by five years, the cumulative percentage ranges from 3 to 6 percent (",
"    <a class=\"graphic graphic_table graphicRef80033 \" href=\"UTD.htm?9/44/9932\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although conclusions vary among studies, infection generally occurs with equal frequency at aortic and mitral sites and on mechanical and bioprosthetic devices during the first postoperative year [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/3-6,9,10\">",
"     3-6,9,10",
"    </a>",
"    ]. As noted above, bioprosthetic valves carry a greater risk for infection than mechanical valves after the first 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. When a valve is replaced in a patient with endocarditis, whether the infection was active or healed at the time of surgery, there is an increased risk for both early (some of which is recrudescence of active endocarditis) and late PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/2,4,6,8\">",
"     2,4,6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Healthcare-associated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of prosthetic valve endocarditis result from infection acquired in healthcare settings, both inpatient (nosocomial) and outpatient (non-nosocomial). The relative frequency of healthcare-associated PVE was evaluated in a prospective, observational cohort multinational study of 556 patients with PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/1\">",
"     1",
"    </a>",
"    ]. Non-nosocomial healthcare-associated infection was defined as PVE diagnosed within 48 hours of admission in an outpatient with extensive healthcare contact, as defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous therapy, wound care, or specialized nursing care at home, or intravenous chemotherapy within the prior 30 days",
"     </li>",
"     <li>",
"      Residence in a nursing home or other long-term care facility",
"     </li>",
"     <li>",
"      Hospitalization in an acute care hospital for two or more days within the prior 90 days",
"     </li>",
"     <li>",
"      Attendance at a hospital or hemodialysis clinic within the prior 30 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Healthcare-associated infection was present in 37 percent of cases: 70 percent were labeled as nosocomial and 30 percent as outpatient acquired. Approximately 70 percent of the healthcare-associated infections were diagnosed within the first year after valve implantation, with the majority occurring within the first sixty days. Staphylococcus aureus was the most common organism, being identified as the pathogen in 34 percent of cases.",
"   </p>",
"   <p>",
"    Nosocomial bacteremia occurring in patients with prosthetic valves carries a significant risk for seeding the prosthesis. Among 115 prosthetic valve recipients experiencing nosocomial bacteremia that was judged not to be the sentinel event of endocarditis, 18 (16 percent) developed PVE with the bacteremic organism between seven and 170 days thereafter (median interval 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/11\">",
"     11",
"    </a>",
"    ]. Similarly, among 37 prosthetic valve patients with postoperative candidemia without evidence of endocarditis, fungal endocarditis developed in four (11 percent) between 26 and 690 days later [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/12\">",
"     12",
"    </a>",
"    ]. The patients who developed candida PVE had persistent fungemia (8.1 mean days fungemia) without evidence of endocarditis during the month after cardiac surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microbiology of prosthetic valve endocarditis (PVE) is relatively predictable depending on the time since implantation (",
"    <a class=\"graphic graphic_table graphicRef87589 \" href=\"UTD.htm?14/19/14653\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/1,13-17\">",
"     1,13-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most frequently encountered pathogens in early PVE (within two months of implantation) were Staphylococcus aureus and coagulase-negative staphylococci; next in frequency were gram-negative bacilli and fungal infection.",
"     </li>",
"     <li>",
"      The most frequently encountered pathogens in late PVE (two months after valve implantation) were streptococci and S. aureus, followed by coagulase negative staphylococci and enterococci. Culture-negative cases occur in all time intervals after valve surgery; they are due largely to the confounding effect of recent or concurrent antibiotic therapy. Coxiella burnetii, although an unusual cause of endocarditis, has a unique predisposition to cause PVE. Thus, in areas where this pathogen is endemic, it must be considered a potential cause of late onset culture-negative PVE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases occurring during the initial two months after surgery are often nosocomial in origin, which accounts for the spectrum of causative organisms. In contrast, those cases presenting more than 12 months after valve surgery are usually caused by the same pathogens that produce native valve endocarditis (NVE) in patients who are not injection drug users, since late PVE, like NVE, usually results from transient bacteremia occurring among ambulatory patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\", section on 'Microbiology'",
"    </a>",
"    ). Cases that present after 2 months and before 12 months post-surgery are a blend of delayed onset nosocomial and community-acquired infections; this is reflected in the spectrum of organisms encountered in these cases.",
"   </p>",
"   <p>",
"    The coagulase-negative staphylococci causing PVE during the initial year after surgery are almost exclusively S. epidermidis. Between 84 and 87 percent of these organisms are methicillin-resistant and thus resistant to all of the beta-lactam antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/3,18\">",
"     3,18",
"    </a>",
"    ], with the likely exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link&amp;anchor=H17417663#H17417663\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Ceftaroline'",
"    </a>",
"    ). By contrast, almost half of the coagulase-negative staphylococci causing PVE one year or more after surgery are non-epidermidis species, and only 22 to 30 percent are methicillin-resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms leading to methicillin-resistance are the same among coagulase-negative staphylococci as for methicillin-resistant S. aureus (MRSA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=see_link\">",
"     \"Treatment of infections due to coagulase-negative staphylococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Methicillin-resistant coagulase-negative staphylococci, while uniformly possessing the resistant genotype, do not always express the phenotype, a phenomenon called heteroresistance. This makes detection of methicillin-resistance among coagulase-negative staphylococci more difficult. As a result, before embarking upon therapy with a beta-lactam antibiotic, the microbiology laboratory must be asked to thoroughly exclude possible methicillin-resistance. If this cannot be done, methicillin resistance should be assumed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10046302#H10046302\">",
"     \"Overview of antibacterial susceptibility testing\", section on 'Heteroresistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sporadic cases of PVE due to a variety of other bacterial organisms, fungi, and the rickettsia Coxiella burnetii have also been reported. One case of IE due to enterovirus has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intracardiac pathology of infection involving mechanical valves, particularly when prosthetic valve endocarditis (PVE) presents during the early months after surgery or when it is caused by invasive organisms, shapes the requirement for therapy. Perivalvular invasion, commonly with associated dehiscence of the prosthesis and a paravalvular regurgitant flow, occurs in approximately 40 percent of patients and frank extension into tissue causing myocardial abscess is seen in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In one series, invasion of perivalvular tissue was noted in more than 80 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, infection of an aortic valve prosthesis extends through the annulus to cause pericarditis or, more commonly, into the membranous portion of the interventricular septum where it disrupts the conduction system, resulting in various degrees of heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Large vegetations may prevent closure of the prosthesis producing incompetence or encroach upon the valve orifice causing functional stenosis.",
"   </p>",
"   <p>",
"    Bioprosthetic valve endocarditis also causes invasive infection. As an example, annular and myocardial invasion was noted in 38 of 85 patients (45 percent) in one study and was more frequent among bioprosthetic PVE occurring in the first year after valve replacement than cases presenting later (59 versus 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/26\">",
"     26",
"    </a>",
"    ]. In another series, invasive disease was more common in patients with early compared with later bioprosthetic PVE (79 versus 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histologic features that characterize PVE in bioprosthetic valves are not well defined. As bioprosthetic valves degenerate, they may form noninfective, calcific, vegetative-like lesions and inflammatory infiltrates thus potentially causing a noninfectious process to be misdiagnosed as PVE. A retrospective pathologic analysis of inflamed bioprosthetic valve tissue from 88 patients who underwent surgical removal of a bioprosthetic valve (21 for suspected endocarditis and 67 for noninfective dysfunction) was conducted to better define the histologic criteria for PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/28\">",
"     28",
"    </a>",
"    ]. Histologically, PVE was characterized by microorganisms, vegetations, and neutrophil-rich, inflammatory infiltrates. In contrast, inflammatory infiltrates in valve tissue samples from the noninfective control group consisted mainly of macrophages and lymphocytes. A neutrophil surface area with a cutoff value of &gt;1.5 percent of total valve tissue surface was highly specific for PVE (94 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prosthetic valve endocarditis (PVE) present with symptoms and signs similar to those encountered in native valve endocarditis (NVE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, when PVE develops prior to discharge from the hospital, findings related to surgery or to perioperative complications may predominate over the subtle features of endocarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Signs and symptoms of invasive infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high frequency of invasive infection results in higher rates of new or changing murmurs, heart failure, and new electrocardiographic conduction disturbances in patients with PVE than in those with NVE. The incidence of clinically overt arterial emboli is 40 percent; central nervous system complications, primarily embolic infarcts or hemorrhages, occur in 20 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/22,29-31\">",
"     22,29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valvular dysfunction, fever which persists for nine days or more despite appropriate antibiotic therapy, new electrocardiographic conduction disturbances, and echocardiographic evidence of abscess formation are clinical manifestations of invasive infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These findings were noted in 64 percent of 116 patients with PVE in one study and occurred significantly more frequently when infection involved an aortic valve prosthesis and when it arose within the first year after valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings in patients with prosthetic valve endocarditis (PVE) are similar to those noted in patients with native valve endocarditis (NVE) of comparable duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of prior antibiotic therapy, blood cultures will be positive in 90 percent or more of patients with PVE. Because bacteremia is continuous, cultures will be positive regardless of whether or not blood cultures are obtained in proximity to the fever. When blood cultures are drawn over a period of hours to days in a patient with a prosthetic valve and all or most are positive, PVE is highly probable. The duration of documented bacteremia is particularly important when the isolate is a common contaminant, such as coagulase-negative staphylococci or diphtheroids. A high rate of blood culture positivity, or molecular evidence that a sporadically isolated organism represents a single clone, helps to distinguish infecting pathogens from contaminants [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If antibiotics have not been administered prior to obtaining blood cultures, it is unusual to have persistently negative blood cultures in patients with clinically overt PVE. Nevertheless, culture-negative cases can occur when infection is caused by fastidious organisms such as Legionella species, Bartonella species, Coxiella burnetii, Mycoplasma hominis, fungi other than Candida species, and the HACEK organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detection of these and other unusual fastidious pathogens causing PVE relies upon the same evaluation used to assess culture-negative NVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of transesophageal echocardiography (TEE) has greatly improved the diagnosis and management of PVE and is considered the procedure of choice if only one type of echocardiogram is to be obtained. Although transthoracic (TTE) and transesophageal echocardiograms are complementary in the diagnosis of PVE, TEE has a sensitivity of 82 to 96 percent compared with 17 to 36 percent for TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. This increased sensitivity is achieved without regard to valve position and without loss of specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef80708 \" href=\"UTD.htm?14/26/14764\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One prospective study compared TTE and TEE in 114 episodes of infective endocarditis suspected on clinical grounds (34 PVE, 80 NVE) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/41\">",
"     41",
"    </a>",
"    ]. The results of the two tests were concordant in 55 percent of cases, but TEE led to a reclassification of the case in 34 percent of patients with prosthetic valves compared to 11 percent of patients with native valves. Twenty-two patients were reclassified as definite infective endocarditis based upon the TEE results; 10 of these patients had prosthetic valves. In two patients with PVE, the diagnosis would have been rejected if the evaluation had been limited to TTE data.",
"   </p>",
"   <p>",
"    Echocardiography, including both TTE and TEE, is essential for both the diagnosis and management of PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/42\">",
"     42",
"    </a>",
"    ]. A high resolution biplane or multiplane transducer that allows continuous-wave and pulse-wave Doppler and color-flow imaging should be employed. TTE provides superior images of the ventricular surfaces of prostheses in the mitral, tricuspid, and aortic positions, whereas the atrial surfaces of the mitral and tricuspid valves and the aortic surface and outflow track of prostheses in the aortic position are better viewed by TEE. TEE is unquestionably superior to TTE for visualizing a mitral valve prosthesis.",
"   </p>",
"   <p>",
"    TEE is also superior to TTE in the detection of abscesses, fistulae, and paraprosthetic leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study that correlated the results of both types of echocardiography with anatomic findings at surgery in 88 valves from patients with endocarditis, the sensitivity of TEE for the detection of valve perforation was significantly higher than that of TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/44\">",
"     44",
"    </a>",
"    ]. TEE detected perforation in 21 of 22 cases compared to only 10 of 22 by TTE.",
"   </p>",
"   <p>",
"    In patients with failing prosthetic valves, echocardiography may define the intracardiac pathology, which can provide evidence of a need for surgical therapy. However, TEE may miss some cases of prosthetic valve dehiscence. In a study that included 26 patients with prosthetic valve endocarditis, 14 (54 percent) had surgically identified valve dehiscence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/45\">",
"     45",
"    </a>",
"    ]. Dehiscence was missed on TEE in 4 cases which all involved an aortic prosthetic valve.",
"   </p>",
"   <p>",
"    The negative predictive value of a full echocardiographic evaluation of a patient with suspected PVE is 86 to 94 percent. Nevertheless, if PVE is strongly suspected in the face of a negative evaluation, repeat echocardiography one week later can provide evidence of PVE in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. In one study among patients with definite PVE, repeat TEE resulted in a shift in diagnostic category from possible to definite endocarditis in 34 of 80 patients with PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/47\">",
"     47",
"    </a>",
"    ]. There was no diagnostic benefit beyond the third TEE. Although echocardiography has replaced other modalities of cardiac imaging in the diagnosis of PVE, including cardiac catheterization (which is now reserved for defining coronary artery anatomy), multislice computed tomography may be comparable to TEE, and in some instances of PVE, may yield diagnostic evidence of infection where TEE has been non-diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying patients with PVE requires a high index of suspicion and an appreciation of the subtle symptoms and signs of endocarditis. Obtaining three or four blood cultures over time, without confounding their utility by antibiotic administration, and an echocardiogram are paramount in the evaluation.",
"   </p>",
"   <p>",
"    When sporadic blood cultures yield coagulase-negative staphylococci or when only several cultures have been obtained and are positive for these organisms, molecular techniques, such as DNA examination by pulsed-field gel electrophoresis, should be used to compare the isolates. Establishing clonality of isolates from separate cultures argues against contamination and favors that the isolates are true pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/34\">",
"     34",
"    </a>",
"    ]. However, there is a potential for polyclonal infections to arise, especially from direct contamination in the operating room.",
"   </p>",
"   <p>",
"    The Duke criteria for the diagnosis of endocarditis provide a systematic approach for diagnosing both NVE and PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/49\">",
"     49",
"    </a>",
"    ]. Among pathologically confirmed cases of PVE, 76 percent have been categorized as definite PVE and 24 percent as possible PVE when judged by the Duke criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The expanded use of TEE in the assessment of patients with possible PVE has enhanced the sensitivity of these criteria for the diagnosis of PVE [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2697/abstract/41\">",
"     41",
"    </a>",
"    ]. The standard for assessing possible PVE should include appropriately obtained blood cultures and echocardiographic imaging, with the results interpreted according to the Duke criteria. Using this approach, few cases of PVE should be missed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H192525761\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prosthetic valve endocarditis (PVE) is a serious infection with potentially fatal consequences. PVE can arise early or late after surgery. The timing of the infection reflects different pathogenic mechanisms that, in turn, influence the epidemiology, microbiology, pathology, and clinical manifestations of the infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microorganisms can reach the valve prosthesis by direct contamination intraoperatively or via hematogenous spread during the initial days and weeks after surgery. These pathogens have direct access to the prosthesis-annulus interface and to perivalvular tissue along suture pathways because the valve sewing ring, cardiac annulus, and anchoring sutures are not endothelialized early after valve implantation. These structures are coated with host proteins, such as fibronectin and fibrinogen, to which some organisms can adhere and initiate infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As the sewing ring, sutures, and adjacent tissues become endothelialized over the months after valve replacement, sites for adherence of microorganisms and access to host tissues adjacent to the prosthesis are altered. The pathogenesis of late PVE has been postulated to resemble native valve endocarditis (NVE). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Late infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of PVE is greatest during the initial three months after surgery, remains high through the sixth month, and then falls gradually with an annual rate of approximately 0.4 percent from 12 months postoperatively onward for the life of the valve recipient. The percentage of patients developing PVE during the initial year after valve replacement ranges from 1 to 3 percent in studies with active follow-up; by five years, the cumulative percentage ranges from 3 to 6 percent (",
"      <a class=\"graphic graphic_table graphicRef80033 \" href=\"UTD.htm?9/44/9932\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The microbiology of PVE is relatively predictable depending on the time since valve implantation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most frequently encountered pathogens in early PVE (within two months of valve implantation) are Staphylococcus aureus and coagulase-negative staphylococci; next in frequency are gram-negative bacilli and fungal infection.",
"     </li>",
"     <li>",
"      The most frequently encountered pathogens in late PVE (two months after valve implantation) are streptococci, S aureus coagulase-negative staphylococci, and enterococci. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood culture-negative PVE can occur in any period after valve implantation and largely results from the confounding effect of recent antibiotic therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high frequency of invasive infection associated with PVE results in higher rates of new or changing murmurs, heart failure, and new electrocardiographic conduction disturbances compared with NVE. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of prior antibiotic therapy, blood cultures will be positive in 90 percent or more of patients with PVE. When blood cultures are drawn over a period of hours to days in a patient with a prosthetic valve and all or most are positive, PVE is highly probable. The duration of documented bacteremia is particularly important when the isolate is a common contaminant, such as coagulase-negative staphylococci or diphtheroids. A high rate of blood culture positivity, or molecular evidence that a sporadically isolated organism represents a single clone, helps to distinguish infecting pathogens from contaminants. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Blood cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transesophageal echocardiography (TEE) has greatly improved the diagnosis and management of PVE and is considered the procedure of choice if only one type of echocardiogram is to be obtained. Although transthoracic echocardiogram (TTE) and TEE are complementary in the diagnosis of PVE, TEE has a sensitivity of 82 to 96 percent compared with 17 to 36 percent for TTE. TEE is also superior to TTE in the detection of abscesses, fistulae, and paraprosthetic leaks. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identifying patients with PVE requires a high index of suspicion and an appreciation of the subtle symptoms and signs of endocarditis. Obtaining three or four blood cultures over time, without confounding their utility by antibiotic administration, and an echocardiogram are paramount in the evaluation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Duke criteria for the diagnosis of endocarditis provide a systematic approach for diagnosing both NVE and PVE. The expanded use of TEE in the assessment of patients with possible PVE has enhanced the sensitivity of these criteria for the diagnosis of PVE. The standard for assessing possible PVE should include appropriately obtained blood cultures and echocardiographic imaging, with the results interpreted according to the Duke criteria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"       \"Infective endocarditis: Historical and Duke criteria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/1\">",
"      Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/2\">",
"      Arvay A, Lengyel M. Incidence and risk factors of prosthetic valve endocarditis. Eur J Cardiothorac Surg 1988; 2:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/3\">",
"      Calderwood SB, Swinski LA, Waternaux CM, et al. Risk factors for the development of prosthetic valve endocarditis. Circulation 1985; 72:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/4\">",
"      Grover FL, Cohen DJ, Oprian C, et al. Determinants of the occurrence of and survival from prosthetic valve endocarditis. Experience of the Veterans Affairs Cooperative Study on Valvular Heart Disease. J Thorac Cardiovasc Surg 1994; 108:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/5\">",
"      Rutledge R, Kim BJ, Applebaum RE. Actuarial analysis of the risk of prosthetic valve endocarditis in 1,598 patients with mechanical and bioprosthetic valves. Arch Surg 1985; 120:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/6\">",
"      Ivert TS, Dismukes WE, Cobbs CG, et al. Prosthetic valve endocarditis. Circulation 1984; 69:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/7\">",
"      Horstkotte D, Piper C, Niehues R, et al. Late prosthetic valve endocarditis. Eur Heart J 1995; 16 Suppl B:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/8\">",
"      Agnihotri AK, McGiffin DC, Galbraith AJ, O'Brien MF. The prevalence of infective endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg 1995; 110:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/9\">",
"      Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/10\">",
"      Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC. Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. N Engl J Med 1991; 324:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/11\">",
"      Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study. Ann Intern Med 1993; 119:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/12\">",
"      Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/13\">",
"      Chu VH, Miro JM, Hoen B, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis--a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. Heart 2009; 95:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/14\">",
"      Rivas P, Alonso J, Moya J, et al. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005; 128:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/15\">",
"      Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Am 2002; 16:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/16\">",
"      Hill EE, Herregods MC, Vanderschueren S, et al. Management of prosthetic valve infective endocarditis. Am J Cardiol 2008; 101:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/17\">",
"      Lee JH, Burner KD, Fealey ME, et al. Prosthetic valve endocarditis: clinicopathological correlates in 122 surgical specimens from 116 patients (1985-2004). Cardiovasc Pathol 2011; 20:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/18\">",
"      Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/19\">",
"      Blumental S, Reynders M, Willems A, et al. Enteroviral infection of a cardiac prosthetic device. Clin Infect Dis 2011; 52:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/20\">",
"      Richardson JV, Karp RB, Kirklin JW, Dismukes WE. Treatment of infective endocarditis: a 10-year comparative analysis. Circulation 1978; 58:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/21\">",
"      Dismukes WE, Karchmer AW, Buckley MJ, et al. Prosthetic valve endocarditis. Analysis of 38 cases. Circulation 1973; 48:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/22\">",
"      Ben Ismail M, Hannachi N, Abid F, et al. Prosthetic valve endocarditis. A survey. Br Heart J 1987; 58:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/23\">",
"      Anderson DJ, Bulkley BH, Hutchins GM. A clinicopathologic study of prosthetic valve endocarditis in 22 patients: morphologic basis for diagnosis and therapy. Am Heart J 1977; 94:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/24\">",
"      Rose AG. Prosthetic valve endocarditis. A clinicopathological study of 31 cases. S Afr Med J 1986; 69:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/25\">",
"      Arnett EN, Roberts WC. Prosthetic valve endocarditis: clinicopathologic analysis of 22 necropsy patients with comparison observations in 74 necropsy patients with active infective endocarditis involving natural left-sided cardiac valves. Am J Cardiol 1976; 38:281.",
"     </a>",
"    </li>",
"    <li>",
"     Karchmer AW. Infections of Prosthetic Heart Valves. In: Infections Associated with Indwelling Medical Devices, 3rd ed, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology, Washington, DC 2000. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/27\">",
"      Lytle BW, Priest BP, Taylor PC, et al. Surgical treatment of prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1996; 111:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/28\">",
"      Lepidi H, Casalta JP, Fournier PE, et al. Quantitative histological examination of bioprosthetic heart valves. Clin Infect Dis 2006; 42:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/29\">",
"      Masur H, Johnson WD Jr. Prosthetic valve endocarditis. J Thorac Cardiovasc Surg 1980; 80:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/30\">",
"      Tornos P, Sanz E, Permanyer-Miralda G, et al. Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992; 101:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/31\">",
"      Keyser DL, Biller J, Coffman TT, Adams HP Jr. Neurologic complications of late prosthetic valve endocarditis. Stroke 1990; 21:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/32\">",
"      Karchmer AW, Dismukes WE, Buckley MJ, Austen WG. Late prosthetic valve endocarditis: clinical features influencing therapy. Am J Med 1978; 64:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/33\">",
"      Calderwood SB, Swinski LA, Karchmer AW, et al. Prosthetic valve endocarditis. Analysis of factors affecting outcome of therapy. J Thorac Cardiovasc Surg 1986; 92:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/34\">",
"      Breen JD, Karchner AW. Usefulness of pulsed-field gel electrophoresis in confirming endocarditis due to Staphylococcus lugdunensis. Clin Infect Dis 1994; 19:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/35\">",
"      Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/36\">",
"      Vered Z, Mossinson D, Peleg E, et al. Echocardiographic assessment of prosthetic valve endocarditis. Eur Heart J 1995; 16 Suppl B:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/37\">",
"      Daniel WG, M&uuml;gge A, Grote J, et al. Comparison of transthoracic and transesophageal echocardiography for detection of abnormalities of prosthetic and bioprosthetic valves in the mitral and aortic positions. Am J Cardiol 1993; 71:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/38\">",
"      Morguet AJ, Werner GS, Andreas S, Kreuzer H. Diagnostic value of transesophageal compared with transthoracic echocardiography in suspected prosthetic valve endocarditis. Herz 1995; 20:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/39\">",
"      Khandheria BK. Transesophageal echocardiography in the evaluation of prosthetic valves. Am J Card Imaging 1995; 9:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/40\">",
"      Stewart WJ, Shan K. The diagnosis of prosthetic valve endocarditis by echocardiography. Semin Thorac Cardiovasc Surg 1995; 7:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/41\">",
"      Roe MT, Abramson MA, Li J, et al. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. Am Heart J 2000; 139:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/42\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/43\">",
"      Daniel WG, M&uuml;gge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/44\">",
"      De Castro S, Cartoni D, d'Amati G, et al. Diagnostic accuracy of transthoracic and multiplane transesophageal echocardiography for valvular perforation in acute infective endocarditis: correlation with anatomic findings. Clin Infect Dis 2000; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/45\">",
"      Hill EE, Herijgers P, Claus P, et al. Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J 2007; 154:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/46\">",
"      Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/47\">",
"      Vieira ML, Grinberg M, Pomerantzeff PM, et al. Repeated echocardiographic examinations of patients with suspected infective endocarditis. Heart 2004; 90:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/48\">",
"      Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol 2009; 53:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/49\">",
"      Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994; 96:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/50\">",
"      John MD, Hibberd PL, Karchmer AW, et al. Staphylococcus aureus prosthetic valve endocarditis: optimal management and risk factors for death. Clin Infect Dis 1998; 26:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2697/abstract/51\">",
"      Nettles RE, McCarty DE, Corey GR, et al. An evaluation of the Duke criteria in 25 pathologically confirmed cases of prosthetic valve endocarditis. Clin Infect Dis 1997; 25:1401.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2138 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2697=[""].join("\n");
var outline_f2_40_2697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H192525761\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Healthcare-associated infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Signs and symptoms of invasive infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H192525761\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/44/9932\" title=\"table 1\">",
"      Cumulative incidence of PVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/19/14653\" title=\"table 2\">",
"      Microbiology of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/26/14764\" title=\"table 3\">",
"      Dx of PVE by echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17718?source=related_link\">",
"      Pathogenesis of vegetation formation in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23815?source=related_link\">",
"      Treatment of infections due to coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_40_2698="Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole";
var content_f2_40_2698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2698/contributors\">",
"     Roland Solensky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2698/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/40/2698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/40/2698/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/40/2698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3200659\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review hypersensitivity (allergic) reactions to macrolides, aminoglycosides, the tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . Hypersensitivity reactions to other antibiotic classes, namely beta-lactams, sulfonamides, fluoroquinolones, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=see_link\">",
"     \"Hypersensitivity reactions to fluoroquinolones antimicrobials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=see_link\">",
"     \"Vancomycin hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3200666\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antimicrobial groups discussed in this review cause hypersensitivity reactions relatively infrequently compared to penicillins, cephalosporins, sulfonamides, and fluoroquinolones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608706\">",
"    <span class=\"h2\">",
"     Types of hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions, or allergic reactions, are immunologic reactions to a drug. There are many types of hypersensitivity reactions, which are broadly divided into immediate and delayed reactions, based upon the time between the first administered dose and the appearance of signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reactions are defined as reactions that begin within one hour of the first administered dose. In reality, symptoms and signs may appear up to one or two hours later if the drug was taken orally or with food or other medications that slow absorption. The most common signs and symptoms of immediate reactions are urticaria (",
"      <a class=\"graphic graphic_picture graphicRef75230 \" href=\"UTD.htm?27/16/27905\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"       picture 2",
"      </a>",
"      ), pruritus, flushing, angioedema of the face, extremities, or laryngeal tissues (leading to throat tightness with stridor, or rarely asphyxiation), wheezing, nausea, abdominal cramping or diarrhea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension or shock. Immediate reactions can be caused by the formation of immunoglobulin E (IgE) to the causative drug, which can then activate mast cells and basophils in the presence of the drug. Some drugs can cause immediate reactions by directly or indirectly activating mast cells and basophils, without the presence of drug-specific IgE. Immediate-type skin testing is used to evaluate immediate reactions. (See",
"      <a class=\"local\" href=\"#H8608938\">",
"       'Allergy evaluation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Delayed reactions begin later than one hour (and sometimes days) after the first dose. Many different reaction types are classified as delayed. The most common are maculopapular or morbilliform exanthems (",
"      <a class=\"graphic graphic_picture graphicRef54205 \" href=\"UTD.htm?37/6/37985\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef70062 \" href=\"UTD.htm?31/30/32239\">",
"       picture 4",
"      </a>",
"      ). There is a lack of consensus about how best to evaluate patients with past maculopapular exanthems. Some allergy experts perform intradermal skin testing that is interpreted 24 to 72 hours after placement, with erythema and induration representing a positive reaction. Others only perform graded challenges to diagnose such reactions, which is the most common approach in the United States.",
"      <br/>",
"      <br/>",
"      There are several types of delayed hypersensitivity reactions that are uncommon but potentially life-threatening, for which no testing is informative. Furthermore, testing can be dangerous, because re-exposure can cause a recurrence of the reaction. Such reactions include Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-induced hypersensitivity",
"      <span class=\"nowrap\">",
"       syndromes/drug",
"      </span>",
"      rash with eosinophilia and systemic symptoms",
"      <span class=\"nowrap\">",
"       (DiHS/DRESS).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intent of discriminating between immediate and delayed drug reactions is to distinguish immediate reactions from other types, since immediate reactions can escalate to potentially life-threatening anaphylaxis if the patient is re-exposed to the causative drug, even in very small amounts.",
"   </p>",
"   <p>",
"    The classification and pathogenesis of drug hypersensitivity reactions are reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608945\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a patient with a past drug reaction always begins with a careful clinical history and an assessment of the type of hypersensitivity reaction the patient most likely experienced. Important questions for the patient with drug allergy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H18#H18\">",
"     \"An approach to the patient with drug allergy\", section on 'Clinical history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough history of the reaction is essential, and usually constitutes the most useful element of the evaluation. Many patients labeled as allergic to a drug actually experienced nonallergic adverse reactions. Common examples include gastrointestinal side effects with macrolides and tetracyclines or photosensitivity with tetracyclines. In some cases, such patients should continue to avoid the causative drug, but they are not candidates for further allergy evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608741\">",
"    <span class=\"h2\">",
"     Referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to an allergy expert with experience in drug-allergic reactions is appropriate in any of the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has reactions to numerous antibiotics and treatment options are becoming limited.",
"     </li>",
"     <li>",
"      The patient experienced a life-threatening reaction to a drug and requires advice about how best to prevent re-exposure and whether related antibiotics can be safely administered.",
"     </li>",
"     <li>",
"      The patient experienced a serious reaction in the context of receiving multiple drugs (eg, perioperative anaphylaxis) and the cause of the reaction is not clear.",
"     </li>",
"     <li>",
"      The patient has a high likelihood of needing future treatment with a certain drug due to the nature of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      underlying medical problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8608938\">",
"    <span class=\"h2\">",
"     Allergy evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history is the most important component of a drug allergy evaluation. Other tools that are widely used include immediate-type skin testing and graded challenge. These procedures should be performed by allergy specialists because they require experience to interpret correctly, and although they are considered safe interventions, there is a risk of inducing another allergic reaction. Skin testing and challenges should be performed in a setting prepared to treat possible severe reactions, including anaphylaxis. In addition, any procedure that involves the deliberate exposure of a patient to a substance to which they may be allergic should be undertaken by someone with specific training in these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609129\">",
"    <span class=\"h3\">",
"     Immediate-type skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing (prick-puncture and intradermal) is helpful in the evaluation of immediate reactions to some drugs. Briefly, prick-puncture skin testing should be performed first, along with positive and negative controls. If prick-puncture tests are negative, they are followed by intradermal skin testing. Skin test results are recorded 15 minutes after placement in the skin. Skin testing techniques and patient preparation are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of skin testing for allergic disease\", section on 'Prick/puncture method'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of skin testing for allergic disease\", section on 'Intradermal method'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike skin testing for penicillin allergy, skin testing for allergy to the drugs discussed in this review is not standardized or validated, and allergy experts may have different approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609147\">",
"    <span class=\"h3\">",
"     Graded challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graded challenge procedures may be required in the evaluation of antibiotic hypersensitivity. Challenges are mentioned briefly here. Indications, contraindications, and protocols are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H30#H30\">",
"     \"An approach to the patient with drug allergy\", section on 'Graded challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Graded challenge is used to exclude allergy to the medication in question, and is",
"    <strong>",
"     most appropriate for a patient who is unlikely to be allergic",
"    </strong>",
"    to that drug.",
"   </p>",
"   <p>",
"    Graded challenge",
"    <strong>",
"     does not modify the allergic response",
"    </strong>",
"    to the drug or prevent recurrent reactions. Therefore:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who tolerate a drug upon graded challenge prove that they are not allergic to it.",
"     </li>",
"     <li>",
"      A challenge procedure in a patient with a possible IgE-mediated drug allergy could potentially induce anaphylaxis and should be performed by an allergy expert in a setting prepared to identify and manage possible reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Challenges with the drug in question should NOT be performed in patients whose past reactions involved exfoliation, blistering, or sloughing or the mucous membranes or skin, (eg, erythema multiforme,",
"    <span class=\"nowrap\">",
"     SJS/TEN)",
"    </span>",
"    or inflammation of internal organs",
"    <span class=\"nowrap\">",
"     (DiHS/DRESS),",
"    </span>",
"    since even small amounts of the suspect drug can reactivate these reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201835\">",
"    <span class=\"h1\">",
"     MACROLIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commonly used macrolide antibiotics include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    . Nonallergic adverse effects, such as QT interval prolongation and gastrointestinal symptoms, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H19#H19\">",
"     \"Azithromycin, clarithromycin, and telithromycin\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201842\">",
"    <span class=\"h2\">",
"     Types of reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions due to macrolides are less common than reactions to beta-lactam antibiotics, sulfonamide antibiotics, and fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most patients reporting macrolide reactions prove not to have a serious allergy. If the patients from the largest published series are combined, the cumulative rate of reactions upon challenge with the culprit drug in patients with history of convincing macrolide allergy was 5 percent",
"    <span class=\"nowrap\">",
"     (13/255",
"    </span>",
"    subjects), and most reactions were mild [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies address specific types of reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IgE-mediated reactions to macrolides are rare and largely confined to anecdotal case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/8-11\">",
"       8-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The vast majority of skin reactions are maculopapular exanthems:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In an analysis of over 40 clinical trials of children treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      for various bacterial infections,",
"      <span class=\"nowrap\">",
"       29/2655",
"      </span>",
"      (1.1 percent) developed skin eruptions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/12\">",
"       12",
"      </a>",
"      ]. Of note, this study was not designed to include control patients treated with placebo, and 1 percent is a common rate of skin eruption to placebo in other drug studies.",
"     </li>",
"     <li>",
"      A retrospective analysis of a general practice database of 150,000 mostly adult patients over an 18-month period revealed an incidence of macrolide-related cutaneous reactions of 1.1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/3\">",
"       3",
"      </a>",
"      ]. Again, there was no placebo group for comparison.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201849\">",
"    <span class=\"h2\">",
"     Cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial differences in structure among macrolides with different sized lactone rings, and one would not expect extensive cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the allergic determinants of macrolide molecules have not been identified.",
"   </p>",
"   <p>",
"    Data regarding allergic cross-reactivity among macrolides is limited to case reports and small series. In these, the majority of patients who reacted to one macrolide (mostly with delayed reactions) tolerated other macrolides, suggesting little allergic cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. However, most patients were only challenged with a macrolide different from the one that caused the initial reaction. Although understandable, this approach is not sufficient to prove lack of cross-reactivity, because many patients will tolerate the culprit drug if it is given again. To conclusively prove lack of cross-reactivity, challenges to both drugs should be done in close temporal association, which is rarely done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201856\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;History is an essential first step in evaluating patients who report an allergy to macrolides. If the patient&rsquo;s history suggests an immunologic reaction, referral to an allergy expert may be appropriate, although this is usually not warranted in patients who report past allergic reactions",
"    <strong>",
"     only",
"    </strong>",
"    to macrolides, because there are multiple alternative groups of antibiotics. Possible exceptions to this include patients predisposed to sinopulmonary infections, because macrolides are very useful for these infections. (See",
"    <a class=\"local\" href=\"#H8608741\">",
"     'Referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201870\">",
"    <span class=\"h3\">",
"     Role of skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest performing skin testing in patients whose past reactions had features of immediate reactions, such as pruritic rashes, urticaria, or angioedema. Others have argued that it is not sufficiently helpful and advocate performing challenge directly [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/7\">",
"     7",
"    </a>",
"    ]. The utility of immediate-type skin testing for IgE-mediated allergy to macrolides has significant limitations, as illustrated in the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 73 consecutive children with cutaneous reactions to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      , reactions consisted of urticaria (62 percent), angioedema (18 percent), and maculopapular rash (19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/6\">",
"       6",
"      </a>",
"      ]. There were no cases of anaphylaxis. Twenty children had immediate reactions, 49 had delayed reactions, and 4 had undetermined timing. All the children were skin tested (prick-puncture and intradermal, read at 20 minutes and 48 hours) using 0.05",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      of IV clarithromycin, which was found to be the highest nonirritating concentration in 18 control subjects. All patients (except nine who refused) underwent blinded five-day oral challenges, regardless of the skin test results. Of the 64 challenged subjects, nine (14 percent) had positive intradermal skin tests at 20 minutes; no patient was positive on prick-puncture tests or 48 hour intradermal tests.",
"      <br/>",
"      <br/>",
"      Overall,",
"      <span class=\"nowrap\">",
"       4/64",
"      </span>",
"      patients (6 percent) reacted on challenge; two immediate (urticaria) and two delayed (day 3 and 4) reactions (maculopapular rashes). Three out of nine skin test-positive patients and 1 of 55 skin test-negative patients reacted on challenge. Thus, based on these small numbers, skin testing had a positive predictive value (PPV) of 33 percent, negative predictive value (NPV) of 98 percent, sensitivity of 75 percent, and specificity of 90 percent. The authors did not report the skin test and challenge results according to the type of reaction (immediate versus delayed) the patients had originally.",
"     </li>",
"     <li>",
"      Another series consisted of 107 consecutive patients evaluated over a five-year period for suspected macrolide allergy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/4\">",
"       4",
"      </a>",
"      ]. Eleven percent of reactions were immediate, 66 percent were delayed, and 23 percent were of unknown type. Five percent of the patients reported anaphylaxis, 53 percent urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema, 24 percent maculopapular rashes, and the rest were unknown. Skin testing (prick-puncture and intradermal) was carried out in only 33 patients using macrolide concentrations of 10",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (there is no mention of a control group). The other 74 patients were not skin tested. All the patients (regardless of skin test results) underwent single-blinded challenges with the culprit macrolide, and 8 of 107 (7.5 percent) reacted, one-half of whom had positive skin tests. In the challenge-negative group,",
"      <span class=\"nowrap\">",
"       7/25",
"      </span>",
"      had positive skin tests. The eight reactions to challenge consisted of four maculopapular rashes, three urticarial reactions, and one case of anaphylaxis, although all were easily treated. Although the study&rsquo;s usefulness was limited by the low percentage of patients skin tested, the PPV of skin testing was 36 percent, NPV was 82 percent, sensitivity 50 percent, and specificity 72 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the author&rsquo;s clinic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is the only macrolide used for skin testing. We use the highest nonirritating concentration of azithromycin, which is 0.01",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (a 1:10,000 dilution of the commercially available 100",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    intravenous formulation) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/18\">",
"     18",
"    </a>",
"    ]. We do not test with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , since it is used less commonly.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     Clarithromycin",
"    </a>",
"    is not commercially available in the US in an IV formulation, and no data are available about using oral formulations of clarithromycin for skin testing. In countries where IV clarithromycin is available, studies have used concentrations ranging from 0.5",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    to ~0.05",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (corresponding to a 1:100 to a 1:1000 dilution of the commercial formulation), which were reported as nonirritating in previously unexposed subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. Of note, the study which used 0.05",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    found 0.167",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    to be irritating in some patients, so we suggest using the more dilute concentration.",
"   </p>",
"   <p>",
"    Although the positive predictive value of macrolide skin testing was low in the studies above, it is our approach to advise patients with positive skin test results to avoid the drugs in question, in part because there are usually equivalent alternative antibiotics. If they require treatment with that macrolide and there are no acceptable antibiotic alternatives, we administer it using a desensitization protocol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with negative macrolide skin testing, first administration of the macrolide should be via graded challenge, since skin testing does not detect all patients at risk for recurrent reactions. The author&rsquo;s approach to macrolide challenges is described below, and a general discussion of challenges is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H30#H30\">",
"     \"An approach to the patient with drug allergy\", section on 'Graded challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201877\">",
"    <span class=\"h3\">",
"     Graded challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graded challenge can be performed with or without prior skin testing, as discussed previously. It is useful for patients with both immediate and delayed past reactions. We prefer to challenge with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (rather than other macrolides) because it is available in both parenteral and oral formulations to treat future infections. Also, azithromycin has a more favorable gastrointestinal side effect profile compared to other macrolides. Patients with recent severe anaphylaxis should undergo rapid desensitization rather than graded challenge (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A representative macrolide graded challenge starts with",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    of the full dose and includes two to four steps until the full dose is reached. The degree of caution exercised may be adjusted based upon the severity of the historical reaction and the time elapsed since the reaction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with immediate past reactions, such as a pruritic rash five years ago, an oral challenge with 2.5 mg, 25 mg, and 250 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , given hourly, under observation, would be suitable.",
"     </li>",
"     <li>",
"      For patients with delayed past reactions, the author&rsquo;s approach to challenge is to administer 25 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      , observe for one hour, and then administer 250 mg, and observe for an additional hour. The reason for giving the initial dose under observation is the author&rsquo;s experience that, unless the patient knows that the drug can be safely ingested, there may be continued reluctance to use it in the future. A delayed reaction may occur during the 24 hours following the initial dose, and patients should be instructed to inform the clinician if this occurs.",
"      <br/>",
"      <br/>",
"      It is important to understand the limitations of challenge procedures for delayed maculopapular exanthema. Some of these reactions only recur after several days of therapy, and there is no practical way to elicit such reactions without administering a full therapeutic course. This should be explained to patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After completion of the challenge procedure, patients who do not need the antibiotic at that time can simply take it normally in the future. Patients who need macrolide therapy at that time can continue the treatment for a full course.",
"   </p>",
"   <p>",
"    If a patient develops a mild exanthema during future courses of therapy, it may be reasonable to attempt to continue the drug and add antihistamine therapy, provided that the reaction lacks any worrisome features. This approach has not been formally studied and is only appropriate when the benefit of continued treatment clearly outweighs the risk of further reaction. Such situations require clinical judgement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201898\">",
"    <span class=\"h1\">",
"     AMINOGLYCOSIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides have been in widespread clinical use since the 1940s and are generally well tolerated. The main nonallergic adverse effects are nephrotoxicity and ototoxicity, as reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=see_link&amp;anchor=H27#H27\">",
"     \"Aminoglycosides\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609049\">",
"    <span class=\"h2\">",
"     Types of reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides uncommonly cause allergic reactions, with the notable exception of allergic contact dermatitis (ACD, a type IV immunologic reaction) to topical aminoglycosides. ACD due to topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    is common, and neomycin is included in the TrueTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    panel and other commercial patch test products [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    in eye and ear drops is implicated in contact dermatitis less often [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link\">",
"     \"Patch testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgE-mediated reactions to aminoglycosides are rare, with only a few reported cases of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic cross-reactivity among aminoglycosides in all types of allergic reactions appears to be extensive, based primarily on patch test data for contact dermatitis and on anecdotal reports of patients developing reactions of other types from multiple aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/25,27-29\">",
"     25,27-29",
"    </a>",
"    ]. Therefore, patients allergic to one aminoglycoside should avoid the entire class.",
"   </p>",
"   <p>",
"    The evaluation of patients with possible allergy to aminoglycosides is warranted only if there is an imminent need for treatment with this class of antibiotics. This clinical scenario is most often encountered in patients with cystic fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28267705\">",
"    <span class=\"h2\">",
"     Skin testing for immediate reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two patients with immediate reactions, IgE-mediated allergy was confirmed by positive prick-puncture skin testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/23,25\">",
"     23,25",
"    </a>",
"    ]. If skin testing is pursued, the highest nonirritating concentration of aminoglycoside should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/18\">",
"     18",
"    </a>",
"    ]. We suggest the following concentrations for both prick-puncture and intradermal testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      : 0.4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (1:100 dilution of the commercially available 40",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      intravenous solution).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      : 4",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      (1:10 dilution of commercially available 40",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      intravenous solution).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with IgE-mediated allergy to aminoglycosides who require the drug for severe infections and there are no suitable alternative may undergo rapid desensitization. This has been successfully accomplished with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    and with inhaled tobramycin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28267712\">",
"    <span class=\"h2\">",
"     Patch testing for contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing is valuable in patients with contact dermatitis-type reactions, and since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    is one of the most common contact allergens, it is included in the commercially-available TrueTest",
"    <sup>",
"     &reg;",
"    </sup>",
"    panel [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/21\">",
"     21",
"    </a>",
"    ]. Patch testing is performed by some allergists and by dermatologists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=see_link\">",
"     \"Patch testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2416917\">",
"    <span class=\"h1\">",
"     TETRACYCLINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    group of antibiotics includes tetracycline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"     demeclocycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    . Nonallergic adverse effects, such as photosensitivity, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=see_link&amp;anchor=H14#H14\">",
"     \"Tetracyclines\", section on 'Adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IgE-mediated reactions due to the tetracyclines are rare, with only a few published reports of single patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Information about skin testing with tetracyclines is limited to case reports. In two patients, prick-puncture skin testing with full-strength drug (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ) was performed and was positive [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2416924\">",
"    <span class=\"h2\">",
"     Minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     Minocycline",
"    </a>",
"    appears to be a relatively common cause of severe non-IgE-mediated reactions, and is implicated far more often than other tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35\">",
"     35",
"    </a>",
"    ]. This may be because minocycline is metabolized to reactive intermediates, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    are not [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactions attributed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug hypersensitivity syndrome",
"      <span class=\"nowrap\">",
"       (DiHS)/drug",
"      </span>",
"      rash with eosinophilia and systemic symptoms (DRESS): In a seven-year prospective study evaluating the incidence of DiHS,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      was the third most common cause, after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"       \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum sickness like reactions [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35,37\">",
"       35,37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=see_link\">",
"       \"Serum sickness and serum sickness-like reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link&amp;anchor=H8#H8\">",
"       \"Causes of pulmonary eosinophilia\", section on 'Medications and toxins'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced lupus:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      is the only",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      associated with drug-induced lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35,37,43\">",
"       35,37,43",
"      </a>",
"      ]. This observation might be due to the fact that minocycline is prescribed much more commonly for long-term use, especially for treatment of acne, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and tetracycline and more likely prescribed for acute infections with short duration of therapy. It is also possible that minocycline metabolism produces more reactive intermediates capable of possibly binding to MHC class II molecules leading to autoimmune reactions. It is important for clinicians to be aware that there may be a long interval between the start of therapy and onset of symptoms. The average time to onset of minocycline-induced lupus is two years after initiation of therapy, and it may be delayed as long as six years [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35\">",
"       35",
"      </a>",
"      ]. In contrast, the other non-IgE-mediated allergic reactions mentioned above typically appear within a month of initiation of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/35\">",
"       35",
"      </a>",
"      ]. Minocycline-induced lupus afflicts the same population (predominantly females) as idiopathic lupus. There are no data to support or refute the safety of minocycline or other drugs associated with drug-induced lupus in patients with idiopathic lupus; however, standard practice is to avoid the tetracyclines in patients with lupus. Drug-induced lupus is reviewed in more detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"       \"Drug-induced lupus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2416931\">",
"    <span class=\"h2\">",
"     Cross-reactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of allergic cross-reactivity among tetracyclines has not been studied. Given that non-IgE-mediated allergic reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    are often severe and the natural history of these reactions is unknown, it seems prudent to advise patients with history of severe hypersensitivity reactions to minocycline (or another",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ) to avoid all tetracyclines unless there is a compelling reason for use of these drugs. However, there are anecdotal reports of patients with minocycline&ndash;induced hypersensitivity reactions who later tolerated other tetracyclines [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609829\">",
"    <span class=\"h1\">",
"     CLINDAMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are uncommon. Clindamycin is a frequent cause of gastrointestinal side effects and also one of the more common causes of Clostridium difficile colitis, and patients may report these side effects as allergies, although they are not immunologic reactions. Nonallergic adverse effects of clindamycin are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23159?source=see_link&amp;anchor=H6#H6\">",
"     \"Clindamycin: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609836\">",
"    <span class=\"h2\">",
"     Types of reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maculopapular eruptions are reported more than any other type of hypersensitivity. In a retrospective review of inpatient pharmacy and medical records, allergic-type reactions were reported in 0.4 percent",
"    <span class=\"nowrap\">",
"     (14/3896)",
"    </span>",
"    courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , seven of which were confounded by concurrent administration of other medications, including other antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/44\">",
"     44",
"    </a>",
"    ]. Almost all of the reactions were maculopapular eruptions; there were no anaphylactic reactions and no severe non-IgE-mediated reactions.",
"   </p>",
"   <p>",
"    Based on available literature, anaphylactic reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/45\">",
"     45",
"    </a>",
"    ]. Severe non-IgE-mediated reactions, such as SJS, TEN, and",
"    <span class=\"nowrap\">",
"     DiHS/DRESS",
"    </span>",
"    have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8609843\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other antibiotics, evaluation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    allergy should start with a complete history and review of medical records if possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2418020\">",
"    <span class=\"h3\">",
"     Maculopapular eruptions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the reaction history is compatible with a possible maculopapular eruption, a graded challenge with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    can be performed. However, this is typically warranted only if patients are likely to require treatment with this antibiotic. This situation is unusual, since the types of bacteria and infections amenable to treatment with clindamycin are relatively narrow compared to other antibiotic classes.",
"   </p>",
"   <p>",
"    For patients with reactions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    as well as multiple other antibiotics, evaluation of allergies to the other antibiotics should usually be pursued first. This is because other antibiotics (such as penicillins, cephalosporins, fluoroquinolones) have broader bacterial coverage (and are therefore more clinically useful), allergies to other antibiotics have a better defined natural history, and testing and challenge procedures are more established for other antibiotics.",
"   </p>",
"   <p>",
"    Neither skin testing nor patch testing appears to be useful for the evaluation of maculopapular eruptions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , as demonstrated in the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 33 consecutive patients who developed maculopapular rashes while taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , evaluation occurred within one year of the reaction in all cases [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/49\">",
"       49",
"      </a>",
"      ]. One-half of patients reported onset of symptoms on days 1 to 6 of the treatment course, the other half on day 6 or later. Twenty-seven of the reactions were graded as mild or moderate, the rest were severe. All subjects underwent prick-puncture skin testing (which was read at 20 minutes and 72 hours) and patch testing, although intradermal skin testing was not performed. Prick-puncture and patch testing were found to be nonirritating in control subjects. Prick-puncture skin testing was negative at 20 minutes in all patients. Five patients had both positive prick-puncture skin tests at three days and positive patch tests, and they were not challenged with clindamycin. Of the remaining 28 patients, 26 underwent graded oral challenges (two refused) and five were positive (three maculopapular rashes, two symmetrical intertriginous exanthems, and one fixed drug eruption).",
"     </li>",
"     <li>",
"      In a review of 31 patients with delayed-onset reactions temporally associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , all patients underwent prick and intradermal skin testing with readings at 20 minutes and 48 to 72 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/51\">",
"       51",
"      </a>",
"      ]. None of the patients had positive skin tests at the 20 minute reading, whereas two patients were positive at 48 hours. All patients were challenged with a single dose of 150 mg of oral clindamycin. Ten of 31 (32 percent) experienced reactions; eight occurred two to six hours after challenge, and two occurred one to two days after challenge. The reactions consisted of eight pruritic maculopapular rashes, one urticaria, one angioedema, and no severe reactions. Of the two patients with positive delayed skin tests, one reacted on challenge (maculopapular rash on day 2) and the other patient did not react. Thus, skin testing was not useful for the identification of clindamycin-allergic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201912\">",
"    <span class=\"h1\">",
"     METRONIDAZOLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is an imidazole with structural similarities to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , miconazole, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    . Nonallergic adverse effects are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=see_link&amp;anchor=H12#H12\">",
"     \"Metronidazole: An overview\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypersensitivity reactions due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are rare, with only a small number of case reports in the published literature [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/22,52-60\">",
"     22,52-60",
"    </a>",
"    ]. However, an array of different reaction types (both immediate and delayed) have been reported, including various generalized exanthems, fixed drug eruption, serum-sickness like reaction, Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    epidermal necrolysis, and anaphylaxis.",
"   </p>",
"   <p>",
"    Based primarily on patch test data (and some challenges), there appears to be a moderate degree of allergic cross-reactivity between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and other imidazoles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Therefore, patients allergic to metronidazole should avoid other imidazoles, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , miconazole, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3201919\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of studies have described skin testing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Prick-puncture testing was positive in one case of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/52\">",
"     52",
"    </a>",
"    ], although other larger studies suggest that the sensitivity is low. In the largest series, 14 patients with history of recent (&lt;1 year) cutaneous reactions to Rhodogil (metronidazole plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/18/14628?source=see_link\">",
"     spiramycin",
"    </a>",
"    ) underwent prick-puncture and intradermal skin testing (20 minute, 48 hour, and 96 hour readings) and oral challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/53\">",
"     53",
"    </a>",
"    ]. Eleven patients were skin test negative, but three of these reacted to a single-dose challenge of metronidazole, developing pruritic rashes and facial angioedema at 45 minutes, 1 hour, and 7 hours. The remaining 10 patients were skin test-negative and passed challenges with metronidazole and spiramycin. The one patient who was prick test-positive was not challenged.",
"   </p>",
"   <p>",
"    Thus, in patients in whom the suspicion of an immediate reaction is high based upon the clinical history, we suggest avoidance of all imidazoles in the future. If the patient requires a specific drug and there are no suitable alternatives, a desensitization procedure can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/40/2698/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients whose history is not suggestive of a true hypersensitivity reaction, we suggest graded challenge to confirm lack of reactivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3203245\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macrolides, aminoglycosides, the tetracyclines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      infrequently cause hypersensitivity reactions, compared with penicillins, sulfonamides, and other classes of antimicrobials. (See",
"      <a class=\"local\" href=\"#H3200666\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of a patient with a past drug always begins with a careful clinical history to determine what type of adverse reaction the patient likely experienced. Hypersensitivity (allergic) reactions are adverse reactions that are mediated by the immune system. Referral to an expert in drug allergy is indicated in specific circumstances. (See",
"      <a class=\"local\" href=\"#H8608741\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of hypersensitivity reactions to the antibiotics discussed in this review is not well characterized and none of the diagnostic tests used to evaluate patients with these reactions is standardized or validated. Thus, skin testing with the antibiotics discussed in this topic is much less informative than that performed to evaluate penicillin allergy. In some cases, the evaluation consists of a careful history and graded challenge. (See",
"      <a class=\"local\" href=\"#H8608938\">",
"       'Allergy evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macrolides cause delayed-onset maculopapular exanthems in about 1 percent of treated patients, which is close to the rate in placebo-treated patients in many drug studies. Anaphylaxis and serious non-IgE-mediated reactions are rare. Skin testing is controversial and graded challenge is often required for conclusive diagnosis, although there are usually alternate classes of antibiotics that can be substituted for macrolides. Patients who have reacted to one macrolide in the past may tolerate other macrolides. (See",
"      <a class=\"local\" href=\"#H3201835\">",
"       'Macrolides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aminoglycosides are well tolerated as a group, with the exception of topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      , which is a relatively common cause of allergic contact dermatitis and is included on many commercial patch testing panels. Rare cases of anaphylaxis have been confirmed with immediate type skin testing. Cross-reactivity appears to be extensive and patients are usually advised to avoid all aminoglycosides if they have had a significant reaction to one. (See",
"      <a class=\"local\" href=\"#H3201898\">",
"       'Aminoglycosides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      causes more hypersensitivity reactions than all others. Minocycline has been implicated in an array of serious non-IgE-mediated reactions, such as drug-induced hypersensitivity syndrome, drug-induced lupus, and toxic epidermal necrolysis. Among the other drugs, rare cases of anaphylaxis have been confirmed with immediate-type skin testing. Cross-reactivity is not well studied, so patients with past reactions are usually advised to avoid the entire group if possible. (See",
"      <a class=\"local\" href=\"#H2416917\">",
"       'Tetracyclines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common reaction to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is maculopapular exanthem. Neither skin testing nor patch testing appears to be useful for the evaluation of this reaction. (See",
"      <a class=\"local\" href=\"#H8609829\">",
"       'Clindamycin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      has been anecdotally implicated in several types of rare hypersensitivity reactions, including anaphylaxis, fixed drug eruption, serum-sickness like reaction, and Stevens-Johnson",
"      <span class=\"nowrap\">",
"       syndrome/toxic",
"      </span>",
"      epidermal necrolysis. (See",
"      <a class=\"local\" href=\"#H3201912\">",
"       'Metronidazole'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/1\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/2\">",
"      Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/3\">",
"      van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/4\">",
"      Benahmed S, Scaramuzza C, Messaad D, et al. The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial. Allergy 2004; 59:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/5\">",
"      Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol 2005; 85:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/6\">",
"      Mori F, Barni S, Pucci N, et al. Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy. Ann Allergy Asthma Immunol 2010; 104:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/7\">",
"      Seitz CS, Br&ouml;cker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr) 2011; 39:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/8\">",
"      Gangemi S, Ricciardi L, Fedele R, et al. Immediate reaction to clarithromycin. Allergol Immunopathol (Madr) 2001; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/9\">",
"      Holmes NE, Hodgkinson M, Dendle C, Korman TM. Report of oral clarithromycin desensitization. Br J Clin Pharmacol 2008; 66:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/10\">",
"      Jorro G, Morales C, Bras&oacute; JV, Pel&aacute;ez A. Anaphylaxis to erythromycin. Ann Allergy Asthma Immunol 1996; 77:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/11\">",
"      Pascual C, Crespo JF, Quiralte J, et al. In vitro detection of specific IgE antibodies to erythromycin. J Allergy Clin Immunol 1995; 95:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/12\">",
"      Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37 Suppl C:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/13\">",
"      Ara&uacute;jo L, Demoly P. Macrolides allergy. Curr Pharm Des 2008; 14:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/14\">",
"      Borja JM, Galindo PA, Feo F, et al. Maculopapular exanthema from diacetyl-midecamycin (MOM). Allergy 1998; 53:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/15\">",
"      Igea JM, L&aacute;zaro M. Hypersensitivity reaction to clarithromycin. Allergy 1998; 53:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/16\">",
"      Igea JM, Quirce S, de la Hoz B, et al. Adverse cutaneous reactions due to macrolides. Ann Allergy 1991; 66:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/17\">",
"      S&aacute;nchez-Morillas L, Laguna-Mart&iacute;nez JJ, Rea&ntilde;o-Martos M, et al. Hypersensitivity to spiramycin with good tolerance of other macrolides. J Investig Allergol Clin Immunol 2007; 17:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/18\">",
"      Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/19\">",
"      Bro P, Harr T, Hecking C, et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy 2012; 67:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/20\">",
"      Menezes de P&aacute;dua CA, Schnuch A, Lessmann H, et al. Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf 2005; 14:725.",
"     </a>",
"    </li>",
"    <li>",
"     The allergens found in various commercial testing kits can be accessed at: file://www.truetest.com/panelallergens.aspx (Accessed on May 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/22\">",
"      S&aacute;nchez-P&eacute;rez J, L&oacute;pez MP, De Vega Haro JM, Garc&iacute;a-D&iacute;ez A. Allergic contact dermatitis from gentamicin in eyedrops, with cross-reactivity to kanamycin but not neomycin. Contact Dermatitis 2001; 44:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/23\">",
"      Connolly M, McAdoo J, Bourke JF. Gentamicin-induced anaphylaxis. Ir J Med Sci 2007; 176:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/24\">",
"      Hall FJ. Anaphylaxis after gentamycin. Lancet 1977; 2:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/25\">",
"      Schulze S, Wollina U. Gentamicin-induced anaphylaxis. Allergy 2003; 58:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/26\">",
"      Proebstle TM, Jugert FK, Merk HF, Gall H. Severe anaphylactic reaction to topical administration of framycetin. J Allergy Clin Immunol 1995; 96:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/27\">",
"      Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/28\">",
"      Guin JD, Phillips D. Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis 1989; 43:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/29\">",
"      Spigarelli MG, Hurwitz ME, Nasr SZ. Hypersensitivity to inhaled TOBI following reaction to gentamicin. Pediatr Pulmonol 2002; 33:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/30\">",
"      Earl HS, Sullivan TJ. Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J Allergy Clin Immunol 1987; 79:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/31\">",
"      Jang JW, Bae YJ, Kim YG, et al. A case of anaphylaxis to oral minocycline. J Korean Med Sci 2010; 25:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/32\">",
"      Ogita A, Takada K, Kawana S. Case of anaphylaxis due to tetracycline hydrochloride. J Dermatol 2011; 38:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/33\">",
"      Okano M, Imai S. Anaphylactoid symptoms due to oral minocycline. Acta Derm Venereol 1996; 76:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/34\">",
"      Raeder JC. Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. Drug Intell Clin Pharm 1984; 18:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/35\">",
"      Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/36\">",
"      Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009; 145:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/37\">",
"      Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996; 132:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/38\">",
"      Maubec E, Wolkenstein P, Loriot MA, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology 2008; 216:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/39\">",
"      Robles DT, Leonard JL, Compton N, et al. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. Dermatology 2008; 217:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/40\">",
"      Sitbon O, Bidel N, Dussopt C, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med 1994; 154:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/41\">",
"      Yoon J, Lee SH, Kim TH, et al. Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy. Case Rep Dermatol 2010; 2:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/42\">",
"      Muller P, Dubreil P, Mah&eacute; A, et al. Drug Hypersensitivity Syndrome in a West-Indian population. Eur J Dermatol 2003; 13:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/43\">",
"      Masson C, Chevailler A, Pascaretti C, et al. Minocycline related lupus. J Rheumatol 1996; 23:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/44\">",
"      Mazur N, Greenberger PA, Regalado J. Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol 1999; 82:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/45\">",
"      Chiou CS, Lin SM, Lin SP, et al. Clindamycin-induced anaphylactic shock during general anesthesia. J Chin Med Assoc 2006; 69:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/46\">",
"      Correia O, Chosidow O, Saiag P, et al. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology 1993; 186:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/47\">",
"      Fulghum DD, Catalano PM. Stevens-Johnson syndrome from clindamycin. JAMA 1973; 223:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/48\">",
"      Miller Quidley A, Bookstaver PB, Gainey AB, Gainey MD. Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Pharmacotherapy 2012; 32:e387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/49\">",
"      Seitz CS, Br&ouml;cker EB, Trautmann A. Allergy diagnostic testing in clindamycin-induced skin reactions. Int Arch Allergy Immunol 2009; 149:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/50\">",
"      Pereira N, Canelas MM, Santiago F, et al. Value of patch tests in clindamycin-related drug eruptions. Contact Dermatitis 2011; 65:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/51\">",
"      Notman MJ, Phillips EJ, Knowles SR, et al. Clindamycin skin testing has limited diagnostic potential. Contact Dermatitis 2005; 53:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/52\">",
"      Asensio S&aacute;nchez T, D&aacute;vila I, Moreno E, et al. Anaphylaxis due to metronidazole with positive skin prick test. J Investig Allergol Clin Immunol 2008; 18:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/53\">",
"      Garc&iacute;a-Rubio I, Mart&iacute;nez-C&oacute;cera C, Santos Magad&aacute;n S, et al. Hypersensitivity reactions to metronidazole. Allergol Immunopathol (Madr) 2006; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/54\">",
"      Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/55\">",
"      Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/56\">",
"      Maize JC, Tomecki KJ. Pityriasis rosea-like drug eruption secondary to metronidazole. Arch Dermatol 1977; 113:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/57\">",
"      Naik RP, Singh G. Fixed drug eruption due to metronidazole. Dermatologica 1977; 155:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/58\">",
"      Shelley WB, Shelley ED. Fixed drug eruption due to metronidazole. Cutis 1987; 39:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/59\">",
"      Short KA, Fuller LC, Salisbury JR. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis. Clin Exp Dermatol 2002; 27:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/60\">",
"      Weart CW, Hyman LC. Serum sickness associated with metronidazole. South Med J 1983; 76:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/61\">",
"      Kanwar AJ, Sharma R, Rajagopalan M, Kaur S. Fixed drug eruption due to tinidazole with cross-reactivity with metronidazole. Dermatologica 1990; 180:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/62\">",
"      Mishra D, Mobashir M, Zaheer MS. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 1990; 29:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/40/2698/abstract/63\">",
"      Thami GP, Kanwar AJ. Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole. Dermatology 1998; 196:368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 84000 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2698=[""].join("\n");
var outline_f2_40_2698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3203245\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3200659\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3200666\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8608706\">",
"      Types of hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8608945\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8608741\">",
"      Referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8608938\">",
"      Allergy evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8609129\">",
"      - Immediate-type skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8609147\">",
"      - Graded challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3201835\">",
"      MACROLIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3201842\">",
"      Types of reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3201849\">",
"      Cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3201856\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3201870\">",
"      - Role of skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3201877\">",
"      - Graded challenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3201898\">",
"      AMINOGLYCOSIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8609049\">",
"      Types of reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28267705\">",
"      Skin testing for immediate reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28267712\">",
"      Patch testing for contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2416917\">",
"      TETRACYCLINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2416924\">",
"      Minocycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2416931\">",
"      Cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8609829\">",
"      CLINDAMYCIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8609836\">",
"      Types of reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8609843\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2418020\">",
"      - Maculopapular eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3201912\">",
"      METRONIDAZOLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3201919\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3203245\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/84000\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/84000|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/16/27905\" title=\"picture 1\">",
"      Urticarial drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 2\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/6/37985\" title=\"picture 3\">",
"      Morbilliform drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 4\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/34/24104?source=related_link\">",
"      Aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=related_link\">",
"      Cephalosporin allergy: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23159?source=related_link\">",
"      Clindamycin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=related_link\">",
"      Hypersensitivity reactions to fluoroquinolones antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31817?source=related_link\">",
"      Metronidazole: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28150?source=related_link\">",
"      Patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36662?source=related_link\">",
"      Tetracyclines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1978?source=related_link\">",
"      Vancomycin hypersensitivity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_40_2699="Gaucher resources";
var content_f2_40_2699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for information on Gaucher disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Children's Gaucher Research Fund",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       www.childrensgaucher.org",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gaucher's Association",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       file://www.gaucher.org.uk/",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       National Gaucher Foundation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       www.gaucherdisease.org",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       International Gaucher Disease Associations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       www.gaucher.org.uk/page.php?id=20",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2699=[""].join("\n");
var outline_f2_40_2699=null;
var title_f2_40_2700="Differential diagnosis for methamphetamine intoxication";
var content_f2_40_2700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Basic differential diagnosis for methamphetamine intoxication",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Toxicologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCP (phencyclidine)/ketamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salicylates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MAOI (monoamine oxidase inhibitors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Theophylline/caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LSD (lysergic acid diethylamine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isoniazid/monomethylhydrazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scorpion envenomation (Centruroides sculpturatus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin Syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroleptic malignant syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol/sedative-hypnotic withdrawal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nontoxicologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis/meningitis/encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intracerebral hemorrhage or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia/hyperglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temporal lobe epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2700=[""].join("\n");
var outline_f2_40_2700=null;
var title_f2_40_2701="Healthy weight nutrition tips B";
var content_f2_40_2701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for maintaining a healthy weight: nutrition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Phase II",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Eat a variety of foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Eat fruits, vegetables, whole grain breads, cereals, rice, and pastas; low-fat and fat-free dairy products; lean chicken, turkey, fish, and legumes; and healthy fats. Use a small amount of added fats and sugars. Avoid fried foods. See the Low-fat, Low-Sugar Eating Guidelines for a list of food choices and sample menus.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Eat proper portion sizes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Young children and inactive girls should choose the lower number of servings from each food group. Most active school-aged children and teen girls, as well as inactive teen boys should choose the middle number of servings. Active teen boys and some very active teen girls should choose the higher number of servings from each food group.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Group",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of servings per day",
"      </td>",
"      <td class=\"subtitle2\">",
"       Serving size",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bread, cereal, rice, pasta and starchy vegetable",
"      </td>",
"      <td>",
"       6 to 11",
"      </td>",
"      <td>",
"       1 slice whole wheat bread; 1/2 cup cooked whole-grain cereal, brown rice, or whole wheat pasta",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fruit",
"      </td>",
"      <td>",
"       2 to 4",
"      </td>",
"      <td>",
"       1 small piece fruit or 1/2 banana; 1 cup fresh fruit such as melon or berries; 1/2 cup canned fruit; four ounces juice; two tablespoons dried fruit",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vegetable",
"      </td>",
"      <td>",
"       3 to 5",
"      </td>",
"      <td>",
"       1/2 cup cooked vegetables or vegetable juice; 1 cup raw vegetables",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Milk, yogurt, and cheese",
"      </td>",
"      <td>",
"       2 to 4",
"      </td>",
"      <td>",
"       1 cup skim or 1 percent milk; 1 cup fat-free or low-fat yogurt; 1 ounce fat-free or reduced fat cheese",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Meat, poultry, fish, dry beans, eggs and nuts",
"      </td>",
"      <td>",
"       2 to 3",
"      </td>",
"      <td>",
"       2 to 3 ounces of skinless chicken, turkey, or fish; 1/2 cup beans or tofu; 1/4 cup nuts; 2 tablespoons nut butter; 1/4 cup egg whites or egg substitute",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fats, oils, sweets",
"      </td>",
"      <td>",
"       Use a small amount",
"      </td>",
"      <td>",
"       1 teaspoon butter, margarine, mayonnaise, oil, or sugar; 1 tablespoon salad dressing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Stock your house with healthful food choices.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Eliminate unhealthful food choices from your house including low-fat cookies, cakes and ice cream as these foods are often enriched with sugar. Instead, stock your house with fresh fruit, cut up vegetables and fat-free or low-fat yogurt. Children can choose between an apple or yogurt for a snack, not an apple or potato chips.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Limit restaurant eating to 1 time per week.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Restaurants provide large food portions. Split entrees or plan to take half home. If time is an issue, choose low-fat frozen dinners with bagged salad and/or a side of frozen vegetables.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"3\">",
"       Take your lunch to school.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Pack a lunch with 2 ounces of lean meat or 1 ounce low-fat or fat-free cheese on whole grain bread with one serving of fruit, vegetables and fat-free milk or yogurt. Avoid eating breakfast at school. Instead, choose a bowl of whole grain cereal at home.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2701=[""].join("\n");
var outline_f2_40_2701=null;
var title_f2_40_2702="Rx of relapsing polychondritis";
var content_f2_40_2702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medical management of polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 241px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of the approach to therapy in relapsing polychondritis according to the severity of the clinical manifestations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2702=[""].join("\n");
var outline_f2_40_2702=null;
var title_f2_40_2703="Hip log roll test";
var content_f2_40_2703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Log roll test for evaluation of hip rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    While keeping the leg straight, the foot is manipulated medially (internal rotation of the hip) and laterally (external rotation of the hip). Pain suggests inflammation, infection, or trauma. Synovitis tends to cause pain at extremes of rotation. Significant hip trauma or septic hip joint causes pain despite minimal rotation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_40_2703=[""].join("\n");
var outline_f2_40_2703=null;
